

CITATION REPORT

List of articles citing

A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability

DOI: 10.1023/a:1016212804288

Pharmaceutical Research, 1995, 12, 413-20.

Source: <https://exaly.com/paper-pdf/26099590/citation-report.pdf>

Version: 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2284	Permeability and clearance views of drug absorption: a commentary. 1995 , 23, 333-43		19
2283	Does fluid flow across the intestinal mucosa affect quantitative oral drug absorption? Is it time for a reevaluation?. <i>Pharmaceutical Research</i> , 1995 , 12, 1573-82	4.5	80
2282	Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. <i>Pharmaceutical Research</i> , 1995 , 12, 1561-72	4.5	523
2281	New perspectives on the theory of permeability and resistance in the study of drug transport and absorption. 1996 , 24, 433-42		18
2280	Comparison between active and passive drug transport in human intestinal epithelial (caco-2) cells in vitro and human jejunum in vivo. 1996 , 127, 103-107		211
2279	Improved passive oral drug delivery via prodrugs. 1996 , 19, 131-148		45
2278	Transport approaches to the biopharmaceutical design of oral drug delivery systems: prediction of intestinal absorption. 1996 , 19, 359-76		261
2277	Physicochemical and drug-delivery considerations for oral drug bioavailability. 1996 , 1, 461-473		117
2276	Comparison between permeability coefficients in rat and human jejunum. <i>Pharmaceutical Research</i> , 1996 , 13, 1336-42	4.5	338
2275	Caco-2 monolayers in experimental and theoretical predictions of drug transport. 1996 , 22, 67-84		219
2274	Jejunal permeability and hepatic extraction of fluvastatin in humans. 1996 , 60, 493-503		75
2273	HT29-MTX/Caco-2 cocultures as an in vitro model for the intestinal epithelium: in vitro-in vivo correlation with permeability data from rats and humans. 1996 , 85, 1070-6		200
2272	Overview of Workshop: In Vitro Dissolution of Immediate Release Dosage Forms: Development of in Vivo Relevance and Quality Control Issues. 1996 , 30, 1029-1037		4
2271	In Vitro Absorption Studies and Their Relevance to Absorption from the GI Tract. 1997 , 23, 879-892		48
2270	Dissolution assay development for in vitro-in vivo correlations. Theory and case studies. 1997 , 423, 17-30		6
2269	The biopharmaceutic drug classification and drugs administered in extended release (ER) formulations. 1997 , 423, 111-28		26
2268	Evaluation of in vitro release rate and in vivo absorption characteristics of four metoprolol tartrate immediate-release tablet formulations. 1997 , 2, 11-24		37

2267	Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH. 1997 , 86, 269-82		443
2266	Oral formulations of adefovir dipivoxil: in vitro dissolution and in vivo bioavailability in dogs. 1997 , 86, 1334-8		29
2265	Selection of development candidates based on in vitro permeability measurements. 1997 , 23, 47-62		34
2264	Simulation models to predict oral drug absorption from in vitro data. 1997 , 23, 199-219		74
2263	Jejunal permeability: a comparison between the ussing chamber technique and the single-pass perfusion in humans. <i>Pharmaceutical Research</i> , 1997 , 14, 667-71	4.5	135
2262	Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion. <i>Pharmaceutical Research</i> , 1997 , 14, 1127-32	4.5	45
2261	A new approach for direct in vivo dissolution studies of poorly soluble drugs. <i>Pharmaceutical Research</i> , 1997 , 14, 1490-2	4.5	23
2260	A population growth model of dissolution. <i>Pharmaceutical Research</i> , 1997 , 14, 1122-6	4.5	27
2259	Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. <i>Pharmaceutical Research</i> , 1998 , 15, 698-705	4.5	668
2258	Jejunal absorption and metabolism of R/S-verapamil in humans. <i>Pharmaceutical Research</i> , 1998 , 15, 856-62	4.5	81
2257	5'-Amino acid esters of antiviral nucleosides, acyclovir, and AZT are absorbed by the intestinal PEPT1 peptide transporter. <i>Pharmaceutical Research</i> , 1998 , 15, 1154-9	4.5	249
2256	Prediction of intestinal drug absorption properties by three-dimensional solubility parameters. <i>Pharmaceutical Research</i> , 1998 , 15, 1370-5	4.5	87
2255	Transport of proteolytic enzymes across Caco-2 cell monolayers. <i>Pharmaceutical Research</i> , 1998 , 15, 1391-400	4.5	24
2254	Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. <i>Pharmaceutical Research</i> , 1998 , 15, 1792-5	4.5	214
2253	Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. <i>Pharmaceutical Research</i> , 1998 , 15, 11-22	4.5	748
2252	Development and internal validation of an in vitro-in vivo correlation for a hydrophilic metoprolol tartrate extended release tablet formulation. <i>Pharmaceutical Research</i> , 1998 , 15, 466-73	4.5	56
2251	Membrane transport of drugs in different regions of the intestinal tract of the rat. 1998 , 87, 360-6		203
2250	Human intestinal permeability. 1998 , 87, 403-10		357

2249	Link between drug absorption solubility and permeability measurements in Caco-2 cells. 1998 , 87, 1604-7	115
2248	Caco-2 cell permeability of a new (hydroxybenzyl)ethylenediamine oral iron chelator: correlation with physicochemical properties and oral activity. 1998 , 87, 1041-5	14
2247	Comparative pharmacokinetic study of a floating multiple-unit capsule, a high-density multiple-unit capsule and an immediate-release tablet containing 25 mg atenolol. 1998 , 73, 81-7	59
2246	Effect of elevated viscosity in the upper gastrointestinal tract on drug absorption in dogs. 1998 , 6, 131-9	41
2245	Development of dissolution tests for oral extended-release products. 1998 , 1, 128-135	12
2244	Novel oral drug delivery gateways for biotechnology products: polypeptides and vaccines. 1998 , 1, 291-299	29
2243	Calculation of the antibiotic level in the lung tissue and bronchial secretion with an oral controlled-release dosage form. 1998 , 6, 321-37	3
2242	In vivo non-linear intestinal permeability of celiprolol and propranolol in conscious dogs: evidence for intestinal secretion. 1998 , 6, 75-81	17
2241	Biopharmaceutical characterization of oral immediate release drug products. In vitro/in vivo comparison of phenoxymethylpenicillin potassium, glimepiride and levofloxacin. 1998 , 46, 305-11	56
2240	Zero-order release of theophylline from a core-in-cup tablet in sequenced simulated gastric and intestinal fluid. 1998 , 24, 163-7	8
2239	Rationales in the Development of Dissolution Testing for Solid Oral Dosage Forms - An Industrial, Biopharmaceutical and Regulatory Perspective. 1998 , 15, 187-207	1
2238	Identification of formulation and manufacturing variables that influence in vitro dissolution and in vivo bioavailability of propranolol hydrochloride tablets. 1998 , 3, 535-47	21
2237	The impact of formulation and process changes on in vitro dissolution and the bioequivalence of piroxicam capsules. 1998 , 3, 443-52	21
2236	Critical dissolution tests of oral systems based on statistically designed experiments. III. In vitro/in vivo correlation for multiple-unit capsules of paracetamol based on PLS modeling. 1998 , 24, 371-83	10
2235	Statistical evaluation of in vitro dissolution of different brands of ciprofloxacin hydrochloride tablets and capsules. 1998 , 24, 549-52	8
2234	When are bioavailability studies required? A German proposal. 1998 , 38, 904-11	22
2233	Pharmacokinetics and metabolism in early drug discovery. 1999 , 3, 373-8	157
2232	Comparative bioavailability of three different preparations of rifampicin. 1999 , 24, 219-25	10

2231	Application of oral bioavailability surrogates in the design of orally active inhibitors of rhinovirus replication. 1999 , 88, 747-53		11
2230	Improvement in solubility and dissolution rate of 1, 2-dithiole-3-thiones upon complexation with beta-cyclodextrin and its hydroxypropyl and sulfobutyl ether-7 derivatives. 1999 , 88, 889-95		42
2229	Gastrointestinal absorption of drugs: methods and studies. 1999 , 13, 154-68		194
2228	The effect of in vivo dissolution, gastric emptying rate, and intestinal transit time on the peak concentration and area-under-the-curve of drugs with different gastrointestinal permeabilities. <i>Pharmaceutical Research</i> , 1999 , 16, 272-80	4.5	36
2227	Heterogeneous tube model for the study of small intestinal transit flow. <i>Pharmaceutical Research</i> , 1999 , 16, 87-91	4.5	27
2226	In vitro and in situ permeability of a 'second generation' hydroxypyridinone oral iron chelator: correlation with physico-chemical properties and oral activity. <i>Pharmaceutical Research</i> , 1999 , 16, 434-40	4.5	15
2225	Absorption potential and its variants. <i>Pharmaceutical Research</i> , 1999 , 16, 1893	4.5	8
2224	Use of 1-methyl-pyrrolidone as a solubilizing agent for determining the uptake of poorly soluble drugs. <i>Pharmaceutical Research</i> , 1999 , 16, 968-71	4.5	20
2223	Albendazole generics--a comparative in vitro study. <i>Pharmaceutical Research</i> , 1999 , 16, 1871-5	4.5	48
2222	An integrated model for determining causes of poor oral drug absorption. <i>Pharmaceutical Research</i> , 1999 , 16, 1883-7	4.5	137
2221	A heterogeneous tube model of intestinal drug absorption based on probabilistic concepts. <i>Pharmaceutical Research</i> , 1999 , 16, 1764-9	4.5	29
2220	Does the dose-solubility ratio affect the mean dissolution time of drugs?. <i>Pharmaceutical Research</i> , 1999 , 16, 1470-6	4.5	27
2219	Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability. <i>Pharmaceutical Research</i> , 1999 , 16, 1047-53	4.5	10
2218	Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. <i>Pharmaceutical Research</i> , 1999 , 16, 1812-7	4.5	170
2217	Forecasting the in vivo performance of four low solubility drugs from their in vitro dissolution data. <i>Pharmaceutical Research</i> , 1999 , 16, 1876-82	4.5	126
2216	Setting bioequivalence requirements for drug development based on preclinical data: optimizing oral drug delivery systems. 1999 , 62, 41-9		52
2215	A comparison between direct determination of in vivo dissolution and the deconvolution technique in humans. 1999 , 8, 19-27		30
2214	Biopharmaceutics and metabolism of yohimbine in humans. 1999 , 9, 79-84		39

2213	The biopharmaceutics classification system (BCS): class III drugs - better candidates for BA/BE waiver?. 1999 , 9, 117-21		110
2212	Drug, meal and formulation interactions influencing drug absorption after oral administration. Clinical implications. 1999 , 36, 233-54		372
2211	Assessment of Plasma Drug Level with Erosion Controlled Release Dosage Forms: Effect of the Shape and Dimensions, and Residence Time in the Gastrointestine. 1999 , 18, 798-813		1
2210	Administration of Emulsions to the Gastrointestinal Tract. 2000 , 323-360		5
2209	Dissolution of ionizable water-insoluble drugs: the combined effect of pH and surfactant. 2000 , 89, 268-74		117
2208	Wetting properties of bile salt solutions and dissolution media. 2000 , 89, 382-95		20
2207	Intrinsic absolute bioavailability prediction in rats based on in situ absorption rate constants and/or in vitro partition coefficients: 6-fluoroquinolones. 2000 , 89, 1395-403		20
2206	Transdermal iontophoresis revisited. 2000 , 4, 468-73		51
2205	Effect of the nature of the polymer and of the process of drug release (diffusion or erosion) for oral dosage forms. 2000 , 10, 383-390		16
2204	Development of a more rapid, reduced serum culture system for Caco-2 monolayers and application to the biopharmaceutics classification system. 2000 , 200, 41-51		66
2203	Charge-dependent interaction of self-emulsifying oil formulations with Caco-2 cells monolayers: binding, effects on barrier function and cytotoxicity. 2000 , 211, 29-36		57
2202	Salt form selection and characterization of LY333531 mesylate monohydrate. 2000 , 198, 239-47		95
2201	Optimized conditions for prediction of intestinal drug permeability using Caco-2 cells. 2000 , 10, 195-204		397
2200	In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. 2000 , 11 Suppl 2, S73-80		409
2199	Development of predictive pharmacokinetic simulation models for drug discovery. 2000 , 65, 55-62		92
2198	pH-metric solubility. 2: correlation between the acid-base titration and the saturation shake-flask solubility-pH methods. <i>Pharmaceutical Research</i> , 2000 , 17, 85-9	4.5	189
2197	Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. <i>Pharmaceutical Research</i> , 2000 , 17, 439-44	4.5	68
2196	Bioequivalence study of stressed and nonstressed hard gelatin capsules using amoxicillin as a drug marker and gamma scintigraphy to confirm time and GI location of in vivo capsule rupture. <i>Pharmaceutical Research</i> , 2000 , 17, 572-82	4.5	28

2195	Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. 2000 , 1, E14	4
2194	Guidances related to bioavailability and bioequivalence: European industry perspective. 2000 , 25, 25-7	8
2193	Differences in reference products: dissolution and in vivo evidence. 2000 , 25, 32-5	
2192	Biopharmaceutical characterisation of herbal medicinal products: are in vivo studies necessary?. 2000 , 25, 41-8	6
2191	33 Methods of establishing in vitro-in vivo relationships for modified release drug products. 2000 , 18, 977-1002	
2190	Effect of solubilizing excipients on permeation of poorly water-soluble compounds across Caco-2 cell monolayers. 2000 , 50, 403-11	66
2189	In vitro drug release testing of controlled release veterinary drug products. 2000 , 311-332	1
2188	Assessment of the drug level in bronchial secretion with patient's noncompliance and oral dosage forms with controlled release. 2000 , 8, 267-283	3
2187	Guidelines on Dissolution Profile Comparison. 2001 , 35, 865-874	29
2186	Calculation of the dimensions of dosage forms with release controlled by diffusion for in vivo use. 2001 , 51, 17-24	9
2185	Molecular and pharmacokinetic properties of 222 commercially available oral drugs in humans. 2001 , 24, 935-40	44
2184	Understanding the scientific issues embedded in the generic drug approval process. 2001 , 41, 856-67	27
2183	The impact of formulation on bioavailability: summary of workshop discussion. 2001 , 131, 1389S-91S	16
2182	Feasibility of interspecies extrapolation in determining the bioequivalence of animal products intended for intramuscular administration. 2001 , 24, 125-35	10
2181	The effect of soybean oil refuse powder used as vehicle on the absorption of oxolinic acid in chickens under fasting and nonfasting conditions and the correlation with in vitro dissolution. 2001 , 24, 333-41	1
2180	Drug delivery: an odyssey of 100 years. 2001 , 5, 439-46	52
2179	Prediction of pharmacokinetic properties using experimental approaches during early drug discovery. 2001 , 5, 452-63	98
2178	Cyclodextrin complexes of salts of acidic drugs. Thermodynamic properties, structural features, and pharmaceutical applications. 2001 , 90, 979-86	89

2177	In vitro-in vivo correlation (IVIVC) models for metformin after administration of modified-release (MR) oral dosage forms to healthy human volunteers. 2001 , 90, 1176-85		53
2176	Effect of common excipients on Caco-2 transport of low-permeability drugs. 2001 , 90, 1776-86		141
2175	High throughput physicochemical profiling for drug discovery. 2001 , 90, 1838-58		269
2174	Regional-dependent intestinal absorption and meal composition effects on systemic availability of LY303366, a lipopeptide antifungal agent, in dogs. 2001 , 90, 47-57		32
2173	Wetting behavior of bile salt-lipid dispersions and dissolution media patterned after intestinal fluids. 2001 , 90, 348-59		26
2172	Human jejunal permeability of two polar drugs: cimetidine and ranitidine. <i>Pharmaceutical Research</i> , 2001 , 18, 742-4	4-5	47
2171	Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. <i>Pharmaceutical Research</i> , 2001 , 18, 380-8	4-5	155
2170	The rate and extent of oral bioavailability versus the rate and extent of oral absorption: clarification and recommendation of terminology. 2001 , 28, 3-6		30
2169	Time-dependent oral absorption models. 2001 , 28, 109-28		35
2168	Bioavailability and bioequivalence: an FDA regulatory overview. <i>Pharmaceutical Research</i> , 2001 , 18, 1645-50	4-5	119
2167	Predictive ability of level A in vitro-in vivo correlation for ringcap controlled-release acetaminophen tablets. <i>Pharmaceutical Research</i> , 2001 , 18, 1729-34	4-5	16
2166	Influence of drug release properties of conventional solid dosage forms on the systemic exposure of highly soluble drugs. 2001 , 3, E24		14
2165	Correlation of in vitro and in vivo acetaminophen availability from albumin microaggregates oral modified release formulations. 2001 , 217, 193-9		5
2164	Caco-2 monolayers in experimental and theoretical predictions of drug transport. 2001 , 46, 27-43		1005
2163	In vitro assessment of oral lipid based formulations. 2001 , 50 Suppl 1, S127-47		292
2162	Direct estimation of the in vivo dissolution of spironolactone, in two particle size ranges, using the single-pass perfusion technique (Loc-I-Gut) in humans. 2001 , 12, 239-50		33
2161	Determination of the passive absorption through the rat intestine using chromatographic indices and molar volume. 2001 , 12, 223-9		62
2160	A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. 2001 , 14, 115-22		231

2159	A dynamic in vitro lipolysis model. II: Evaluation of the model. 2001 , 14, 237-44	167
2158	High throughput prediction of oral absorption: improvement of the composition of the lipid solution used in parallel artificial membrane permeation assay. 2001 , 6, 189-96	169
2157	Human peptide transporters: therapeutic applications. 2002 , 12, 1329-1350	46
2156	Effect of physicochemical and formulation variables on the in vivo absorption of ABT-761. 2002 , 28, 287-95	3
2155	Analysis and prediction of absorption behavior for theophylline orally administered as powders based on gastrointestinal-transit-absorption (Gita) model. 2002 , 17, 307-15	13
2154	Intestinal metabolism promotes regional differences in apical uptake of indinavir: coupled effect of P-glycoprotein and cytochrome P450 3A on indinavir membrane permeability in rat. 2002 , 301, 586-93	45
2153	Gastrointestinal transit and drug absorption. 2002 , 25, 149-64	148
2152	A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. 2002 , 42, 620-43	392
2151	Predicting drug absorption: how nature made it a difficult problem. 2002 , 303, 889-95	88
2150	Theoretical predictions of drug absorption in drug discovery and development. 2002 , 41, 877-99	48
2149	In vitro evaluation of microcrystalline chitosan (MCCh) as gel-forming excipient in matrix granules. 2002 , 54, 33-40	23
2148	Effect of bovine serum albumin on drug permeability estimation across Caco-2 monolayers. 2002 , 54, 319-24	66
2147	Enantioselective analytical methods in pharmacokinetics with specific reference to genetic polymorphic metabolism. 2002 , 54, 57-70	17
2146	Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. 2002 , 22, 154-9	65
2145	Application of hydrogen bonding calculations in property based drug design. 2002 , 7, 1056-63	148
2144	In vitro simulation of food effect on dissolution of deramciclone film-coated tablets and correlation with in vivo data in healthy volunteers. 2002 , 15, 157-62	13
2143	The effect of amiloride on the in vivo effective permeability of amoxicillin in human jejunum: experience from a regional perfusion technique. 2002 , 15, 271-7	73
2142	Optimized conditions for MDCK permeability and turbidimetric solubility studies using compounds representative of BCS classes I-IV. 2002 , 15, 331-40	53

2141	In silico prediction of ADME and pharmacokinetics. Report of an expert meeting organised by COST B15. 2002 , 17, 183-93		119
2140	[The power of packaging. NSAID: concepts for dosage form optimization]. 2002 , 31, 170-8		
2139	Tacrolimus is a class II low-solubility high-permeability drug: the effect of P-glycoprotein efflux on regional permeability of tacrolimus in rats. 2002 , 91, 719-29		104
2138	A new method for characterizing the release of drugs from tablets in low liquid surroundings. 2002 , 91, 776-84		22
2137	Characterization of the interaction of 2-hydroxypropyl-beta-cyclodextrin with itraconazole at pH 2, 4, and 7. 2002 , 91, 1414-22		206
2136	Development and validation of a non-linear IVIVC model for a diltiazem extended release formulation. 2002 , 23, 1-8		40
2135	Complete bioavailability and lack of food-effect on pharmacokinetics of gliclazide 30 mg modified release in healthy volunteers. 2002 , 23, 151-7		39
2134	Non-linear mixed effects modeling of sparse concentration data from rats: application to a glycogen phosphorylase inhibitor. 2002 , 27, 203-12		1
2133	Challenges associated with the evaluation of veterinary product bioequivalence: an AAVPT perspective. 2002 , 25, 201-20		6
2132	Development of level A, B and C in vitro-in vivo correlations for modified-release levosimendan capsules. 2002 , 241, 87-95		20
2131	Factors affecting incorporation of drug into solid solution with HPMCP during solvent change co-precipitation. 2002 , 245, 99-108		32
2130	Effect of moisture on polyvinylpyrrolidone in accelerated stability testing. 2002 , 246, 143-51		89
2129	Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781. 2002 , 234, 113-9		23
2128	Intestinal transport of cefuroxime axetil in rats: absorption and hydrolysis processes. 2002 , 234, 101-11		28
2127	Drug disposition viewed in terms of the fractal volume of distribution. <i>Pharmaceutical Research</i> , 2002 , 19, 696-703	4-5	18
2126	Thermal Properties of Hot-Stage Extrudates of Itraconazole and Eudragit E100. Phase separation and polymorphism. 2002 , 68, 591-601		55
2125	Improvement of dissolution rates of poorly water soluble APIs using novel spray freezing into liquid technology. <i>Pharmaceutical Research</i> , 2002 , 19, 1278-84	4-5	93
2124	Rate-limited steps of human oral absorption and QSAR studies. <i>Pharmaceutical Research</i> , 2002 , 19, 1446-53		465

2123	Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. <i>Pharmaceutical Research</i> , 2002 , 19, 1400-16	4.5	305
2122	Human jejunal permeability of cyclosporin A: influence of surfactants on P-glycoprotein efflux in Caco-2 cells. <i>Pharmaceutical Research</i> , 2003 , 20, 749-56	4.5	82
2121	Absorption rate limit considerations for oral phosphate prodrugs. <i>Pharmaceutical Research</i> , 2003 , 20, 848-56	4.5	64
2120	Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion, Part II. <i>Pharmaceutical Research</i> , 2003 , 20, 1047-54	4.5	98
2119	In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs. <i>Pharmaceutical Research</i> , 2003 , 20, 1674-80	4.5	116
2118	Quantitative biopharmaceutics classification system: the central role of dose/solubility ratio. <i>Pharmaceutical Research</i> , 2003 , 20, 1917-25	4.5	112
2117	Development of a 7-day, 96-well Caco-2 permeability assay with high-throughput direct UV compound analysis. <i>Pharmaceutical Research</i> , 2003 , 20, 1961-9	4.5	74
2116	Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption. <i>Pharmaceutical Research</i> , 2003 , 20, 1984-8	4.5	62
2115	The composite solubility versus pH profile and its role in intestinal absorption prediction. 2003 , 5, E4		52
2114	Implications of density correction in gravimetric method for water flux determination using rat single-pass intestinal perfusion technique: a technical note. 2003 , 4, E16		29
2113	Identification of phase separation in solid dispersions of itraconazole and Eudragit E100 using microthermal analysis. <i>Pharmaceutical Research</i> , 2003 , 20, 135-8	4.5	60
2112	The mean dissolution time depends on the dose/solubility ratio. <i>Pharmaceutical Research</i> , 2003 , 20, 406-8.5	4.5	64
2111	Permeability of porcine nasal mucosa correlated with human nasal absorption. 2003 , 18, 47-53		32
2110	Enantioselective transport and CYP3A4-mediated metabolism of R/S-verapamil in Caco-2 cell monolayers. 2003 , 19, 57-65		19
2109	Do cell culture conditions influence the carrier-mediated transport of peptides in Caco-2 cell monolayers?. 2003 , 19, 433-42		95
2108	Spray freezing into liquid (SFL) particle engineering technology to enhance dissolution of poorly water soluble drugs: organic solvent versus organic/aqueous co-solvent systems. 2003 , 20, 295-303		107
2107	Development and evaluation of bio-dissolution systems capable of detecting the food effect on a polysaccharide-based matrix system. 2003 , 93, 309-18		23
2106	A computational model for particle size influence on drug absorption during controlled-release colonic delivery. 2003 , 86, 293-304		24

2105	Combinatorial use of sodium laurate with taurine or L-glutamine enhances colonic absorption of rebamipide, poorly absorbable antiulcer drug, without any serious histopathological mucosal damages. 2003 , 92, 911-21	24
2104	General pharmaceuticals--the new physical pharmacy. 2003 , 92, 1331-42	22
2103	Pulmonary absorption rate and bioavailability of drugs in vivo in rats: structure-absorption relationships and physicochemical profiling of inhaled drugs. 2003 , 92, 1216-33	106
2102	Characterization of dexloxiglumide in vitro biopharmaceutical properties and active transport. 2003 , 92, 1968-80	10
2101	Characterization of a quaternary liquid system improving the bioavailability of poorly water soluble drugs. 2003 , 263, 590-6	16
2100	Thermodynamic dissociation constants of silychristin, silybin, silydianin and mycophenolate by the regression analysis of spectrophotometric data. 2003 , 486, 125-141	32
2099	Microwave generated nanocomposites for making insoluble drugs soluble. 2003 , 23, 791-795	39
2098	In vivo evaluation of matrix granules containing microcrystalline chitosan as a gel-forming excipient. 2003 , 250, 227-37	28
2097	Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion--Part I. 2003 , 251, 165-74	166
2096	Effect of buffer media composition on the solubility and effective permeability coefficient of ibuprofen. 2003 , 253, 49-59	91
2095	Prediction of human intestinal permeability using artificial membrane permeability. 2003 , 257, 245-51	101
2094	Hydrogen bonding descriptors in the prediction of human in vivo intestinal permeability. 2003 , 21, 273-87	87
2093	The effect of ketoconazole on the in vivo intestinal permeability of fexofenadine using a regional perfusion technique. 2003 , 55, 182-90	60
2092	Gastric function measurements in drug development. 2003 , 56, 156-64	10
2091	Predicting Passive Intestinal Absorption Using A Single Parameter. 2003 , 22, 247-257	14
2090	Estimation of Aqueous Solubility By The General Solubility Equation (GSE) The Easy Way. 2003 , 22, 258-262	39
2089	A compaction process to enhance dissolution of poorly water-soluble drugs using hydroxypropyl methylcellulose. 2003 , 250, 3-11	49
2088	Comparison of dissolution profiles for albendazole tablets using USP apparatus 2 and 4. 2003 , 29, 777-84	13

2087	Clinical pharmacokinetics of atorvastatin. 2003 , 42, 1141-60	391
2086	Pharmacokinetic strategies in deciphering atypical drug absorption profiles. 2003 , 43, 211-27	100
2085	Absorption and metabolism of glycosidic sweeteners of stevia mixture and their aglycone, steviol, in rats and humans. 2003 , 41, 875-83	96
2084	Development pharmaceuticals of microbicide formulations. Part I: preformulation considerations and challenges. 2003 , 17, 17-32	37
2083	Enhanced bioavailability of piroxicam using Gelucire 44/14 and labrasol: in vitro and in vivo evaluation. 2003 , 56, 453-9	100
2082	The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy. 2003 , 43, 52-8	16
2081	Minimizing bioavailability variations with oral controlled release formulations. 2003 , 1, 103-112	1
2080	In silico tools for drug absorption prediction. 2003 , 1, 133-148	3
2079	DRUG SOLUBILIZATION WITH ORGANIC SOLVENTS, SURFACTANTS AND LIPIDS. 2003 , 631-648	
2078	Predicting oral absorption and bioavailability. 2003 , 41, 1-59	26
2077	Design of experiment (DOE) methods maximize information from a minimal number of animals in special cases of preclinical bioavailability testing. 2003 , 8, 453-8	3
2076	DISCOVER A DRUG SUBSTANCE, FORMULATE AND DEVELOP IT TO A PRODUCT. 2003 , 687-695	1
2075	Differentiation of gut and hepatic first-pass loss of verapamil in intestinal and vascular access-ported (IVAP) rabbits. 2004 , 32, 1293-8	18
2074	Prodrugs of bisthiazolium salts are orally potent antimalarials. 2004 , 101, 15458-63	101
2073	Pharmacokinetics of carbamazepine from extended release dosage forms: bioavailability/bioequivalence and in vitro-in vivo correlation studies. 2004 , 14, 401-407	1
2072	Rapid release tablet formulation of micronized danazol powder produced by spray-freezing into liquid (SFL). 2004 , 14, 305-311	5
2071	Time delay avoids interaction between guar gum and sulphadiazine after oral administration. 2004 , 14, 395-399	2
2070	Biopharmaceutics classification by high throughput solubility assay and PAMPA. 2004 , 30, 181-5	48

2069	Cyclodextrin-based pharmaceuticals: past, present and future. 2004 , 3, 1023-35		1386
2068	Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine. 2004 , 99, 63-71		18
2067	A new approach to the in vivo and in vitro investigation of drug release from locoregionally delivered microspheres. 2004 , 100, 121-33		26
2066	A stochastic differential equation model for drug dissolution and its parameters. 2004 , 100, 267-74		13
2065	Multiple level C in vitro/in vivo correlation of dissolution profiles of two L-thyroxine tablets with pharmacokinetics data obtained from patients treated for hypothyroidism. 2004 , 21, 655-60		19
2064	Solid-state characterization of rifampicin samples and its biopharmaceutic relevance. 2004 , 22, 127-44		108
2063	Food effects on tablet disintegration. 2004 , 22, 165-72		92
2062	Biowaiver extension potential to BCS Class III high solubility-low permeability drugs: bridging evidence for metformin immediate-release tablet. 2004 , 22, 297-304		96
2061	Improvement of gliquidone hypoglycaemic effect in rats by cyclodextrin formulations. 2004 , 23, 57-64		12
2060	Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. 2004 , 23, 287-96		158
2059	Prodrug research: futile or fertile?. 2004 , 68, 2097-106		94
2058	Permeability classification of representative fluoroquinolones by a cell culture method. 2004 , 6, 1-6		81
2057	The "high solubility" definition of the current FDA Guidance on Biopharmaceutical Classification System may be too strict for acidic drugs. <i>Pharmaceutical Research</i> , 2004 , 21, 293-9	4.5	194
2056	Identification of biowaivers among Class II drugs: theoretical justification and practical examples. <i>Pharmaceutical Research</i> , 2004 , 21, 1567-72	4.5	59
2055	Effects of extracts of commonly consumed food supplements and food fractions on the permeability of drugs across Caco-2 cell monolayers. <i>Pharmaceutical Research</i> , 2004 , 21, 1904-16	4.5	23
2054	Drug delivery to the small intestine. 2004 , 6, 371-6		22
2053	Verbesserte Therapie durch optimierte Arzneiformen?: Schnelle Freisetzung oder Retardformulierung?. 2004 , 33, 456-465		0
2052	Increased physical stability and improved dissolution properties of itraconazole, a class II drug, by solid dispersions that combine fast- and slow-dissolving polymers. 2004 , 93, 124-31		185

2051	Partial characterization of different mixtures of solids by measuring the optical nonlinear response. 2004, 93, 733-42	11
2050	In vitro nimesulide absorption from different formulations. 2004, 93, 540-52	22
2049	The use of three different solid dispersion formulations--melt extrusion, film-coated beads, and a glass thermoplastic system--to improve the bioavailability of a novel microsomal triglyceride transfer protein inhibitor. 2004, 93, 1217-28	25
2048	Variation of peptide transporter (PepT1 and HPT1) expression in Caco-2 cells as a function of cell origin. 2004, 93, 1743-54	46
2047	Comparative bioavailability study in dogs of a self-emulsifying formulation of progesterone presented in a pellet and liquid form compared with an aqueous suspension of progesterone. 2004, 93, 1495-502	54
2046	Analytical derivation of time required for dissolution of monodisperse drug particles. 2004, 93, 1941-4	4
2045	Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. 2004, 93, 1945-56	112
2044	Importance of using physiologically relevant volume of dissolution medium to correlate the oral exposure of formulations of BMS-480188 mesylate. 2004, 269, 195-202	16
2043	Feasibility studies of utilizing disk intrinsic dissolution rate to classify drugs. 2004, 270, 221-7	138
2042	Influence of chitosan and its glutamate and hydrochloride salts on naproxen dissolution rate and permeation across Caco-2 cells. 2004, 271, 257-67	54
2041	The effect of solubilization on the oral bioavailability of three benzimidazole carbamate drugs. 2004, 272, 29-36	75
2040	Pharmaceutical evaluation of early development candidates "the 100 mg-approach". 2004, 275, 1-12	114
2039	Dissolution test as a surrogate for quality evaluation of rifampicin containing fixed dose combination formulations. 2004, 287, 97-112	27
2038	Solution calorimetry as a tool for investigating drug interaction with intestinal fluid. 2004, 419, 259-266	6
2037	Valproic acid-hydrophilic cyclodextrin complexes and valproic acid-solid dispersions: evaluation of their potential pharmaceutical use. 2004, 30, 53-64	7
2036	Melting of Nanostructured Drugs Embedded into a Polymeric Matrix. 2004, 108, 15488-15493	26
2035	Global Regulatory And Biopharmaceutics Strategies In New Drug Development: Biowaivers. 2004, 225-243	
2034	Factors affecting mechanism and kinetics of drug release from matrix-based oral controlled drug delivery systems. 2004, 2, 43-57	106

2033	Biowaivers for oral immediate-release products: implications of linear pharmacokinetics. 2004 , 43, 1117-26	12
2032	Characterization of an active pharmaceutical ingredient by its dissolution properties: amoxicillin trihydrate as a model drug. 2004 , 50, 234-44	7
2031	Role of cyclodextrins in improving oral drug delivery. 2004 , 2, 261-275	205
2030	Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. 2004 , 58, 173-82	854
2029	A possibility to predict the absorbability of poorly water-soluble drugs in humans based on rat intestinal permeability assessed by an in vitro chamber method. 2004 , 58, 659-65	53
2028	The thermodynamic dissociation constants of ambroxol, antazoline, naphazoline, oxymetazoline and ranitidine by the regression analysis of spectrophotometric data. 2004 , 62, 511-22	38
2027	Characterization of jejunal absorption and apical efflux of ropivacaine, lidocaine and bupivacaine in the rat using in situ and in vitro absorption models. 2004 , 21, 553-60	62
2026	Development and evaluation of glyburide fast dissolving tablets using solid dispersion technique. 2004 , 30, 525-34	63
2025	Classification of loratadine based on the biopharmaceutics drug classification concept and possible in vitro-in vivo correlation. 2004 , 27, 1630-5	42
2024	Short term Caco-2/TC7 cell culture: comparison between conventional 21-d and a commercially available 3-d system. 2004 , 27, 1986-92	22
2023	The effect of clodronate on the integrity and viability of rat small intestine in vitro-a comparison with EDTA. 2005 , 28, 1249-53	2
2022	Dissolution Method Development. 2005 , 351-372	1
2021	LC-MS/MS in der Wirkstoffsuche. 2005 , 53, 917-920	
2020	pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs 1. Simultaneous determination of quinidine and permeability markers in rat in situ perfusion samples. 2005 , 816, 243-9	17
2019	Sustained release of lidocaine from Poloxamer 407 gels. 2005 , 288, 235-44	170
2018	Effect of adsorbents on the absorption of lansoprazole with surfactant. 2005 , 289, 69-77	53
2017	An investigation of the disintegration of tablets in biorelevant media. 2005 , 290, 121-7	38
2016	Novel lipid-based formulations enhancing the in vitro dissolution and permeability characteristics of a poorly water-soluble model drug, piroxicam. 2005 , 301, 209-16	74

2015	Stabilizer choice for rapid dissolving high potency itraconazole particles formed by evaporative precipitation into aqueous solution. 2005 , 302, 113-24	46
2014	Unbiased membrane permeability parameters for gabapentin using boundary layer approach. 2005 , 7, E224-30	15
2013	Drug compounding for veterinary patients. 2005 , 7, E281-7	31
2012	Generalization of a prototype intelligent hybrid system for hard gelatin capsule formulation development. 2005 , 6, E449-57	11
2011	Adsorption of meloxicam on porous calcium silicate: characterization and tablet formulation. 2005 , 6, E618-25	55
2010	The crystal structure and physicochemical characteristics of 2-hydroxy-N-[3(5)-pyrazolyl]-1,4-naphthoquinone-4-imine, a new antitrypanosomal compound. 2005 , 6, E655-63	10
2009	Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport. 2005 , 2, 12-21	122
2008	In silico predictions of drug solubility and permeability: two rate-limiting barriers to oral drug absorption. 2005 , 96, 156-61	49
2007	Modeling and Monte Carlo simulations in oral drug absorption. 2005 , 96, 200-5	14
2006	In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. 2005 , 24, 115-22	44
2005	Clinical study of solid dispersions of itraconazole prepared by hot-stage extrusion. 2005 , 24, 179-86	126
2004	Effect of liquid volume and food intake on the absolute bioavailability of danazol, a poorly soluble drug. 2005 , 24, 297-303	89
2003	In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. 2005 , 24, 305-13	127
2002	Correlation between the release characteristics of theophylline and the free volume of polyvinylpyrrolidone. 2005 , 24, 351-4	20
2001	Fast-dissolving mucoadhesive microparticulate delivery system containing piroxicam. 2005 , 24, 355-61	28
2000	Transfer of lipophilic drugs between liposomal membranes and biological interfaces: consequences for drug delivery. 2005 , 26, 251-65	141
1999	Canine versus in vitro data for predicting input profiles of L-sulpiride after oral administration. 2005 , 26, 324-33	44
1998	Enhancement of dissolution rate of piroxicam using liquisolid compacts. 2005 , 60, 361-5	71

1997	Improved solubility and dissolution rate of piroxicam using gelucire 44/14 and labrasol. 2005 , 60, 777-82	57
1996	Assessment of the feasibility of oral controlled release in an exploratory development setting. 2005 , 10, 1159-66	53
1995	Oral solid gentamicin preparation using emulsifier and adsorbent. 2005 , 105, 23-31	78
1994	Development of a glyburide-metformin fixed combination tablet with optimized glyburide particle size. 2005 , 66, 25-35	1
1993	Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. 2005 , 26, 321-34	41
1992	Influence of the intermediate digestion phases of common formulation lipids on the absorption of a poorly water-soluble drug. 2005 , 94, 481-92	81
1991	Trends in solubility of polymorphs. 2005 , 94, 929-39	347
1990	Comparison of statistical analysis and Bayesian Networks in the evaluation of dissolution performance of BCS Class II model drugs. 2005 , 94, 2764-76	18
1989	IV-IVC considerations in the development of immediate-release oral dosage form. 2005 , 94, 1396-417	42
1988	Bioavailability of seocalcitol I: Relating solubility in biorelevant media with oral bioavailability in rats--effect of medium and long chain triglycerides. 2005 , 94, 1830-8	43
1987	The influence of thermal and mechanical preparative techniques on the amorphous state of four poorly soluble compounds. 2005 , 94, 1998-2012	113
1986	Biowaiver monographs for immediate release solid oral dosage forms: ibuprofen. 2005 , 94, 2121-31	161
1985	Cationic analog of deoxycholate as an oral delivery carrier for ceftriaxone. 2005 , 94, 2541-8	21
1984	pH-dependent functional activity of P-glycoprotein in limiting intestinal absorption of protic drugs: kinetic analysis of quinidine efflux in situ. 2005 , 94, 2632-43	23
1983	Determination of the optical second harmonic response of pharmaceutical solid-solid mixtures. 2005 , 43, 209-220	13
1982	Evaluation of in-vitro dissolution and in-vivo absorption for two different film-coated pellets of clarithromycin. 2005 , 28, 977-82	10
1981	pH-dependent dissolution in vitro and absorption in vivo of weakly basic drugs: development of a canine model. <i>Pharmaceutical Research</i> , 2005 , 22, 188-92	4.5 99
1980	Predicting drug disposition via application of BCS: transport/absorption/ elimination interplay and development of a biopharmaceutics drug disposition classification system. <i>Pharmaceutical Research</i> , 2005 , 22, 11-23	4.5 1062

1979	The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. <i>Pharmaceutical Research</i> , 2005 , 22, 2141-51	4.5	226
1978	Pharmaceutical formulations of nimesulide. 2005 , 121-132		
1977	MDR1 genotype-related pharmacokinetics: fact or fiction?. 2005 , 20, 391-414		117
1976	Prediction of absorbability of poorly water-soluble drugs based on permeability obtained through modified in vitro chamber method. 2005 , 20, 428-34		3
1975	Increased dissolution rate and bioavailability through comiconization with microcrystalline cellulose. 2005 , 10, 451-60		11
1974	Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions. 2005 , 31, 917-22		59
1973	17 LC/MS application in high-throughput adme screen. 2005 , 413-446		1
1972	Absorption enhancement, mechanistic and toxicity studies of medium chain fatty acids, cyclodextrins and bile salts as peroral absorption enhancers. 2005 , 60, 884-93		50
1971	Cyclodextrins in drug delivery. 2005 , 2, 335-51		507
1970	Oral sustained delivery of atenolol from floating matrix tablets-formulation and in vitro evaluation. 2005 , 31, 367-74		26
1969	Use of nonlinear mixed effect modeling for the intestinal absorption data: application to ritonavir in the rat. 2005 , 61, 20-6		13
1968	Design of biodegradable nanoparticles: a novel approach to encapsulating poorly soluble phytochemical ellagic acid. 2005 , 16, 2819-2822		60
1967	Characterization of the absorption of theophylline from immediate- and controlled-release dosage forms with a numerical approach using the in vitro dissolution-permeation process using caco-2 cells. 2005 , 31, 397-404		2
1966	The rise of PAMPA. 2005 , 1, 325-42		140
1965	Computational models to predict aqueous drug solubility, permeability and intestinal absorption. 2005 , 1, 613-27		26
1964	High-throughput physicochemical and in vitro ADMET screening. 2005 , 3, 83-100		14
1963	PHARMACEUTICAL ANALYSIS Dissolution Testing. 2005 , 101-106		1
1962	Cell culture models of the respiratory tract relevant to pulmonary drug delivery. 2005 , 18, 137-82		116

1961	Oral delivery of hematopoietic factors. 2006 , 4, 65-77	3
1960	Use of simulated intestinal fluids with Caco-2 cells and rat ileum. 2006 , 32, 151-61	46
1959	Mixed-micellar proliposomal systems for enhanced oral delivery of progesterone. 2006 , 13, 227-32	38
1958	Strategies to assess the drug interaction potential in translational medicine. 2006 , 2, 675-86	2
1957	Maleic- and fumaric-diamides of (O,O-diacetyl)-L-Dopa-methylester as anti-Parkinson prodrugs in liposomal formulation. 2006 , 14, 652-61	26
1956	Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. 2006 , 45, 385-99	38
1955	Recent progress in the computational prediction of aqueous solubility and absorption. 2006 , 8, E27-40	80
1954	Promoting absorption of drugs in humans using medium-chain fatty acid-based solid dosage forms: GIPET. 2006 , 3, 685-92	88
1953	A cell-based molecular transport simulator for pharmacokinetic prediction and cheminformatic exploration. 2006 , 3, 704-16	33
1952	Rapid identification of P-glycoprotein substrates and inhibitors. 2006 , 34, 1976-84	127
1951	The road map to oral bioavailability: an industrial perspective. 2006 , 2, 591-608	114
1950	Intestinal permeability of metformin using single-pass intestinal perfusion in rats. 2006 , 12, 4064-70	66
1949	Analysis of the release process of phenylpropanolamine hydrochloride from ethylcellulose matrix granules III. Effects of the dissolution condition on the release process. 2006 , 54, 1091-6	7
1948	Therapeutic drug monitoring of itraconazole and the relevance of pharmacokinetic interactions. 2006 , 12, 97-106	26
1947	The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. 2006 , 29, 191-7	30
1946	Mucosal permeability of water-soluble drugs in the equine jejunum: a preliminary investigation. 2006 , 29, 379-85	26
1945	Comparison of bovine in vivo bioavailability of two sulfamethazine oral boluses exhibiting different in vitro dissolution profiles. 2006 , 29, 459-67	3
1944	Prediction of human absorption of natural compounds by the non-everted rat intestinal sac model. 2006 , 41, 605-10	111

1943	Microemulsions as transdermal drug delivery vehicles. 2006 , 123-126, 369-85		447
1942	Modelling intestinal absorption of salbutamol sulphate in rats. 2006 , 314, 21-30		4
1941	Evaluation of Inutec SP1 as a new carrier in the formulation of solid dispersions for poorly soluble drugs. 2006 , 316, 1-6		73
1940	Preparation and evaluation of oral solid heparin using emulsifier and adsorbent for in vitro and in vivo studies. 2006 , 317, 114-9		43
1939	Evaluation of melt granulation and ultrasonic spray congealing as techniques to enhance the dissolution of praziquantel. 2006 , 318, 92-102		118
1938	The effects of surfactants on the dissolution profiles of poorly water-soluble acidic drugs. 2006 , 321, 35-41		85
1937	A century of dissolution research: from Noyes and Whitney to the biopharmaceutics classification system. 2006 , 321, 1-11		467
1936	Infrared study of the acidic and basic forms of betaxolol. 2006 , 64, 279-86		11
1935	Quantitation of drug content in a low dosage formulation by transmission near infrared spectroscopy. 2006 , 7, E29		77
1934	Intragastric floating drug delivery system of cefuroxime axetil: in vitro evaluation. 2006 , 7, E17		99
1933	In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery. 2006 , 58, 1030-60		257
1932	Quantitative structure-pharmacokinetic/pharmacodynamic relationships. 2006 , 58, 1326-56		68
1931	Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. <i>Pharmaceutical Research</i> , 2006 , 23, 165-76	4.5	486
1930	Advances in the use of tocals as drug delivery vehicles. <i>Pharmaceutical Research</i> , 2006 , 23, 243-55	4.5	117
1929	Adaptive neuro-fuzzy modeling of poorly soluble drug formulations. <i>Pharmaceutical Research</i> , 2006 , 23, 1157-64	4.5	7
1928	Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. <i>Pharmaceutical Research</i> , 2006 , 23, 1373-81	4.5	130
1927	Development of an in vitro rat intestine segmental perfusion model to investigate permeability and predict oral fraction absorbed. <i>Pharmaceutical Research</i> , 2006 , 23, 1543-53	4.5	6
1926	Mass transport properties of progesterone and estradiol in model microemulsion formulations. <i>Pharmaceutical Research</i> , 2006 , 23, 2482-90	4.5	11

1925	Use of a glutaric acid cocrystal to improve oral bioavailability of a low solubility API. <i>Pharmaceutical Research</i> , 2006 , 23, 1888-97	4.5	556
1924	Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. <i>Pharmaceutical Research</i> , 2006 , 23, 1675-86	4.5	293
1923	Use of a dynamic in vitro lipolysis model to rationalize oral formulation development for poor water soluble drugs: correlation with in vivo data and the relationship to intra-enterocyte processes in rats. <i>Pharmaceutical Research</i> , 2006 , 23, 2165-74	4.5	160
1922	A modern view of excipient effects on bioequivalence: case study of sorbitol. <i>Pharmaceutical Research</i> , 2007 , 24, 73-80	4.5	62
1921	A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. <i>Pharmaceutical Research</i> , 2006 , 23, 742-51	4.5	66
1920	Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide. 2006 , 33, 441-59		13
1919	Comparative analysis of the effects of rice and bread meals on bioavailability of itraconazole using NONMEM in healthy volunteers. 2006 , 62, 1033-9		10
1918	Characterization of itraconazole semisolid dosage forms prepared by hot melt technique. 2006 , 29, 1055-60		14
1917	A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study. 2006 , 27, 91-9		94
1916	Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy. 2006 , 28, 1-6		36
1915	Bioavailability of seocalcitol II: development and characterisation of self-microemulsifying drug delivery systems (SMEDDS) for oral administration containing medium and long chain triglycerides. 2006 , 28, 233-42		91
1914	Review of global regulations concerning biowaivers for immediate release solid oral dosage forms. 2006 , 29, 315-24		50
1913	Biorelevant dissolution media as a predictive tool for glyburide a class II drug. 2006 , 29, 45-52		99
1912	Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. 2006 , 29, 306-14		89
1911	A new self-emulsifying formulation of itraconazole with improved dissolution and oral absorption. 2006 , 110, 332-338		163
1910	Novel oral formulation safely improving intestinal absorption of poorly absorbable drugs: utilization of polyamines and bile acids. 2006 , 111, 27-34		34
1909	Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. 2006 , 111, 56-64		367
1908	Critical freezing rate in freeze drying nanocrystal dispersions. 2006 , 111, 185-92		109

1907	Role of antioxidants in prophylaxis and therapy: A pharmaceutical perspective. 2006 , 113, 189-207	547
1906	Effects of renal failure on drug transport and metabolism. 2006 , 109, 1-11	214
1905	Lack of in vivo correlation between indinavir and saquinavir exposure and cytochrome P450 3A phenotype as assessed with oral midazolam as a phenotype probe. 2006 , 26, 1051-9	1
1904	Prediction of ADMET Properties. 2006 , 1, 920-37	128
1903	Biowaiver monographs for immediate release solid oral dosage forms: acetaminophen (paracetamol). 2006 , 95, 4-14	103
1902	Relative bioavailability estimation of carbamazepine crystal forms using an artificial stomach-duodenum model. 2006 , 95, 116-25	96
1901	Biowaiver monographs for immediate release solid oral dosage forms: cimetidine. 2006 , 95, 974-84	45
1900	Biowaiver monographs for immediate release solid oral dosage forms: amitriptyline hydrochloride. 2006 , 95, 966-73	40
1899	High throughput solubility measurement with automated polarized light microscopy analysis. 2006 , 95, 2115-22	49
1898	Preclinical drug metabolism and pharmacokinetic evaluation of GW844520, a novel anti-malarial mitochondrial electron transport inhibitor. 2006 , 95, 2657-72	40
1897	Corticosteroid microparticles produced by supercritical-assisted atomization: process optimization, product characterization, and "in vitro" performance. 2006 , 95, 2062-76	13
1896	Towards a universal dissolution medium for carbamazepine. 2006 , 32, 893-905	6
1895	First-pass effects of verapamil on the intestinal absorption and liver disposition of fexofenadine in the porcine model. 2006 , 34, 1182-9	34
1894	Lipophilic drug transfer between liposomal and biological membranes: what does it mean for parenteral and oral drug delivery?. 2006 , 16, 281-301	24
1893	Hit and Lead identification: efficient practices for drug discovery. 2007 , 45, 1-61	13
1892	Polymorphic change of a triglyceride base in hot melt coating process and stability acceleration by tempering process. 2007 , 17, 347-352	9
1891	Development of a multi-unit floating drug delivery system by hot melt coating technique with drug-lipid dispersion. 2007 , 17, 333-338	13
1890	Oral drug absorption and the Biopharmaceutics Classification System. 2007 , 17, 237-244	12

1889	Advantages and disadvantages of using bovine serum albumin and/or Cremophor EL as extracellular additives during transport studies of lipophilic compounds across Caco-2 monolayers. 2007 , 17, 259-266	4
1888	Cyclodextrins in ocular drug delivery: theoretical basis with dexamethasone as a sample drug. 2007 , 17, 3-9	39
1887	Dissolution and Solubility. 2007 , 399-423	13
1886	Solubility and dissolution profile assessment in drug discovery. 2007 , 22, 225-54	148
1885	Nonlinear intestinal pharmacokinetics of mitemincal, the first acid-resistant non-peptide motilin receptor agonist, in rats. 2007 , 37, 1421-32	5
1884	Enhanced oral bioavailability of piroxicam in rats by hyaluronate microspheres. 2007 , 33, 485-91	16
1883	Antiepileptic drug formulation and treatment in the elderly: biopharmaceutical considerations. 2007 , 81, 299-311	10
1882	Modelling and simulation in drug absorption processes. 2007 , 37, 1052-65	15
1881	Long-acting hydrocortisone for glucocorticoid replacement therapy. 2007 , 68 Suppl 5, 182-8	17
1880	Practical Aspects of Solubility Determination in Pharmaceutical Preformulation. 2007 , 137-149	2
1879	Magnesium hydroxide/aluminium hydroxide-containing antacid does not affect the pharmacokinetics of the targeted phosphodiesterase 4 inhibitor roflumilast. 2007 , 47, 660-6	16
1878	Analysis of the release process of phenylpropanolamine hydrochloride from ethylcellulose matrix granules IV.(1)) Evaluation of the controlled release properties for in vivo and in vitro release systems. 2007 , 55, 1569-73	4
1877	Improving the high variable bioavailability of griseofulvin by SEDDS. 2007 , 55, 1713-9	37
1876	[Safe improvement of drug absorption by combinatorial use of sodium laurate with amino acids: cytoprotection by amino acids and its mechanisms]. 2007 , 127, 589-99	1
1875	Physicochemical Properties in Drug Profiling. 2007 , 25-52	2
1874	Drug Ionization and Physicochemical Profiling. 2007 , 53-83	1
1873	H-Bonding Parameterization in Quantitative Structure-Activity Relationships and Drug Design. 2007 , 127-154	5
1872	Studies on dissolution enhancement and mathematical modeling of drug release of a poorly water-soluble drug using water-soluble carriers. 2007 , 65, 26-38	236

1871	Monolayers of porcine alveolar epithelial cells in primary culture as an in vitro model for drug absorption studies. 2007 , 66, 372-82	19
1870	A formulation comparison, using a solution and different nanosuspensions of a poorly soluble compound. 2007 , 67, 540-7	53
1869	Preparation of a novel freeze thawed poly(vinyl alcohol) composite hydrogel for drug delivery applications. 2007 , 67, 377-86	77
1868	Poly(ethylene oxide)-poly(propylene oxide) block copolymer micelles as drug delivery agents: improved hydrosolubility, stability and bioavailability of drugs. 2007 , 66, 303-17	460
1867	Predictive models for oral drug absorption: from in silico methods to integrated dynamical models. 2007 , 3, 491-505	36
1866	Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. 2007 , 3, 641-65	38
1865	Dissolution test for citalopram in tablets and comparison of in vitro dissolution profiles. 2007 , 67, 524-30	19
1864	Classification of Drug Permeability with a Caco-2 Cell Monolayer Assay. 2007 , 24, 39-47	45
1863	Preparation and characterization of solid dispersions of piroxicam with hydrophilic carriers. 2007 , 33, 45-56	60
1862	Current perspectives of solubilization: potential for improved bioavailability. 2007 , 33, 865-73	46
1861	The Biopharmaceutics Classification System. 2007 , 971-988	2
1860	Dissolution Methodology for Evaluation of Rifampicin-Containing Fixed-Dose Combinations Using Biopharmaceutic Classification System Based Approach. 2007 , 24, 61-76	1
1859	Fast-dissolving tablets of glyburide based on ternary solid dispersions with PEG 6000 and surfactants. 2007 , 14, 247-55	22
1858	Intestinal permeability and its relevance for absorption and elimination. 2007 , 37, 1015-51	211
1857	Artificial Membrane Technologies to Assess Transfer and Permeation of Drugs in Drug Discovery. 2007 , 453-487	12
1856	Influence of loading volume of mefenamic acid on granules and tablet characteristics using a compaction simulator. 2007 , 12, 627-35	5
1855	Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. 2007 , 82, 277-96	112
1854	Supercritical antisolvent versus coevaporation: preparation and characterization of solid dispersions. 2007 , 33, 975-83	6

1853	Design of potent amorphous drug nanoparticles for rapid generation of highly supersaturated media. 2007 , 4, 782-93	126
1852	Trends in active pharmaceutical ingredient salt selection based on analysis of the Orange Book database. 2007 , 50, 6665-72	188
1851	Overcoming Poor Aqueous Solubility of Drugs for Oral Delivery. 2007 , 157-215	17
1850	The Biology and Function of Transporters. 2007 , 51-85	4
1849	Prodrug Objectives and Design. 2007 , 1009-1041	6
1848	In Silico Models to Predict Oral Absorption. 2007 , 669-697	6
1847	In Silico Prediction of Oral Bioavailability. 2007 , 699-724	10
1846	Nanoporous and Nanosize Materials for Drug Delivery Systems. 2007 ,	2
1845	Passive Permeability and Active Transport Models for the Prediction of Oral Absorption. 2007 , 259-278	6
1844	Gut instincts: CYP3A4 and intestinal drug metabolism. 2007 , 117, 3173-6	74
1843	Permeability of atenolol and propranolol in the presence of dimethyl sulfoxide in rat single-pass intestinal perfusion assay with liquid chromatography/UV detection. 2007 , 21, 484-90	11
1842	Bioavailability and pharmacokinetic model for ritonavir in the rat. 2007 , 96, 633-43	7
1841	Development and validation of a preclinical food effect model. 2007 , 96, 459-72	70
1840	Biowaiver monographs for immediate release solid oral dosage forms: prednisolone. 2007 , 96, 27-37	48
1839	Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: in vitro/in vivo case studies. 2007 , 96, 235-48	144
1838	Conference report: Bio-International 2005. 2007 , 96, 747-54	21
1837	Biowaiver monographs for immediate release solid oral dosage forms: prednisone. 2007 , 96, 1480-9	32
1836	PQRI recommendations on particle-size analysis of drug substances used in oral dosage forms. 2007 , 96, 1451-67	9

1835	Predicting human drug pharmacokinetics from in vitro permeability using an absorption-disposition model. 2007 , 96, 2161-70	4
1834	Role of nanotechnology in pharmaceutical product development. 2007 , 96, 2547-65	145
1833	Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. 2007 , 96, 2686-702	272
1832	Development of a high throughput equilibrium solubility assay using miniaturized shake-flask method in early drug discovery. 2007 , 96, 3052-71	87
1831	Enhanced dissolution of oxcarbazepine microcrystals using a static mixer process. 2007 , 59, 208-14	9
1830	Freeze-casting technique in the development of solid drug delivery systems. 2007 , 46, 230-238	37
1829	Automated measurement of permeation and dissolution of propranolol HCl tablets using sequential injection analysis. 2007 , 581, 174-80	16
1828	Polymer-mediated disruption of drug crystallinity. 2007 , 336, 42-8	62
1827	Development and optimization of solid dispersion containing pellets of itraconazole prepared by high shear pelletization. 2007 , 337, 80-7	33
1826	Development and validation of dissolution test for ritonavir soft gelatin capsules based on in vivo data. 2007 , 338, 119-24	26
1825	Pharmacokinetics of gefitinib in humans: the influence of gastrointestinal factors. 2007 , 341, 134-42	50
1824	Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. 2007 , 342, 168-75	139
1823	Characterisation of colloidal drug delivery systems from the naked eye to Cryo-FESEM. 2007 , 38, 796-803	31
1822	Classification of alpha-cyclodextrins inclusion complexes into Type 1 and Type 2: a prelude to log K prediction. 2007 , 25, 731-9	3
1821	Does the preferred orientation of crystallites in tablets affect the intrinsic dissolution?. 2007 , 43, 1315-23	17
1820	Physicochemical profile of nimesulide. Exploring the interplay of lipophilicity, solubility and ionization. 2007 , 44, 57-62	22
1819	Determination of surface-adsorbed excipients of various types on drug particles prepared by antisolvent precipitation using HPLC with evaporative light scattering detection. 2007 , 44, 874-80	9
1818	Simple and universal HPLC-UV method to determine cimetidine, ranitidine, famotidine and nizatidine in urine: application to the analysis of ranitidine and its metabolites in human volunteers. 2007 , 860, 235-40	50

1817	P-glycoprotein-mediated transport of oxytetracycline in the Caco-2 cell model. 2007 , 30, 25-31	21
1816	Pharmacokinetics of dirloapid in the dog. 2007 , 30 Suppl 1, 24-32	6
1815	When do differences in dissolution profiles predict clinical problems?. 2007 , 32, 111-2	5
1814	A novel dissolution method relevant to intestinal release behaviour and its application in the evaluation of modified release mesalazine products. 2007 , 30, 15-20	42
1813	Pharmacokinetic simulation of biowaiver criteria: the effects of gastric emptying, dissolution, absorption and elimination rates. 2007 , 30, 155-66	67
1812	The use of a new hydrophilic polymer, Kollicoat IR, in the formulation of solid dispersions of Itraconazole. 2007 , 30, 288-94	52
1811	Stable carbamazepine colloidal systems using the cosolvent technique. 2007 , 30, 367-74	59
1810	Bioavailability of seocalcitol III. Administration of lipid-based formulations to minipigs in the fasted and fed state. 2007 , 31, 8-15	32
1809	When poor solubility becomes an issue: from early stage to proof of concept. 2007 , 31, 249-61	367
1808	In vitro and in vivo evaluation of a fast-disintegrating lyophilized dry emulsion tablet containing griseofulvin. 2007 , 32, 58-68	62
1807	A decision-support tool for the formulation of orally active, poorly soluble compounds. 2007 , 32, 128-39	54
1806	Improvement of dissolution rate of piroxicam by inclusion into MCM-41 mesoporous silicate. 2007 , 32, 216-22	79
1805	Enhanced bioavailability of metoclopramide HCl by intranasal administration of a mucoadhesive in situ gel with modulated rheological and mucociliary transport properties. 2007 , 32, 296-307	147
1804	The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: comparison between anesthetized and freely moving conscious rat models. 2007 , 32, 367-74	24
1803	Turbidimetric measurement and prediction of dissolution rates of poorly soluble drug nanocrystals. 2007 , 117, 351-9	60
1802	Prediction of oral absorption of griseofulvin, a BCS class II drug, based on GITA model: utilization of a more suitable medium for in-vitro dissolution study. 2007 , 119, 222-8	20
1801	Transport mechanisms of mmePEG750P(CL-co-TMC) polymeric micelles across the intestinal barrier. 2007 , 124, 134-43	76
1800	The Use of Solubilizing Excipients and Approaches to Generate Toxicology Vehicles for Contemporary Drug Pipelines. 2007 , 221-256	7

1799	High throughput solubility measurement in drug discovery and development. 2007 , 59, 546-67		278
1798	Estimating drug solubility in the gastrointestinal tract. 2007 , 59, 591-602		169
1797	Cyclodextrins as pharmaceutical solubilizers. 2007 , 59, 645-66		1355
1796	Process optimization and characterization of poloxamer solid dispersions of a poorly water-soluble drug. 2007 , 8, Article 29		39
1795	Monitoring ibuprofen release from multiparticulates: in situ fiber-optic technique versus the HPLC method: a technical note. 2007 , 8, E52		42
1794	Influence of a niosomal formulation on the oral bioavailability of acyclovir in rabbits. 2007 , 8, E106		84
1793	Bioavailability of boswellic acids: in vitro/in vivo correlation. 2007 , 41, 569-572		14
1792	Development of biodegradable nanoparticles for oral delivery of ellagic acid and evaluation of their antioxidant efficacy against cyclosporine A-induced nephrotoxicity in rats. <i>Pharmaceutical Research</i> , 2007 , 24, 899-908	4-5	110
1791	Predicting effect of food on extent of drug absorption based on physicochemical properties. <i>Pharmaceutical Research</i> , 2007 , 24, 1118-30	4-5	119
1790	Low dose lipid formulations: effects on gastric emptying and biliary secretion. <i>Pharmaceutical Research</i> , 2007 , 24, 2084-96	4-5	85
1789	Computational models to assign biopharmaceutics drug disposition classification from molecular structure. <i>Pharmaceutical Research</i> , 2007 , 24, 2249-62	4-5	51
1788	Dexamethasone delivery to posterior segment of the eye. 2007 , 57, 585-589		17
1787	Development of octanol membranes for drug screening. 2007 , 57, 613-617		5
1786	Comparison of the Wetting Properties of Three Commonly Used Simulated Intestinal Fluids Used as Dissolution Media in the Characterization of Drugs. 2007 , 36, 835-843		1
1785	Development and validation of RP-HPLC-UV method for simultaneous determination of buparvaquone, atenolol, propranolol, quinidine and verapamil: a tool for the standardization of rat in situ intestinal permeability studies. 2007 , 43, 1546-51		39
1784	Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data. 2008 , 47, 547-52		20
1783	Appearance of double peaks in plasma concentration-time profile after oral administration depends on gastric emptying profile and weight function. <i>Pharmaceutical Research</i> , 2008 , 25, 886-95	4-5	43
1782	Pharmaceutical quality by design: product and process development, understanding, and control. <i>Pharmaceutical Research</i> , 2008 , 25, 781-91	4-5	807

1781	The use of BDDCS in classifying the permeability of marketed drugs. <i>Pharmaceutical Research</i> , 2008 , 25, 483-8	4.5	111
1780	Polyethylene glycol 400 enhances the bioavailability of a BCS class III drug (ranitidine) in male subjects but not females. <i>Pharmaceutical Research</i> , 2008 , 25, 2327-33	4.5	69
1779	Bioavailability and bioequivalence: focus on physiological factors and variability. <i>Pharmaceutical Research</i> , 2008 , 25, 1956-62	4.5	34
1778	Miniaturized rotating disk intrinsic dissolution rate measurement: effects of buffer capacity in comparisons to traditional wood's apparatus. <i>Pharmaceutical Research</i> , 2008 , 25, 2613-27	4.5	89
1777	Investigation of the relationship between in vitro and in vivo release behaviors of acamprostate from enteric-coated tablets. 2008 , 31, 798-804		2
1776	Pharmacokinetics in drug discovery. 2008 , 97, 654-90		81
1775	Rapid throughput solubility screening method for BCS class II drugs in animal GI fluids and simulated human GI fluids using a 96-well format. 2008 , 97, 1427-42		17
1774	Physical and biological considerations for the use of nonaqueous solvents in oral bioavailability enhancement. 2008 , 97, 1071-88		14
1773	Oral delivery of antisense oligonucleotides in man. 2008 , 97, 225-36		87
1772	Characterization of ternary solid dispersions of itraconazole, PEG 6000, and HPMC 2910 E5. 2008 , 97, 2110-20		59
1771	Role of thermodynamic, molecular, and kinetic factors in crystallization from the amorphous state. 2008 , 97, 1329-49		328
1770	Engineering of pharmaceutical materials: an industrial perspective. 2008 , 97, 2855-77		105
1769	Design and characterization of a new miniaturized rotating disk equipment for in vitro dissolution rate studies. 2008 , 97, 3344-55		7
1768	Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed. 2008 , 97, 4815-29		33
1767	Formulation development and process scale up of a high shear wet granulation formulation containing a poorly wettable drug. 2008 , 97, 5274-89		12
1766	Proposal for a standardised identification of the mono-exponential terminal phase for orally administered drugs. 2008 , 29, 145-57		2
1765	Investigation on different levels of in vitro-in vivo correlation: gemfibrozil immediate release capsule. 2008 , 29, 349-55		4
1764	The assessment of absorption of periplocin in situ via intestinal perfusion of rats by HPLC. 2008 , 22, 196-201		7

1763	Viability and permeability across Caco-2 cells of CBZ solubilized in fully dilutable microemulsions. 2008 , 66, 1-12	25
1762	Orally bioavailable prodrugs of a BCS class 2 molecule, an inhibitor of HIV-1 reverse transcriptase. 2008 , 18, 6344-7	11
1761	Physicochemical properties of water and its effect on drug delivery. A commentary. 2008 , 354, 248-54	25
1760	An investigation of the thermodynamic miscibility between VeTPGS and polymers. 2008 , 350, 212-9	6
1759	Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. 2008 , 352, 36-43	17
1758	Nimodipine semi-solid capsules containing solid dispersion for improving dissolution. 2008 , 359, 144-9	39
1757	Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide. 2008 , 360, 213-8	83
1756	In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors. 2008 , 361, 19-25	57
1755	High bioavailability from nebulized itraconazole nanoparticle dispersions with biocompatible stabilizers. 2008 , 361, 177-88	95
1754	Biopharmaceutics classification systems for new molecular entities (BCS-NMEs) and marketed drugs (BCS-MD): theoretical basis and practical examples. 2008 , 361, 70-7	19
1753	Microwave generated solid dispersions containing Ibuprofen. 2008 , 361, 125-30	66
1752	The gastrointestinal microbiota as a site for the biotransformation of drugs. 2008 , 363, 1-25	449
1751	Hydrotalcite-like compounds: Versatile layered hosts of molecular anions with biological activity. 2008 , 107, 149-160	235
1750	Amorphous compositions using concentration enhancing polymers for improved bioavailability of itraconazole. 2008 , 5, 968-80	150
1749	FDA critical path initiatives: opportunities for generic drug development. 2008 , 10, 103-9	75
1748	Pharmacokinetically-guided lead optimization of nitrofuranylamide anti-tuberculosis agents. 2008 , 10, 157-65	29
1747	Use of the Biopharmaceutical Classification System in early drug development. 2008 , 10, 208-12	137
1746	Application of gastrointestinal simulation for extensions for biowaivers of highly permeable compounds. 2008 , 10, 213-26	64

1745	Current methods for predicting human food effect. 2008 , 10, 282-8	126
1744	Scientific perspectives on extending the provision for waivers of in vivo bioavailability and bioequivalence studies for drug products containing high solubility-low permeability drugs (BCS-Class 3). 2008 , 10, 300-5	16
1743	Clinical relevance of dissolution testing in quality by design. 2008 , 10, 380-90	73
1742	Application of the biopharmaceutical classification system in clinical drug development--an industrial view. 2008 , 10, 306-10	55
1741	Drug absorption modeling as a tool to define the strategy in clinical formulation development. 2008 , 10, 473-9	41
1740	Studies on formulation development of mucoadhesive sustained release itraconazole tablet using response surface methodology. 2008 , 9, 998-1005	15
1739	Hydroxypropyl methylcellulose acetate succinate: potential drug-exipient incompatibility. 2008 , 9, 991-7	33
1738	Applications of physiologically based absorption models in drug discovery and development. 2008 , 5, 760-75	94
1737	The biopharmaceutical classification system-experimental model of prediction of drug bioavailability. 2008 , 2, 235-244	4
1736	Particle design of poorly water-soluble drug substances using supercritical fluid technologies. 2008 , 60, 388-98	110
1735	Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. 2008 , 60, 717-33	329
1734	Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration. 2008 , 60, 747-56	164
1733	Biopharmaceutical challenges associated with drugs with low aqueous solubility--the potential impact of lipid-based formulations. 2008 , 60, 617-24	207
1732	Advanced screening assays to rapidly identify solubility-enhancing formulations: high-throughput, miniaturization and automation. 2008 , 60, 657-72	52
1731	Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery. 2008 , 60, 1663-73	199
1730	Influence of solute carriers on the pharmacokinetics of CYP3A4 probes. 2008 , 84, 704-9	45
1729	Prodrugs: design and clinical applications. 2008 , 7, 255-70	991
1728	Debate: Substitution of generic drugs in epilepsy: is there cause for concern?. 2008 , 49 Suppl 9, 56-62	21

1727	Effect of food or antacid on pharmacokinetics and pharmacodynamics of febuxostat in healthy subjects. 2008 , 65, 355-63	56
1726	A pharmacokinetic study of etravirine (TMC125) co-administered with ranitidine and omeprazole in HIV-negative volunteers. 2008 , 66, 508-16	45
1725	Absorption-excipient-pH classification gradient maps: sparingly soluble drugs and the pH partition hypothesis. 2008 , 33, 29-41	38
1724	Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers. 2008 , 33, 159-65	72
1723	High throughput UV method for the estimation of thermodynamic solubility and the determination of the solubility in biorelevant media. 2008 , 33, 230-40	71
1722	Improved understanding of the effect of food on drug absorption and bioavailability for lipophilic compounds using an intestinal pig perfusion model. 2008 , 34, 22-9	24
1721	Transport of amino acids and GABA analogues via the human proton-coupled amino acid transporter, hPAT1: characterization of conditions for affinity and transport experiments in Caco-2 cells. 2008 , 35, 86-95	30
1720	Free flowing solid dispersions of the anti-HIV drug UC 781 with Poloxamer 407 and a maximum amount of TPGS 1000: investigating the relationship between physicochemical characteristics and dissolution behaviour. 2008 , 35, 104-13	33
1719	Relative bioavailability of griseofulvin lyophilized dry emulsion tablet vs. immediate release tablet: a single-dose, randomized, open-label, six-period, crossover study in healthy adult volunteers in the fasted and fed states. 2008 , 35, 219-25	19
1718	A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying. 2008 , 128, 179-83	127
1717	Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. 2008 , 129, 1-10	247
1716	In vitro-in vivo correlation for wet-milled tablet of poorly water-soluble cilostazol. 2008 , 130, 29-37	53
1715	Melt extrusion and spray drying of carbamazepine and dipyridamole with polyvinylpyrrolidone/vinyl acetate copolymers. 2008 , 34, 95-106	42
1714	Molecular and Physicochemical Properties Impacting Oral Absorption of Drugs. 2008 , 26-46	3
1713	Intestinal efflux transporters and drug absorption. 2008 , 4, 923-39	142
1712	Assessment of intestinal absorption of vitexin-2''-o-rhamnoside in hawthorn leaves flavonoids in rat using in situ and in vitro absorption models. 2008 , 34, 164-70	13
1711	System biology and its application in compound recipe of traditional Chinese medicine study. 2008 , 10, 116-121	10
1710	Pharmacokinetics and ADME optimization in drug discovery. 2008 , 131-153	3

1709	The angiotensin converting enzyme inhibitory tripeptides Ile-Pro-Pro and Val-Pro-Pro show increasing permeabilities with increasing physiological relevance of absorption models. 2008 , 29, 1312-20	61
1708	Replacement therapy of oral hydrocortisone in adrenal insufficiency: the influence of gastrointestinal factors. 2008 , 4, 749-58	15
1707	The Emerging Utility of Co-Crystals in Drug Discovery and Development. 2008 , 43, 373-404	22
1706	Physicochemical Properties and Stability of Two Differently Prepared Amorphous Forms of Simvastatin. 2008 , 8, 128-135	77
1705	In Vitro ^{In Vivo} Correlation in Dosage Form Development: Case Studies. 2008 , 359-382	
1704	Formulation and characterization of ternary solid dispersions made up of Itraconazole and two excipients, TPGS 1000 and PVPVA 64, that were selected based on a supersaturation screening study. 2008 , 69, 158-66	79
1703	Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. 2008 , 69, 648-57	43
1702	Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. 2008 , 70, 649-56	40
1701	Dissolution enhancement of the anti-HIV drug UC 781 by formulation in a ternary solid dispersion with TPGS 1000 and Eudragit E100. 2008 , 70, 861-8	49
1700	Application of melt extrusion in the development of a physically and chemically stable high-energy amorphous solid dispersion of a poorly water-soluble drug. 2008 , 5, 994-1002	158
1699	Enhanced bioavailability of a poorly soluble VR1 antagonist using an amorphous solid dispersion approach: a case study. 2008 , 5, 981-93	112
1698	Application of rat in situ single-pass intestinal perfusion in the evaluation of presystemic extraction of indinavir under different perfusion rates. 2008 , 107, 37-45	26
1697	Effect of polymer molecular weight on nanocomminution of poorly soluble drug. 2008 , 15, 347-53	43
1696	Difficulties in the production of identical drug products from a pharmaceutical technology viewpoint. 2008 , 9, 65-72	14
1695	In situ intestinal absorption of cyclosporine A solid dispersion in rats. 2008 , 34, 627-31	4
1694	The improvement of ibuprofen dissolution rate through microparticles spray drying processed in an aqueous system. 2008 , 34, 485-91	16
1693	Characterization of gastrointestinal drug absorption in cynomolgus monkeys. 2008 , 5, 340-8	29
1692	Enhancement of Shelf Life and Handling Properties of Drug Nanoparticles: Nanoscale Mixing of Itraconazole with Silica. 2008 , 47, 4717-4725	19

1691	Dissolution Testing. 2008 , 47-74	4
1690	Effect of food on the pharmacokinetics of a vildagliptin/metformin (50/1000 mg) fixed-dose combination tablet in healthy volunteers. 2008 , 24, 1703-9	17
1689	Drug Absorption Principles. 2008 , 75-100	6
1688	Introduction to Biopharmaceutics and its Role in Drug Development. 2008 , 1-25	2
1687	Testing the effectiveness of nutrient delivery systems. 2008 , 53-106	7
1686	Influence of loading volume of mefenamic acid on granules and tablet characteristics using a compaction simulator. 2008 , 13, 57-64	4
1685	The effect of chronic renal failure on drug metabolism and transport. 2008 , 4, 1065-74	164
1684	Dissolution and permeation properties of naproxen from solid-state systems with chitosan. 2008 , 15, 303-12	16
1683	Gastrointestinal Dissolution and Absorption of Class II Drugs. 2008 , 33-51	14
1682	Drug Solubilization with Organic Solvents, or Using Micellar Solutions or Other Colloidal Dispersed Systems. 2008 , 786-812	
1681	Discover a Drug Substance, Formulate and Develop It to a Product. 2008 , 855-866	
1680	In Vivo Dissolution: Predominant Factor Affecting the Bioavailability of Rifampicin in its Solid Oral Dosage Forms. 2008 , 25, 1-12	6
1679	Regulatory aspects of nutrient delivery systems. 2008 , 429-449	
1678	In Vivo Permeability Studies in the Gastrointestinal Tract of Humans. 2008 , 185-219	1
1677	Parameters for Carbamate Pesticide QSAR and PBPK/PD Models for Human Risk Assessment. 2008 , 193, 53-212	10
1676	Application of the Biopharmaceutics Classification System Now and in the Future. 2008 , 521-558	1
1675	Introduction. 2008 , 1-4	
1674	Prediction of Solubility. 2008 , 23-59	

1673	Preformulation Aspects of Insoluble Compounds. 2008 , 61-90	1
1672	Regulatory Aspects of Dissolution for Low Solubility Drug Products. 2008 , 101-112	
1671	Formulation Strategies and Practice Used for Drug Candidates with Water-Insoluble Properties for Toxicology, Biology, and Pharmacology Studies in Discovery Support. 2008 , 113-132	
1670	Drug release kinetics from stent device-based delivery systems. 2008 , 51, 118-25	27
1669	Preparation and in vivo evaluation of piroxicam-loaded gelatin microcapsule by spray drying technique. 2008 , 31, 1284-7	18
1668	Physicochemical Approaches to Drug Absorption. 2008 , 69-99	3
1667	Reduction of Particle Size of Drug Substance for Low-Dose Drug Products. 2008 , 205-222	2
1666	optimization of extended zero-order release gliclazide tablets using D-optimal mixture design. 2008 , 128, 1475-83	12
1665	Permeabilities of rebamipide via rat intestinal membranes and its colon specific delivery using chitosan capsule as a carrier. 2008 , 14, 4928-37	23
1664	Pharmacokinetic, pharmacodynamic, and pharmacogenetic targeted therapy of antiepileptic drugs. 2008 , 30, 173-80	51
1663	Effect of magnesium stearate concentration on dissolution properties of ranitidine hydrochloride coated tablets. 2007 , 7, 279-83	22
1662	Avalia ^o de derivados polim ^{er} icos intercalados em montmorilonita organof ^{os} na prepara ^o de novos materiais de uso farmac ^o utico. 2008 , 18, 222-229	4
1661	Dissolution test optimization for meloxicam in the tablet pharmaceutical form. 2009 , 45, 67-73	15
1660	Calculation of fraction of dose absorbed: comparison between analytical solution based on one compartment steady state concentration approximation and dynamic seven compartment model. 2009 , 9, 75-93	16
1659	Effect of some commercial grades of microcrystalline cellulose on flowability, compressibility, and dissolution profile of piroxicam liquisolid compacts. 2009 , 35, 243-51	34
1658	Use of thin film freezing to enable drug delivery: a review. 2009 , 19, 89-98	42
1657	Biopharmaceutical aspects of gastro-retentive dosage forms: the gabapentin paradigm. 2009 , 19, 233-239	7
1656	Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs. 2009 , 37, 1443-7	30

1655	Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. 2009 , 37, 2028-36	84
1654	Method for predicting the risk of drug-drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. 2009 , 39, 430-43	59
1653	Dissolution tests as a tool for predicting bioaccessibility of nutrients during digestion. 2009 , 23, 1228-1235	33
1652	Segmental-dependent membrane permeability along the intestine following oral drug administration: Evaluation of a triple single-pass intestinal perfusion (TSPIP) approach in the rat. 2009 , 36, 320-9	75
1651	Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: linear kinetics (I). 2009 , 36, 137-46	19
1650	Computer simulations of bioequivalence trials: selection of design and analyte in BCS drugs with first-pass hepatic metabolism: Part II. Non-linear kinetics. 2009 , 36, 147-56	16
1649	Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. 2009 , 37, 434-41	94
1648	Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production. 2009 , 38, 224-9	34
1647	Itraconazole/TPGS/Aerosil200 solid dispersions: characterization, physical stability and in vivo performance. 2009 , 38, 270-8	45
1646	Formulate-ability of ten compounds with different physicochemical profiles in SMEDDS. 2009 , 38, 479-88	51
1645	Self-emulsifying system for improving drug dissolution and bioavailability: in vitro/in vivo evaluation. 2009 , 71, n/a-n/a	2
1644	Solvent-mediated solid phase transformations of carbamazepine: Effects of simulated intestinal fluid and fasted state simulated intestinal fluid. 2009 , 98, 985-96	44
1643	Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs. 2009 , 98, 2648-58	212
1642	Supersaturating drug delivery systems: the answer to solubility-limited oral bioavailability?. 2009 , 98, 2549-72	664
1641	Structural characterisation and dehydration behaviour of siramesine hydrochloride. 2009 , 98, 3596-607	9
1640	Estimation of the extent of oral absorption in animals from oral and intravenous pharmacokinetic data in drug discovery. 2009 , 98, 4027-38	12
1639	Correlation between in vitro dissolution profiles from enteric-coated dosage forms and in vivo absorption in rats for high-solubility and high-permeability model drugs. 2009 , 98, 4141-52	6
1638	Drug mechanochemical activation. 2009 , 98, 3961-86	109

1637	Characterisation of the thermal, spectroscopic and drug dissolution properties of mefenamic acid and polyoxyethylene-polyoxypropylene solid dispersions. 2009 , 98, 4545-56		26
1636	Cryoprotectants for freeze drying of drug nano-suspensions: effect of freezing rate. 2009 , 98, 4808-17		106
1635	Miniaturization of powder dissolution measurement and estimation of particle size. 2009 , 6, 1796-811		23
1634	Recent advances in physicochemical and ADMET profiling in drug discovery. 2009 , 6, 1887-99		36
1633	A PAMPA study of the permeability-enhancing effect of new ceramide analogues. 2009 , 6, 1867-74		30
1632	Influence of the microwave technology on the physical-chemical properties of solid dispersion with Nimesulide. 2009 , 195, 259-263		36
1631	Nano-mixing of dipyridamole drug and excipient nanoparticles by sonication in liquid CO ₂ . 2009 , 196, 36-49		20
1630	Comparison of solid dispersions produced by supercritical antisolvent and spray-freezing technologies. 2009 , 377, 25-34		47
1629	Achievement of pH-independence of poorly-soluble, ionizable loratadine by inclusion complex formation with dimethyl-β-cyclodextrin. 2009 , 64, 249-254		16
1628	Influence of the solid form of siramesine hydrochloride on its behavior in aqueous environments. <i>Pharmaceutical Research</i> , 2009 , 26, 846-54	4.5	11
1627	Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. <i>Pharmaceutical Research</i> , 2009 , 26, 883-92	4.5	69
1626	The science of USP 1 and 2 dissolution: present challenges and future relevance. <i>Pharmaceutical Research</i> , 2009 , 26, 1289-302	4.5	80
1625	Manufacturing nanosized fenofibrate by salt assisted milling. <i>Pharmaceutical Research</i> , 2009 , 26, 1365-70	4.5	29
1624	In vitro gastrointestinal lipolysis of four formulations of piroxicam and cinnarizine with the self emulsifying excipients Labrasol and Gelucire 44/14. <i>Pharmaceutical Research</i> , 2009 , 26, 1901-10	4.5	76
1623	Powder dissolution method for estimating rotating disk intrinsic dissolution rates of low solubility drugs. <i>Pharmaceutical Research</i> , 2009 , 26, 2093-100	4.5	54
1622	The role of transporters in the pharmacokinetics of orally administered drugs. <i>Pharmaceutical Research</i> , 2009 , 26, 2039-54	4.5	325
1621	Solution and Mixing Thermodynamics of Propranolol and Atenolol in Aqueous Media. 2009 , 38, 73-81		6
1620	Bioequivalence of antiepileptic drugs: how close is close enough?. 2009 , 9, 333-7		5

1619	Aqueous Solubility Enhancement Through Engineering of Binary Solid Composites: Pharmaceutical Applications. 2009 , 4, 36-49	40
1618	Two different approaches for the prediction of in vivo plasma concentration-time profile from in vitro release data of once daily formulations of diltiazem hydrochloride. 2009 , 32, 1317-29	8
1617	Analytical tools for the physicochemical profiling of drug candidates to predict absorption/distribution. 2009 , 394, 707-29	63
1616	Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. 2009 , 2, 2	349
1615	Uptake/efflux transport of tramadol enantiomers and O-desmethyl-tramadol: focus on P-glycoprotein. 2009 , 105, 199-206	32
1614	Generic products of antiepileptic drugs: a perspective on bioequivalence and interchangeability. 2010 , 51, 941-50	40
1613	Proof-of-concept study on the suitability of ¹³ C-urea as a marker substance for assessment of in vivo behaviour of oral colon-targeted dosage forms. 2009 , 158, 532-40	17
1612	P-glycoprotein is not involved in the differential oral potency of naloxone and naltrexone. 2009 , 23, 543-8	9
1611	In vitro evaluation of the dissolution behaviour of itraconazole in bio-relevant media. 2009 , 366, 117-23	32
1610	Solubility behavior and biopharmaceutical classification of novel high-solubility ciprofloxacin and norfloxacin pharmaceutical derivatives. 2009 , 371, 106-13	90
1609	An interesting relationship between drug absorption and melting point. 2009 , 373, 24-40	42
1608	Do gastrointestinal transit parameters influence the pharmacokinetics of gefitinib?. 2009 , 376, 7-12	22
1607	Nanoparticle formation from probucol/PVP/sodium alkyl sulfate co-ground mixture. 2009 , 376, 169-75	30
1606	In vitro drug release studies of polymeric freeze-dried wafers and solvent-cast films using paracetamol as a model soluble drug. 2009 , 378, 66-72	55
1605	Rational design of drug-polymer co-formulations by CO ₂ anti-solvent precipitation. 2009 , 48, 176-182	24
1604	Application of organic nonsolvent in the process of solution-enhanced dispersion by supercritical CO ₂ to prepare puerarin fine particles. 2009 , 49, 394-402	47
1603	Production of PLGA micro- and nanocomposites by supercritical fluid extraction of emulsions: II. Encapsulation of Ketoprofen. 2009 , 50, 336-343	30
1602	Design and optimization of a new self-nanoemulsifying drug delivery system. 2009 , 330, 443-8	260

1601	Assessment of solubilization characteristics of different surfactants for carvedilol phosphate as a function of pH. 2009 , 335, 242-9	66
1600	Prodrugs: bridging pharmacodynamic/pharmacokinetic gaps. 2009 , 13, 338-44	61
1599	Bioavailability of nanoparticles in nutrient and nutraceutical delivery. 2009 , 14, 3-15	588
1598	Influence of drug polarity upon the solid-state structure and release properties of self-emulsifying drug delivery systems in relation with water affinity. 2009 , 71, 73-8	9
1597	The H2 receptor antagonist nizatidine is a P-glycoprotein substrate: characterization of its intestinal epithelial cell efflux transport. 2009 , 11, 205-13	24
1596	Population-based mechanistic prediction of oral drug absorption. 2009 , 11, 225-37	298
1595	Practical anticipation of human efficacious doses and pharmacokinetics using in vitro and preclinical in vivo data. 2009 , 11, 602-14	28
1594	Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. 2009 , 11, 740-6	282
1593	In vitro and in vivo characteristics of a thermogelling rectal delivery system of etodolac. 2009 , 10, 724-31	29
1592	Evaluation of griseofulvin binary and ternary solid dispersions with HPMCAS. 2009 , 10, 1172-7	70
1591	Development and validation of a discriminative dissolution test for nimesulide suspensions. 2009 , 10, 1145-52	5
1590	Influence of formulation factors on tablet formulations with liquid permeation enhancer using factorial design. 2009 , 10, 1437-43	11
1589	Effect of cyclodextrin complexation on the aqueous solubility and solubility/dose ratio of praziquantel. 2009 , 10, 1444-51	17
1588	Safety and efficacy of sodium caprate in promoting oral drug absorption: from in vitro to the clinic. 2009 , 61, 1427-49	162
1587	Oral cyclosporine A--the current picture of its liposomal and other delivery systems. 2009 , 14, 139-52	52
1586	Physicochemical investigation of the solid dispersion systems of etoricoxib with poloxamer 188. 2009 , 14, 373-9	15
1585	Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation. 2009 , 64, 101-8	67
1584	Toward an increased understanding of the barriers to colonic drug absorption in humans: implications for early controlled release candidate assessment. 2009 , 6, 60-73	97

1583	Mechanistic implication for cross-linking in sterculia-based hydrogels and their use in GIT drug delivery. 2009 , 10, 2515-32	56
1582	Drug permeability assay using microhole-trapped cells in a microfluidic device. 2009 , 81, 1944-51	38
1581	Increased understanding of intestinal drug permeability determined by the LOC-I-GUT approach using multislice computed tomography. 2009 , 6, 2-10	32
1580	Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations. 2009 , 6, 1429-40	36
1579	Formulation and characterization of a compacted multiparticulate system for modified release of water-soluble drugs--part 1--acetaminophen. 2009 , 35, 337-51	12
1578	Computer simulations using GastroPlus to justify a biowaiver for etoricoxib solid oral drug products. 2009 , 72, 91-8	86
1577	In vitro and in vivo evaluation of nimesulide lyophilized orally disintegrating tablets. 2009 , 73, 162-71	89
1576	Biopharmaceutical classification of drugs using intrinsic dissolution rate (IDR) and rat intestinal permeability. 2009 , 73, 102-6	103
1575	Lipid--an emerging platform for oral delivery of drugs with poor bioavailability. 2009 , 73, 1-15	294
1574	Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogs. 2009 , 47, 2257-68	86
1573	Can adenosine substitute for SAM-e as an adjunct in the treatment of depression?. 2009 , 73, 857-9	3
1572	Synthesis and Structural Characterization of Cocrystals and Pharmaceutical Cocrystals: Mechanochemistry vs Slow Evaporation from Solution. 2009 , 9, 1106-1123	346
1571	Pros and cons of methods used for the prediction of oral drug absorption. 2009 , 2, 195-208	9
1570	Bioequivalence studies and sugar-based excipients effects on the properties of new generic ketoconazole tablets formulations and stability evaluation by using direct compression method. 2009 , 14, 530-9	4
1569	The use of liquid self-microemulsifying drug delivery systems based on peanut oil/tween 80 in the delivery of griseofulvin. 2009 , 35, 185-91	18
1568	Controlling Particle Size of a Poorly Water-Soluble Drug Using Ultrasound and Stabilizers in Antisolvent Precipitation. 2009 , 48, 7581-7593	153
1567	Effect of abdominal surgery on the intestinal absorption of lipophilic drugs: possible role of the lymphatic transport. 2009 , 153, 296-300	3
1566	Rapidly disintegrating oramucosal drug delivery technologies. 2009 , 14, 588-601	4

1565	Molecular dynamics study of non-nucleoside reverse transcriptase inhibitor 4-[[4-[[4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzotrile (TMC278/rilpivirine) aggregates: correlation between amphiphilic properties of the drug and oral bioavailability. 2009 , 52, 5896-905	17
1564	Justification of biowaiver for carbamazepine, a low soluble high permeable compound, in solid dosage forms based on IVIVC and gastrointestinal simulation. 2009 , 6, 40-7	72
1563	Piroxicam bioadhesive ocular inserts: physicochemical characterization and evaluation in prostaglandin-induced inflammation. 2009 , 34, 1065-73	21
1562	Formation Kinetics and Stability of Carbamazepine-Nicotinamide Cocrystals Prepared by Mechanical Activation. 2009 , 9, 2377-2386	77
1561	Solid state interaction of raloxifene HCl with different hydrophilic carriers during co-grinding and its effect on dissolution rate. 2009 , 35, 455-70	31
1560	Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. 2009 , 297, G371-7	82
1559	Quality and stability of ramipril generics/copies versus reference ramipril (Tritace): a 3-month stability comparative study. 2009 , 29, 667-76	7
1558	The utility of rat jejunal permeability for biopharmaceutics classification system. 2009 , 35, 1496-502	26
1557	Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. 2009 , 6, 19-28	122
1556	Oral Drug Absorption, Evaluation, and Prediction. 2009 , 289-308	3
1555	Salt Screening and Selection. 2009 , 75-86	3
1554	Solubility of Pharmaceutical Solids. 2009 , 1-24	2
1553	Modern Pharmaceutical Quality Regulations. 2009 , 885-901	2
1552	Dissolution Testing of Solid Products. 2009 , 319-340	4
1551	Analysis of risk factors in human bioequivalence study that incur bioinequivalence of oral drug products. 2009 , 6, 48-59	16
1550	Toward an in vivo dissolution methodology: a comparison of phosphate and bicarbonate buffers. 2009 , 6, 29-39	69
1549	Association of a weakly acidic anti-inflammatory drug (ibuprofen) with a poly(amidoamine) dendrimer as studied by molecular dynamics simulations. 2009 , 113, 10984-93	71
1548	Gefitinib-cyclodextrin inclusion complexes: physico-chemical characterization and dissolution studies. 2009 , 35, 1113-20	26

1547	Integration of Physical, Chemical, Mechanical, and Biopharmaceutical Properties in Solid Oral Dosage Form Development. 2009 , 407-441	7
1546	Spray-drying process optimization for manufacture of drug-cyclodextrin complex powder using design of experiments. 2009 , 35, 1219-29	30
1545	In vitro systems for studying epithelial transport of macromolecules. 2009 , 480, 151-64	8
1544	Enhanced oral bioavailability and antioxidant profile of ellagic acid by phospholipids. 2009 , 57, 4559-65	61
1543	Development of glyburide fast-dissolving tablets based on the combined use of cyclodextrins and polymers. 2009 , 35, 73-82	20
1542	Modeling kinetics of subcellular disposition of chemicals. 2009 , 109, 1793-899	59
1541	Synthesis and characterization of Zwitterionic co-polymers as matrices for sustained metoprolol tartrate delivery. 2009 , 20, 181-97	8
1540	Recent advances in liposomal dry powder formulations: preparation and evaluation. 2009 , 6, 71-89	63
1539	Introduction to computational oral absorption simulation. 2009 , 5, 259-93	95
1538	Particle size reduction for improvement of oral absorption of the poorly soluble drug UG558 in rats during early development. 2009 , 35, 1479-86	54
1537	Biopharmaceutics classification system: validation and learnings of an in vitro permeability assay. 2009 , 6, 11-8	75
1536	The use of drug metabolism for prediction of intestinal permeability (dagger). 2009 , 6, 74-81	39
1535	Solubility Advantage of Pharmaceutical Cocrystals. 2009 , 9, 2252-2264	614
1534	Drug administration through an enteral feeding tube. 2009 , 109, 34-42; quiz 43	33
1533	[BCS strategies at drug discovery and development stages]. 2009 , 134, 24-7	1
1532	Introduction. 2009 , 1-67	
1531	Nanoparticulation of poorly water soluble drugs using a wet-mill process and physicochemical properties of the nanopowders. 2009 , 57, 1050-7	43
1530	Design and in vitro/in vivo evaluation of multi-layer film coated pellets for omeprazole. 2009 , 57, 122-8	13

1529	The Role of Permeability in Drug ADME/PK, Interactions and Toxicity, and the Permeability-Based Classification System (PCS). 2010 , 367-380	1
1528	Assessing The Bioavailability of Drug Delivery Systems: Mathematical Modeling. 2010 , 753-866	
1527	Design and development of oral mucoadhesive multiparticulate system containing atenolol: in vitro-in vivo characterization. 2010 , 58, 1168-75	16
1526	Role of Preformulation in Development of Solid Dosage Forms. 2010 , 1	
1525	Formulation and evaluation of a protein-loaded solid dispersions by non-destructive methods. 2010 , 12, 158-70	19
1524	The use of biorelevant dissolution media to forecast the in vivo performance of a drug. 2010 , 12, 397-406	253
1523	Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy. 2010 , 12, 569-75	27
1522	Development and validation of a discriminating in vitro dissolution method for a poorly soluble drug, olmesartan medoxomil: comparison between commercial tablets. 2010 , 11, 637-44	12
1521	Dissolution enhancement of a drug exhibiting thermal and acidic decomposition characteristics by fusion processing: a comparative study of hot melt extrusion and KinetiSol dispersing. 2010 , 11, 760-74	65
1520	Enhancement of bioavailability of cefpodoxime proxetil using different polymeric microparticles. 2010 , 11, 1368-75	20
1519	Improved albendazole dissolution rate in pluronic 188 solid dispersions. 2010 , 11, 1518-25	34
1518	In-vitro in-vivo correlation models for glibenclamide after administration of metformin/glibenclamide tablets to healthy human volunteers. 2000 , 52, 831-8	16
1517	Evaluation of absorbability of centpropazine in rats: in-situ and in-vivo approaches. 2001 , 53, 901-6	
1516	The influence of caprate on rectal absorption of phenoxymethylpenicillin: experience from an in-vivo perfusion in humans. 2002 , 54, 499-508	32
1515	Direct, differential-equation-based in-vitro-in-vivo correlation (IVIVC) method. 2003 , 55, 495-504	48
1514	Estimation of absorption parameters from the non-steady-state phase in the rat gut perfusion model. 2003 , 55, 487-93	3
1513	Intestinal drug absorption and bioavailability: beyond involvement of single transport function. 2003 , 55, 429-33	21
1512	The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. 2005 , 57, 273-85	134

1511	Molecular interactions in celecoxib-PVP-meglumine amorphous system. 2005 , 57, 303-10	46
1510	Thermotropic liquid crystalline drugs. 2005 , 57, 807-16	39
1509	Fast-dissolving microparticles fail to show improved oral bioavailability. 2006 , 58, 1319-26	6
1508	In-vitro mutagenic potential and effect on permeability of co-administered drugs across Caco-2 cell monolayers of <i>Rubus idaeus</i> and its fortified fractions. 2006 , 58, 1545-52	10
1507	A comparison of intestinal lymphatic transport and systemic bioavailability of saquinavir from three lipid-based formulations in the anaesthetised rat model. 2006 , 58, 917-25	47
1506	Is bicarbonate buffer suitable as a dissolution medium?. 2007 , 59, 1375-82	37
1505	Determination of calcium salt solubility with changes in pH and P(CO(2)), simulating varying gastrointestinal environments. 2007 , 59, 1485-92	97
1504	Characterization of the bulk properties of pharmaceutical solids using nonlinear optics--a review. 2007 , 59, 241-50	8
1503	A theoretical and spectroscopic study of gamma-crystalline and amorphous indometacin. 2007 , 59, 261-9	60
1502	Physicochemical characterization of solid dispersions of three antiepileptic drugs prepared by solvent evaporation method. 2007 , 59, 645-53	21
1501	Evaluation and suggested improvements of the Biopharmaceutics Classification System (BCS). 2007 , 59, 751-7	27
1500	Improving glyburide solubility and dissolution by complexation with hydroxybutenyl- β -cyclodextrin. 2010 , 61, 23-30	16
1499	Comparison of WHO and US FDA biowaiver dissolution test conditions using bioequivalent doxycycline hyclate drug products. 2010 , 61, 331-337	3
1498	Review: physical chemistry of solid dispersions. 2010 , 61, 1571-1586	393
1497	Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation. 2010 , 62, 173-80	25
1496	Bioavailability of lycopene in the rat: the role of intestinal lymphatic transport. 2010 , 62, 323-31	37
1495	Development of an itraconazole-loaded gelatin microcapsule with enhanced oral bioavailability: physicochemical characterization and in-vivo evaluation. 2010 , 62, 448-55	3
1494	Pure drug and polymer based nanotechnologies for the improved solubility, stability, bioavailability and targeting of anti-HIV drugs. 2010 , 62, 491-502	124

1493	Pharmacokinetic/ pharmacodynamic-driven drug development. 2010 , 77, 381-8		21
1492	A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers. 2010 , 27, 260-73		62
1491	A modified physiological BCS for prediction of intestinal absorption in drug discovery. 2010 , 7, 1478-87		43
1490	Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys. 2010 , 65, 1109-16		11
1489	Rationale and conditions for the requirement of chiral bioanalytical methods in bioequivalence studies. 2010 , 66, 599-604		14
1488	Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. 2010 , 387, 272-7		101
1487	Analysis of nucleation kinetics of poorly water-soluble drugs in presence of ultrasound and hydroxypropyl methyl cellulose during antisolvent precipitation. 2010 , 387, 172-9		70
1486	Effective polymeric dispersants for vacuum, convection and freeze drying of drug nanosuspensions. 2010 , 397, 218-24		59
1485	Comparative study of itraconazole-cyclodextrin inclusion complex and its commercial product. 2010 , 33, 1009-17		8
1484	Development of novel itraconazole-loaded solid dispersion without crystalline change with improved bioavailability. 2010 , 33, 1217-25		19
1483	Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations. <i>Pharmaceutical Research</i> , 2010 , 27, 340-9	4-5	12
1482	Electrospun nanofibers in oral drug delivery. <i>Pharmaceutical Research</i> , 2010 , 27, 576-88	4-5	113
1481	Multivariate data analysis of factors affecting the in vitro dissolution rate and the apparent solubility for a model basic drug substance in aqueous media. <i>Pharmaceutical Research</i> , 2010 , 27, 1309-17	4-5	4
1480	In vitro-in vivo correlations of scalable PLGA-risperidone implants for the treatment of schizophrenia. <i>Pharmaceutical Research</i> , 2010 , 27, 1730-7	4-5	75
1479	Effect of crystal size on the in vitro dissolution and oral absorption of nitrendipine in rats. <i>Pharmaceutical Research</i> , 2010 , 27, 1965-76	4-5	91
1478	Development of PLGA-based injectable delivery systems for hydrophobic fenretinide. <i>Pharmaceutical Research</i> , 2010 , 27, 2063-74	4-5	46
1477	From drug delivery systems to drug release, dissolution, IVIVC, BCS, BDDCS, bioequivalence and biowaivers. <i>Pharmaceutical Research</i> , 2010 , 27, 2018-29	4-5	15
1476	Multicomponent amorphous nanofibers electrospun from hot aqueous solutions of a poorly soluble drug. <i>Pharmaceutical Research</i> , 2010 , 27, 2466-77	4-5	72

1475	Oligoarginine-linked polymers as a new class of penetration enhancers. 2010 , 148, 187-96	30
1474	Simultaneous production and co-mixing of microparticles of nevirapine with excipients by supercritical antisolvent method for dissolution enhancement. 2010 , 39, 164-74	27
1473	Novel crystalline solid dispersion of tranilast with high photostability and improved oral bioavailability. 2010 , 39, 256-62	55
1472	What is modulating solubility in simulated intestinal fluids?. 2010 , 41, 452-7	46
1471	Preparation and solid state characterisation of chlorothiazide sodium intermolecular self-assembly suprastructure. 2010 , 41, 603-11	19
1470	A review on cyclodextrin encapsulation of essential oils and volatiles. 2010 , 25, 313-326	433
1469	Particle engineering: a strategy for establishing drug substance physical property specifications during small molecule development. 2010 , 99, 51-75	36
1468	Absorption barriers in the rat intestinal mucosa: 1. Application of an in situ perfusion model to simultaneously assess drug permeation and metabolism. 2010 , 99, 982-98	16
1467	The intestinal absorption of a prodrug of the mGlu2/3 receptor agonist LY354740 is mediated by PEPT1: in situ rat intestinal perfusion studies. 2010 , 99, 1574-81	17
1466	Mechanisms of membrane transport of poorly soluble drugs: role of micelles in oral absorption processes. 2010 , 99, 1336-45	77
1465	New binary solid dispersion of indomethacin with surfactant polymer: from physical characterization to in vitro dissolution enhancement. 2010 , 99, 1399-413	7
1464	Analysis of nifedipine absorption from soft gelatin capsules using PBPK modeling and biorelevant dissolution testing. 2010 , 99, 2899-904	24
1463	The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. 2010 , 99, 2739-49	156
1462	The utility of sulfonate salts in drug development. 2010 , 99, 2948-61	71
1461	Templated open flocs of anisotropic particles for pulmonary delivery with pressurized metered dose inhalers. 2010 , 99, 3150-65	19
1460	Soft gelatin capsules (softgels). 2010 , 99, 4107-48	77
1459	Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation--classification and comparison with crystallization tendency from undercooled melts. 2010 , 99, 3826-38	128
1458	The developability classification system: application of biopharmaceutics concepts to formulation development. 2010 , 99, 4940-54	253

1457	Precipitation of a poorly soluble model drug during in vitro lipolysis: characterization and dissolution of the precipitate. 2010 , 99, 4982-91	118
1456	A solid-state approach to enable early development compounds: selection and animal bioavailability studies of an itraconazole amorphous solid dispersion. 2010 , 99, 3901-22	96
1455	Changes of ginsenosides in Korean red ginseng (<i>Panax ginseng</i>) fermented by <i>Lactobacillus plantarum</i> M1. 2010 , 45, 1319-1324	53
1454	Solid self-emulsifying nitrendipine pellets: preparation and in vitro/in vivo evaluation. 2010 , 383, 1-6	98
1453	Fabrication of drug nanoparticles by evaporative precipitation of nanosuspension. 2010 , 383, 285-92	78
1452	Hydrophilic and hydrophobic amino acid copolymers for nano-comminution of poorly soluble drugs. 2010 , 384, 173-80	22
1451	The effects of excipients on transporter mediated absorption. 2010 , 393, 17-31	63
1450	Improved dissolution and pharmacokinetic behavior of cyclosporine A using high-energy amorphous solid dispersion approach. 2010 , 399, 94-101	55
1449	Risperidone solid dispersion for orally disintegrating tablet: its formulation design and non-destructive methods of evaluation. 2010 , 400, 49-58	53
1448	Enhanced solubility and dissolution rate of amiodarone by complexation with β -cyclodextrin through different methods. 2010 , 30, 1008-1013	29
1447	Fabrication of pectin-based nanoemulsions loaded with itraconazole for pharmaceutical application. 2010 , 82, 384-393	52
1446	Piroxicam solid state studies after processing with SAS technique. 2010 , 55, 340-347	12
1445	Sucrose esters with various hydrophilic-lipophilic properties: novel controlled release agents for oral drug delivery matrix tablets prepared by direct compaction. 2010 , 6, 3101-9	37
1444	Controlled liquid antisolvent precipitation using a rapid mixing device. 2010 , 65, 5669-5675	59
1443	Probing the probes: fitness factors for small molecule tools. 2010 , 17, 561-77	198
1442	Ammonium methacrylate units polymer content and their effect on acyclovir colloidal nanoparticles properties and bioavailability in human volunteers. 2010 , 75, 398-404	15
1441	Variability and impact on design of bioequivalence studies. 2010 , 106, 146-53	33
1440	The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences. 2010 , 106, 73-85	35

1439	Predicting drug disposition via application of a Biopharmaceutics Drug Disposition Classification System. 2010 , 106, 162-7	92
1438	Biopharmaceutical classification based on solubility and dissolution: a reappraisal of criteria for hypothesis models in the light of the experimental observations. 2010 , 106, 168-72	9
1437	Acceptability and characteristics of 124 human bioequivalence studies with active substances classified according to the Biopharmaceutic Classification System. 2010 , 70, 694-702	51
1436	Current challenges facing the determination of product bioequivalence in veterinary medicine. 2010 , 33, 418-33	10
1435	The FDA should eliminate the ambiguities in the current BCS biowaiver guidance and make public the drugs for which BCS biowaivers have been granted. 2010 , 88, 405-7	31
1434	Membrane transporters in drug development. 2010 , 9, 215-36	2464
1433	Coexistence of passive and carrier-mediated processes in drug transport. 2010 , 9, 597-614	428
1432	Effect of high-pressure homogenization on the physical and antioxidant properties of Quercus resinosa infusions encapsulated by spray-drying. 2010 , 75, N57-61	22
1431	Enhanced Dissolution and Oral Bioavailability of Piroxicam Formulations: Modulating Effect of Phospholipids. 2010 , 2, 339-350	28
1430	Small Volume Dissolution Testing as a Powerful Method during Pharmaceutical Development. 2010 , 2, 351-363	26
1429	Development of a dissolution test for lamotrigine in tablet form using an ultraviolet method. 2010 , 46, 179-186	6
1428	Mechanism of controlled release kinetics from medical devices. 2010 , 27, 211-225	44
1427	Dissolution studies of physical mixtures of indomethacin with alpha- and gamma-cyclodextrins. 2010 , 10, 197-203	3
1426	Design and Pharmaceutical Applications of Prodrugs. 2010 , 1	
1425	Cyclosporine a-nanosuspension: formulation, characterization and in vivo comparison with a marketed formulation. 2010 , 78, 345-61	30
1424	Preclinical Drug Development Planning. 2010 , 1	
1423	Crystal structures of two polymeric bis(triphenyltin) malonates. 2010 , 63, 4031-4040	4
1422	Deposition, imaging, and clearance: what remains to be done?. 2010 , 23 Suppl 2, S39-57	34

1421	Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans. 2010 , 38, 2023-31	81
1420	Mitigating permeability-mediated risks in drug discovery. 2010 , 6, 171-87	11
1419	Physicochemical Characterization and Oral Dosage Form Selection Based on the Biopharmaceutics Classification System. 2010 , 25-62	3
1418	Provisional BCS Classification of the Leading Oral Drugs on the Global Market. 2010 , 353-366	
1417	Cyclodextrins in drug delivery systems. 2010 , 20, 289-301	66
1416	Microemulsions as Drug Delivery Systems. 2010 , 1	
1415	Oral absorption enhancement: taking the next steps in therapeutic delivery. 2010 , 1, 5-9	8
1414	Nanoparticulate delivery systems for antiviral drugs. 2010 , 21, 53-70	119
1413	Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke. 2010 , 1207, 134-42	3
1412	Milling Operations in the Pharmaceutical Industry. 2010 , 365-378	5
1411	Preclinical Development for Suspensions. 2010 , 127-176	3
1410	Nanoparticulate strategies for effective delivery of poorly soluble therapeutics. 2010 , 1, 149-67	15
1409	Introduction and Overview of Oral Controlled Release Formulation Design. 2010 , 1-19	13
1408	Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs. 2010 , 7, 227-36	119
1407	Efavirenz-loaded polymeric micelles for pediatric anti-HIV pharmacotherapy with significantly higher oral bioavailability [corrected]. 2010 , 5, 11-23	133
1406	ADME Strategies in Lead Optimization. 2010 , 25-88	
1405	Bioanalytical Strategies. 2010 , 131-204	
1404	Development and characterization of a lovastatin-loaded self-microemulsifying drug delivery system. 2010 , 15, 469-83	43

1403	Absorption and Physicochemical Properties of the NCE. 2010 , 125-144	2
1402	ADME. 2010 , 145-200	3
1401	Intestinal permeability and excretion into bile control the arrival of amlodipine into the systemic circulation after oral administration. 2006 , 58, 827-36	16
1400	Solvent change co-precipitation with hydroxypropyl methylcellulose phthalate to improve dissolution characteristics of a poorly water-soluble drug. 2002 , 54, 1041-7	24
1399	Multiple peaking phenomena in pharmacokinetic disposition. 2010 , 49, 351-77	86
1398	Physiological parameters for oral delivery and in vitro testing. 2010 , 7, 1388-405	287
1397	Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates. 2010 , 53, 5897-905	54
1396	Simultaneous release and ADME processes of poorly water-soluble drugs: mathematical modeling. 2010 , 7, 1488-97	13
1395	The biowaiver extension for BCS class III drugs: the effect of dissolution rate on the bioequivalence of BCS class III immediate-release drugs predicted by computer simulation. 2010 , 7, 1235-43	57
1394	Dissolution rate and apparent solubility of poorly soluble drugs in biorelevant dissolution media. 2010 , 7, 1419-30	133
1393	Exposure of aerosols and nanoparticle dispersions to in vitro cell cultures: A review on the dose relevance of size, mass, surface and concentration. 2010 , 41, 1123-1142	44
1392	Predicting in vivo absorption behavior of oral modified release dosage forms containing pH-dependent poorly soluble drugs using a novel pH-adjusted biphasic in vitro dissolution test. 2010 , 76, 105-11	65
1391	Mechanism-based prediction of particle size-dependent dissolution and absorption: cilostazol pharmacokinetics in dogs. 2010 , 76, 83-94	53
1390	Species comparison of oral bioavailability, first-pass metabolism and pharmacokinetics of acetaminophen. 2010 , 89, 113-9	44
1389	Pharmaceutical applications of cyclodextrins: basic science and product development. 2010 , 62, 1607-21	578
1388	New perspectives on lipid and surfactant based drug delivery systems for oral delivery of poorly soluble drugs. 2010 , 62, 1622-36	205
1387	Bioavailability of indomethacin-saccharin cocrystals. 2010 , 62, 1560-8	136
1386	Biopharmaceutical parameters to consider in order to alter the fate of nanocarriers after oral delivery. 2010 , 5, 287-306	223

1385	Improving oral delivery. 2010 , 345-98	21
1384	Structure-Stability Relationships in Cocrystal Hydrates: Does the Promiscuity of Water Make Crystalline Hydrates the Nemesis of Crystal Engineering?. 2010 , 10, 2152-2167	192
1383	Development and application of a biorelevant dissolution method using USP apparatus 4 in early phase formulation development. 2010 , 7, 1466-77	11
1382	Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. 2010 , 7, 522-32	73
1381	Physicochemical characterization of gliclazide-macrogol solid dispersion and tablets based on optimized dispersion. 2010 , 36, 893-902	12
1380	Similar modes of inclusion in complexes of β -cyclodextrin with sulfonylurea hypoglycemic drugs. 2010 , 12, 517-525	7
1379	High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. 2010 , 7, 1827-34	84
1378	Polymorphic Crystal Forms and Cocrystals in Drug Delivery (Crystal Engineering). 2010 , 187-218	8
1377	Thermodynamics and Relative Solubility Prediction of Polymorphic Systems. 2010 , 477-490	3
1376	Glibenclamide-loaded self-nanoemulsifying drug delivery system: development and characterization. 2010 , 36, 933-45	58
1375	Liquisolid technology for dissolution rate enhancement or sustained release. 2010 , 7, 1227-34	23
1374	Oral Controlled Drug Delivery: Quality by Design (QbD) Approach to Drug Development. 2010 , 279-303	2
1373	In situ gels of Metoclopramide Hydrochloride for intranasal delivery: in vitro evaluation and in vivo pharmacokinetic study in rabbits. 2010 , 17, 19-27	45
1372	Assessment of intestinal absorption of total flavones of Hippophae rhamnoides L. in rat using in situ absorption models. 2010 , 36, 787-94	12
1371	A comparative bioavailability study of two formulations of itraconazole 100 mg capsule in healthy human Indian subjects under fasting conditions. 2010 , 27, 128-132	1
1370	Particle size reduction and pharmacokinetic evaluation of a poorly soluble acid and a poorly soluble base during early development. 2011 , 37, 243-51	27
1369	Highly soluble olanzapinium maleate crystalline salts. 2011 , 13, 1759	65
1368	Oral Drug Delivery with Cyclodextrins. 2011 , 177-196	

1367	Nonlinear pharmacokinetics of oral quinidine and verapamil in healthy subjects: a clinical microdosing study. 2011 , 90, 263-70	37
1366	Key Technologies and Opportunities for Innovation at the Drug Substance/Drug Product Interface. 2011 , 229-254	
1365	Formulation of a Poorly Water-Soluble Drug Sirolimus in Solid Dispersions to Improve Dissolution. 2011 , 32, 778-783	11
1364	A novel marker design for magnetic marker monitoring in the human gastrointestinal tract. 2011 , 58, 3368-75	6
1363	Automated selection of compounds with physicochemical properties to maximize bioavailability and druglikeness. 2011 , 51, 148-58	18
1362	Effect of organic-phase solvents on physicochemical properties and cellular uptake of astaxanthin nanodispersions. 2011 , 59, 8733-41	44
1361	Cyclodextrins as Bioavailability Enhancers. 2011 , 45-64	2
1360	An optimized commercially feasible milling technique for molecular encapsulation of meloxicam in β -cyclodextrin. 2011 , 37, 1318-28	12
1359	Solid dispersions, part II: new strategies in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. 2011 , 8, 1663-80	55
1358	Simulation of Population Variability in Pharmacokinetics. 2011 , 59-92	
1357	Novel methods to assess bioequivalence. 2011 , 7, 79-88	5
1356	Characterization of Carbamazepine-Nicotinamide Cocrystal Polymorphs with Rapid Heating DSC and XRPD. 2011 , 11, 1177-1181	26
1355	Opportunities and challenges for oral delivery of hydrophobic versus hydrophilic peptide and protein-like drugs using lipid-based technologies. 2011 , 2, 1633-53	26
1354	Fast Dissolving Curcumin Cocrystals. 2011 , 11, 4135-4145	150
1353	Design and evaluation of self-nanoemulsifying drug delivery system of flutamide. 2011 , 3, 4-8	44
1352	Sex differences in pharmacokinetics of cilostazol in rats. 2011 , 41, 903-13	11
1351	Chapter 1: Pharmaceutical Salts and Co-crystals: Retrospect and Prospects. 2011 , 1-8	2
1350	Solubility of Pharmaceutical Solids. 2011 , 21-38	

1349	In Vitro In Vivo Correlations of Pharmaceutical Dosage Forms. 2011 , 77-89	
1348	Pharmacokinetic Behaviors of Orally Administered Drugs. 2011 , 183-219	2
1347	Effects of Food on Drug Absorption. 2011 , 221-231	3
1346	In vivo Methods for Oral Bioavailability Studies. 2011 , 493-503	
1345	Flip-flop pharmacokinetics--delivering a reversal of disposition: challenges and opportunities during drug development. 2011 , 2, 643-72	135
1344	Chapter 3: The Learning and Evolution of Medicinal Chemistry against Kinase Targets. 2011 , 79-95	1
1343	Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. 2011 , 54, 1539-54	342
1342	Pharmacokinetic and Biopharmaceutical Considerations in Prodrug Discovery and Development. 2011 , 415-452	
1341	Bioequivalence of oral products and the biopharmaceutics classification system: science, regulation, and public policy. 2011 , 90, 467-70	35
1340	Absorption. 2011 , 39-71	
1339	Bioequivalence Studies. 2011 , 315-346	
1338	The use of spray-drying to enhance celecoxib solubility. 2011 , 37, 1463-72	45
1337	Predictive models for drugs exhibiting negative food effects based on their biopharmaceutical characteristics. 2011 , 37, 1429-38	6
1336	Oral delivery of poorly soluble compounds by supersaturated systems. 2011 , 2, 685-90	3
1335	Nanoemulsions of cancer chemopreventive agent benzyl isothiocyanate display enhanced solubility, dissolution, and permeability. 2011 , 59, 12396-404	34
1334	Preformulation studies on host-guest composites for oral administration of BCS class IV drugs: HTlc and furosemide. 2011 , 53, 696-703	22
1333	The influence of crystallization inhibition of HPMC and HPMCAS on model substance dissolution and release in swellable matrix tablets. 2011 , 78, 125-33	51
1332	Comparison of ibuprofen release from minitables and capsules containing ibuprofen: Cyclodextrin complex. 2011 , 78, 58-66	18

1331	State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. 2011 , 78, 1-9	470
1330	Use of conventional surfactant media as surrogates for FaSSIF in simulating in vivo dissolution of BCS class II drugs. 2011 , 78, 531-8	30
1329	Improvement of oxaprozin solubility and permeability by the combined use of cyclodextrin, chitosan, and bile components. 2011 , 78, 385-93	40
1328	Solid self-nanoemulsifying drug delivery system (S-SNEDDS) containing phosphatidylcholine for enhanced bioavailability of highly lipophilic bioactive carotenoid lutein. 2011 , 79, 250-7	97
1327	Study on dissolution and absorption of four dosage forms of isosorbide mononitrate: level A in vitro-in vivo correlation. 2011 , 79, 364-71	21
1326	Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. 2011 , 79, 552-8	65
1325	Developing Performance Specifications for Pulmonary Products. 2011 , 529-541	
1324	Pharmaceutical composition of hydrochlorothiazide:β-cyclo-dextrin: preparation by three different methods, physico-chemical characterization and in vivo diuretic activity evaluation. 2011 , 16, 4482-99	34
1323	Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety. 2011 , 24, 1420-56	371
1322	Formulation of Self-Nanoemulsifying Drug Delivery System for Telmisartan with Improved Dissolution and Oral Bioavailability. 2011 , 32, 958-968	32
1321	Solid dispersions, part I: recent evolutions and future opportunities in manufacturing methods for dissolution rate enhancement of poorly water-soluble drugs. 2011 , 8, 1501-19	140
1320	Strategies to improve dissolution and oral absorption of glimepiride tablets: solid dispersion versus micronization techniques. 2011 , 37, 727-36	36
1319	The apparent solubilizing capacity of simulated intestinal fluids for poorly water-soluble drugs. 2011 , 16, 278-86	27
1318	Solubilities of Pharmaceutical Compounds in Ionic Liquids. 2011 , 56, 2039-2043	83
1317	The solubility-permeability interplay: mechanistic modeling and predictive application of the impact of micellar solubilization on intestinal permeation. 2011 , 8, 1848-56	149
1316	Advanced technologies for oral controlled release: cyclodextrins for oral controlled release. 2011 , 12, 1276-92	58
1315	Imbuing aqueous solubility to amphotericin B and nystatin with a vitamin. 2011 , 8, 297-301	7
1314	Human jejunal effective permeability and its correlation with preclinical drug absorption models. 1997 , 49, 627-38	143

1313	A residence-time distribution analysis of the hydrodynamics within the intestine in man during a regional single-pass perfusion with Loc-I-Gut: in-vivo permeability estimation. 1997 , 49, 682-6	34
1312	Micellar systems for oral drug delivery. 2011 , 50, 13-13	
1311	Concentration- and region-dependent intestinal permeability of fluvastatin in the rat. 1998 , 50, 737-44	21
1310	Formulation and stability testing of itraconazole crystalline nanoparticles. 2011 , 12, 811-20	27
1309	Dissolution and solid-state characterization of poorly water-soluble drugs in the presence of a hydrophilic carrier. 2011 , 12, 1227-33	22
1308	A perspective for biowaivers of human bioequivalence studies on the basis of the combination of the ratio of AUC to the dose and the biopharmaceutics classification system. 2011 , 8, 1113-9	1
1307	Nimodipine (NM) tablets with high dissolution containing NM solid dispersions prepared by hot-melt extrusion. 2011 , 37, 934-44	53
1306	An HPLC-UV method for the measurement of permeability of marker drugs in the Caco-2 cell assay. 2011 , 44, 531-7	19
1305	Population pharmacokinetic analysis of sorafenib in patients with solid tumours. 2011 , 72, 294-305	100
1304	Feasibility of the Ussing chamber technique for the determination of in vitro jejunal permeability of passively absorbed compounds in different animal species. 2011 , 34, 290-7	22
1303	Nanonization of megestrol acetate by laser fragmentation in aqueous milieu. 2011 , 149, 273-80	51
1302	Baclofen ester and carbamate prodrug candidates: a simultaneous chromatographic assay, resolution optimized with DryLab. 2011 , 56, 569-76	6
1301	Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods. 2011 , 417, 94-100	108
1300	Mathematical modeling of simultaneous drug release and in vivo absorption. 2011 , 418, 130-41	50
1299	In vivo imaging of drug delivery systems in the gastrointestinal tract. 2011 , 417, 216-26	40
1298	Enhanced bioavailability after oral and pulmonary administration of baicalein nanocrystal. 2011 , 420, 180-8	103
1297	Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. 2011 , 420, 1-10	752
1296	Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001). 2011 , 420, 244-50	78

1295	Supported bilayer on a nanopatterned membrane as model PAMPA membranes. 2011 , 421, 170-5	5
1294	Improvement of low bioavailability of a novel factor Xa inhibitor through formulation of cationic additives in its oral dosage form. 2011 , 421, 244-51	7
1293	Challenges in the development of hydrate phases as active pharmaceutical ingredients--an example. 2011 , 42, 116-29	25
1292	Enteric-coated tablets improve oral bioavailability of DX-9065, a novel anticoagulant. 2011 , 42, 392-9	10
1291	Drug metabolism of CYP3A4, CYP2C9 and CYP2D6 substrates in pigs and humans. 2011 , 43, 89-98	44
1290	Influence of solvent evaporation rate and formulation factors on solid dispersion physical stability. 2011 , 44, 610-20	56
1289	Efavirenz is a substrate and in turn modulates the expression of the efflux transporter ABCG2/BCRP in the gastrointestinal tract of the rat. 2011 , 82, 1227-33	40
1288	Chapter 6:Role of Co-crystals in the Pharmaceutical Development Continuum. 2011 , 110-127	2
1287	The Clinical Significance of Drug Transporters in Drug Disposition and Drug Interactions. 2011 , 285-313	2
1286	Chapter 11:Co-crystal Solubility and Thermodynamic Stability. 2011 , 247-279	5
1285	Recent Advances in Bioresponsive Nanomaterials. 2011 , 379-435	1
1284	Biological activity of aldose reductase and lipophilicity of pyrrolyl-acetic acid derivatives. 2011 , 85, 1803-1809	0
1283	Computational systems chemical biology. 2011 , 672, 459-88	18
1282	Physiologically based pharmacokinetic model of amphotericin B disposition in rats following administration of deoxycholate formulation (Fungizone [®]): pooled analysis of published data. 2011 , 13, 255-64	20
1281	Dissolution testing for generic drugs: an FDA perspective. 2011 , 13, 328-35	134
1280	Comparison of spray freeze drying and the solvent evaporation method for preparing solid dispersions of baicalein with Pluronic F68 to improve dissolution and oral bioavailability. 2011 , 12, 104-13	61
1279	In vitro-in vivo correlation for gliclazide immediate-release tablets based on mechanistic absorption simulation. 2011 , 12, 165-71	43
1278	Evaluation of the membrane permeability (PAMPA and skin) of benzimidazoles with potential cannabinoid activity and their relation with the Biopharmaceutics Classification System (BCS). 2011 , 12, 573-8	13

1277	Nitrendipine nanocrystals: its preparation, characterization, and in vitro-in vivo evaluation. 2011 , 12, 1136-43		30
1276	Drug delivery strategies for poorly water-soluble drugs: the industrial perspective. 2011 , 8, 1481-500		95
1275	Solubility Advantage of Amorphous Drugs and Pharmaceutical Cocrystals. 2011 , 11, 2662-2679		664
1274	BDDCS applied to over 900 drugs. 2011 , 13, 519-47		447
1273	LbL coated microcapsules for delivering lipid-based drugs. 2011 , 63, 837-46		77
1272	Biomagnetic methods: technologies applied to pharmaceutical research. <i>Pharmaceutical Research</i> , 2011 , 28, 438-55	4.5	17
1271	The BCS, BDDCS, and regulatory guidances. <i>Pharmaceutical Research</i> , 2011 , 28, 1774-8	4.5	70
1270	Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte?. <i>Pharmaceutical Research</i> , 2011 , 28, 2176-90	4.5	11
1269	Design of dry nanosuspension with highly spontaneous dispersible characteristics to develop solubilized formulation for poorly water-soluble drugs. <i>Pharmaceutical Research</i> , 2011 , 28, 2339-49	4.5	32
1268	CLSM as quantitative method to determine the size of drug crystals in a solid dispersion. <i>Pharmaceutical Research</i> , 2011 , 28, 2567-74	4.5	4
1267	Effect of cryogrinding on chemical stability of the sparingly water-soluble drug furosemide. <i>Pharmaceutical Research</i> , 2011 , 28, 3220-36	4.5	34
1266	Molecular imaging techniques to study the biodistribution of orally administered (99m)Tc-labelled naive and ligand-tagged nanoparticles. 2011 , 13, 1215-23		22
1265	Development and validation of discriminating method of dissolution for fosamprenavir tablets based on in vivo data. 2011 , 54, 439-44		17
1264	Diffusion coefficients in ethanol and in water at 298 K: Linear free energy relationships. 2011 , 303, 45-55		53
1263	Investigation of triacetin effect on indomethacin release from poly(methyl methacrylate) microspheres: evaluation of interactions using FT-IR and NMR spectroscopies. 2011 , 404, 102-9		31
1262	Formation of bicalutamide nanodispersion for dissolution rate enhancement. 2011 , 404, 257-63		50
1261	Simultaneous micronization and surface modification for improvement of flow and dissolution of drug particles. 2011 , 415, 185-95		113
1260	Studies on Flash Evaporation for Preparation of Porous Solid Dispersions Using Piroxicam as a Model Drug. 2011 , 6, 232-240		1

1259	Comparison of the solubility and pharmacokinetics of sildenafil salts. 2011 , 34, 451-4	36
1258	Role of metabolism by intestinal bacteria in arbutin-induced toxicity in vitro. 2011 , 34, 687-93	16
1257	Self-microemulsifying drug delivery system for improved oral bioavailability of dipyridamole: preparation and evaluation. 2011 , 34, 1113-23	29
1256	Interplay of pharmacogenetic variations in ABCB1 transporters and cytochrome P450 enzymes. 2011 , 34, 1817-28	13
1255	Preparation of lovastatin matrix sustained-release pellets by extrusion-spheronization combined with microcrystal dispersion technique. 2011 , 34, 1931-8	3
1254	Drug dissolution chip (DDC): a microfluidic approach for drug release. 2011 , 7, 3011-5	20
1253	Pharmacokinetics. 2011 , 3, 332-342	3
1252	Biowaiver monographs for immediate release solid oral dosage forms: ciprofloxacin hydrochloride. 2011 , 100, 22-33	61
1251	The biowaiver procedure: its application to antituberculosis products in the WHO prequalification programme. 2011 , 100, 822-30	3
1250	Investigation on the possibility of biowaivers for ibuprofen. 2011 , 100, 2343-9	37
1249	Characterization of nicergoline polymorphs crystallized in several organic solvents. 2011 , 100, 2610-22	9
1248	Single-step preparation and deagglomeration of itraconazole microflakes by supercritical antisolvent method for dissolution enhancement. 2011 , 100, 2952-65	19
1247	Monitoring lidocaine single-crystal dissolution by ultraviolet imaging. 2011 , 100, 3405-3410	42
1246	Fluoroquinolone salts with carboxylic acids. 2011 , 100, 3160-3176	48
1245	Preclinical pharmacokinetic evaluation of resveratrol trimethyl ether in sprague-dawley rats: the impacts of aqueous solubility, dose escalation, food and repeated dosing on oral bioavailability. 2011 , 100, 4491-500	36
1244	Two-dimensional pH mapping of release kinetics of silica-encapsulated drugs. 2011 , 100, 4401-12	4
1243	Phase behavior of TPGS-PEG400/1450 systems and their application to liquid formulation: a formulation platform approach. 2011 , 100, 4907-21	10
1242	Development of a new permeability assay using low-efflux MDCKII cells. 2011 , 100, 4974-85	220

1241	Biopharmaceutical characterization of ciprofloxacin HCl-ferrous sulfate interaction. 2011 , 100, 5174-84	17
1240	Computational-Regulatory Developments in the Prediction of Oral Drug Absorption. 2011 , 30, 112-21	1
1239	Oral Bioavailability of Peptide and Peptidomimetic Drugs. 2011 , 277-292	1
1238	Ionic liquids as active pharmaceutical ingredients. 2011 , 6, 975-85	238
1237	Recent advances of discrete coordination complexes and coordination polymers in drug delivery. 2011 , 255, 1623-1641	239
1236	A fast high throughput method for the determination of acidity constants by capillary electrophoresis. 3. Basic internal standards. 2011 , 1218, 3928-34	31
1235	Poly(lactide-co-glycolide) nanoparticles for peroral delivery of bioactives. 2011 , 16, 238-245	36
1234	Spray freeze drying with polyvinylpyrrolidone and sodium caprate for improved dissolution and oral bioavailability of oleanolic acid, a BCS Class IV compound. 2011 , 404, 148-58	60
1233	Carvedilol dissolution improvement by preparation of solid dispersions with porous silica. 2011 , 406, 41-8	105
1232	Self-double-emulsifying drug delivery system (SDEDDS): a new way for oral delivery of drugs with high solubility and low permeability. 2011 , 409, 245-51	74
1231	Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility. 2011 , 413, 237-44	102
1230	Physico-chemical characterization and in vitro/in vivo evaluation of loratadine:dimethyl-β-cyclodextrin inclusion complexes. 2011 , 55, 294-300	13
1229	Self-emulsifying pellets in a lab-scale high shear mixer: Formulation and production design. 2011 , 207, 113-118	18
1228	Formulation development of Carbamazepine-Nicotinamide co-crystals complexed with β-cyclodextrin using supercritical fluid process. 2011 , 55, 1070-1078	31
1227	Early development evaluation of AZD8081: a substrate for the NK receptors. 2011 , 37, 702-13	7
1226	Co-administration of a nanosuspension of a poorly soluble basic compound and a solution of a proton pump inhibitor--the importance of gastrointestinal pH and solubility for the in vivo exposure. 2011 , 37, 1036-42	8
1225	Enhancement of drug solubility and absorption by copolymers of 2-methacryloyloxyethyl phosphorylcholine and n-butyl methacrylate. 2011 , 26, 79-86	12
1224	Correlation between the systemic clearance of drugs and their food effects in humans. 2011 , 37, 1311-7	9

1223	The 18th European symposium on quantitative structure-activity relationships. 2011 , 6, 453-6	2
1222	Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. 2011 , 4, 347-53	19
1221	Amino acid prodrugs for oral delivery: challenges and opportunities. 2011 , 2, 959-62	10
1220	A pharmacokinetic model for evaluating the impact of hepatic and intestinal first-pass loss of saquinavir in the rat. 2011 , 39, 294-301	9
1219	The Microstructure and Digestion of Particles. 2011 , 11-29	1
1218	Fast disintegrating tablets: Opportunity in drug delivery system. 2011 , 2, 223-35	77
1217	Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. 2011 , 39, 2155-61	13
1216	In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans. 2011 , 403-47	23
1215	Technical Requirements for Biopharmaceutics Classification System-Based Biowaiver in China. 2011 , 45, 619-625	
1214	In Vitro Dissolution of Pharmaceutical Solids. 2011 , 39-49	1
1213	In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5 α -reductase inhibitor finasteride and the effects of coadministered ketoconazole. 2011 , 39, 847-57	15
1212	Study on the impact of SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) on the bioavailability of ibandronate (IBN) in postmenopausal women. 2011 , 21, 521-525	8
1211	Oral self-emulsifying drug delivery systems, from biopharmaceutical to technical formulation aspects. 2011 , 21, 17-26	33
1210	A formulation comparison between micro- and nanosuspensions: the importance of particle size for absorption of a model compound, following repeated oral administration to rats during early development. 2011 , 37, 185-92	31
1209	PepFect 14, a novel cell-penetrating peptide for oligonucleotide delivery in solution and as solid formulation. 2011 , 39, 5284-98	164
1208	Evaluating the Controlled Release Properties of Inhaled Nanoparticles Using Isolated, Perfused, and Ventilated Lung Models. 2011 , 2011, 1-16	24
1207	Development of Quantitative Structure-Property Relationship Models for Self-Emulsifying Drug Delivery System of 2-Aryl Propionic Acid NSAIDs. 2011 , 2011, 1-12	2
1206	Preparation of Fluconazole β -Cyclodextrin Complex Ocuserts: In Vitro and In Vivo Evaluation. 2011 , 2011, 237501	2

1205	Extensive intestinal glucuronidation of raloxifene in vivo in pigs and impact for oral drug delivery. 2012 , 42, 917-28	11
1204	Modeling and mechanistic approaches for oral absorption: quality by design in action. 2012 , 3, 147-50	5
1203	Comparison of the in vitro release characteristics of mucosal freeze-dried wafers and solvent-cast films containing an insoluble drug. 2012 , 38, 47-54	26
1202	Influence of a fat-rich meal on bioavailability of extended-release and immediate-release propiverine. 2012 , 52, 681-90	5
1201	Bioavailability and Bioequivalence. 2012 , 1	
1200	Involvement of concentrative nucleoside transporter 1 in intestinal absorption of trifluorothymidine, a novel antitumor nucleoside, in rats. 2012 , 340, 457-62	5
1199	Preparation method for solubilizing poorly oil-soluble compound in oil phase and the sustained release characteristics after subcutaneous administration in rats. 2012 , 22, 181-187	
1198	Intra-articular drug delivery for arthritis diseases: the value of extended release and targeting strategies. 2012 , 22, 409-419	5
1197	Physicochemical Properties of Encapsulated Red Raspberry (<i>Rubus idaeus</i>) Powder: Influence of High-Pressure Homogenization. 2012 , 30, 484-493	35
1196	Single process for manufacturing spheres with a lipid base (HCO). 2012 , 17, 303-14	2
1195	Dissolution enhancement of glimepiride using modified gum karaya as a carrier. 2012 , 2, 42-7	8
1194	In vitro-in vivo correlation evaluation of generic alfuzosin modified release tablets. 2012 , 2012, 813836	1
1193	Darunavir: a critical review of its properties, use and drug interactions. 2012 , 90, 102-9	21
1192	The Potential of In Silico and In Vitro Approaches to Predict In Vivo Drug-Drug Interactions and ADMET/TOX Properties. 2012 , 307-329	
1191	Cyclodextrin-based nanosponges as drug carriers. 2012 , 8, 2091-9	215
1190	Increasing the oral bioavailability of poorly water-soluble carbamazepine using immediate-release pellets supported on SBA-15 mesoporous silica. 2012 , 7, 5807-18	52
1189	Influence of the efavirenz micronization on tableting and dissolution. 2012 , 4, 430-41	7
1188	Mechanism of Drug Action: Basic Concepts. 2012 , 9-38	

1187	A primer for best practices in tissue preparation for bioanalysis. 2012 , 4, 2621-36	12
1186	Long-term stability of quercetin nanocrystals prepared by different methods. 2012 , 64, 1394-402	28
1185	Binding processes determine the stereoselective intestinal and hepatic extraction of verapamil in vivo. 2012 , 9, 3034-45	5
1184	The use of amorphous solid dispersions: A formulation strategy to overcome poor solubility and dissolution rate. 2012 , 9, e71-e174	344
1183	Molecular mobility as an effective predictor of the physical stability of amorphous trehalose. 2012 , 9, 3209-17	69
1182	Considerations in the development of an in vitro dissolution condition for lacidipine tablets: in vivo pharmacokinetic evaluation. 2012 , 38, 1099-106	10
1181	Improving solubility and pharmacokinetics of meloxicam via multiple-component crystal formation. 2012 , 9, 2094-102	89
1180	Biopharmaceutics classification and intestinal absorption study of apigenin. 2012 , 436, 311-7	101
1179	Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. 2012 , 34, S11-24	50
1178	Nanotechnology as Emerging Tool for Enhancing Solubility of Poorly Water-Soluble Drugs. 2012 , 2, 227-250	62
1177	Study of interaction between PEG carrier and three relevant drug molecules: piroxicam, paclitaxel, and hematoporphyrin. 2012 , 116, 7334-41	44
1176	Drug Absorption and Bioavailability. 2012 , 41-53	1
1175	Crystal morphology modification by the addition of tailor-made stereocontrolled poly(N-isopropyl acrylamide). 2012 , 9, 1932-41	10
1174	Overcoming poor oral bioavailability using nanoparticle formulations - opportunities and limitations. 2012 , 9, e71-e174	124
1173	The solubility-permeability interplay and its implications in formulation design and development for poorly soluble drugs. 2012 , 14, 244-51	168
1172	Fabrication of carvedilol nanosuspensions through the anti-solvent precipitation-ultrasonication method for the improvement of dissolution rate and oral bioavailability. 2012 , 13, 295-304	80
1171	Ditosylate salt of itraconazole and dissolution enhancement using cyclodextrins. 2012 , 13, 863-74	7
1170	Using USP I and USP IV for discriminating dissolution rates of nano- and microparticle-loaded pharmaceutical strip-films. 2012 , 13, 1473-82	51

1169	Towards a Greener Pharmacy by More Eco Design. 2012 , 3, 395-407		16
1168	Development and optimization of self-nanoemulsifying drug delivery system with enhanced bioavailability by Box-Behnken design and desirability function. 2012 , 101, 4584-96		48
1167	GC Determination of Famotidine, Ranitidine, Cimetidine, and Metformin in Pharmaceutical Preparations and Serum Using Methylglyoxal as Derivatizing Reagent. 2012 , 75, 1311-1317		17
1166	Instant and supersaturated dissolution of naproxen and sesamin (poorly water-soluble drugs and supplements) nanoparticles prepared by continuous expansion of liquid carbon dioxide solution through long dielectric nozzle. 2012 , 14, 1		1
1165	Electrolyte-stimulated biphasic dissolution profile and stability enhancement for tablets containing drug-polyelectrolyte complexes. <i>Pharmaceutical Research</i> , 2012 , 29, 2710-21	4-5	11
1164	Development of solid self-emulsifying drug delivery system (SEDDS) I: use of poloxamer 188 as both solidifying and emulsifying agent for lipids. <i>Pharmaceutical Research</i> , 2012 , 29, 2817-32	4-5	36
1163	Dedication to professor Leslie Z. Benet: 50 years of scientific excellence and still going strong!. <i>Pharmaceutical Research</i> , 2012 , 29, 2345-53	4-5	3
1162	Preclinical studies of YK-4-272, an inhibitor of class II histone deacetylases by disruption of nucleocytoplasmic shuttling. <i>Pharmaceutical Research</i> , 2012 , 29, 3373-83	4-5	8
1161	Preparation and evaluation of self-microemulsifying drug delivery system of baicalein. 2012 , 83, 1532-9		64
1160	Single-pass intestinal perfusion to establish the intestinal permeability of model drugs in mouse. 2012 , 436, 472-7		28
1159	Long-term stability, biocompatibility and oral delivery potential of risperidone-loaded solid lipid nanoparticles. 2012 , 436, 798-805		80
1158	Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement. 2012 , 437, 288-93		109
1157	The influence of supercritical carbon dioxide (SC-CO ₂) processing conditions on drug loading and physicochemical properties. 2012 , 439, 92-9		25
1156	Application of mixtures of polymeric carriers for dissolution enhancement of oxeglitazar using hot-melt extrusion. 2012 , 439, 145-56		25
1155	Self-reference chemical profiling in the comprehensive dissolution test of herbal medicines. 2012 , 70, 117-25		2
1154	Assessment and modulation of forsythiaside absorption with MDCKII cells and validation with in situ intestinal experiment. 2012 , 37, 179-86		3
1153	Use of highly compressible Ceolus [®] microcrystalline cellulose for improved dosage form properties containing a hydrophilic solid dispersion. 2012 , 38, 180-9		25
1152	Association colloids as delivery systems: principles and applications in the food and nutraceutical industries. 2012 , 257-292		1

1151	Formulation of ternary complexes of glyburide with hydroxypropyl-β-cyclodextrin and other solubilizing agents and their effect on release behavior of glyburide in aqueous and buffered media at different agitation speeds. 2012 , 38, 1328-36		17
1150	Determination of pharmacokinetics of itraconazole in healthy Indian subjects under fed condition and incurred sample analysis using a validated liquid chromatography tandem mass spectrometric method. 2012 , 29, 35-40		3
1149	Hybrid nanocrystals: University of Kentucky US20060280680A1. 2012 , 22, 341-8		5
1148	Structural and Physicochemical Aspects of Dasatinib Hydrate and Anhydrate phases. 2012 , 12, 2122-2126		57
1147	Novel polyvinylpyrrolidones to improve delivery of poorly water-soluble drugs: from design to synthesis and evaluation. 2012 , 9, 2237-47		4
1146	The fraction dose absorbed, in humans, and high jejunal human permeability relationship. 2012 , 9, 1847-51		64
1145	Synthesis and evaluation of sulfonylnitrophenylthiazoles (SNPTs) as thyroid hormone receptor-coactivator interaction inhibitors. 2012 , 55, 2301-10		20
1144	Saliva versus plasma pharmacokinetics: theory and application of a salivary excretion classification system. 2012 , 9, 2358-63		30
1143	New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis. <i>Pharmaceutical Research</i> , 2012 , 29, 2845-59	4-5	21
1142	Predicting feasibility and characterizing performance of extended-release formulations using physiologically based pharmacokinetic modeling. 2012 , 3, 1047-59		14
1141	Current regulatory approaches of bioequivalence testing. 2012 , 8, 929-42		12
1140	Simultaneous Determination of Assay and Related Substances in Nevirapine Suspension by HPLC. 2012 , 75, 893-901		1
1139	Drug-nutrient interactions: a broad view with implications for practice. 2012 , 112, 506-17		50
1138	Emulsion crystallization of phenanthrene by supercritical fluid extraction of emulsions. 2012 , 77, 249-258		17
1137	Fabrication of quercetin nanocrystals: comparison of different methods. 2012 , 80, 113-21		92
1136	Assessment of enzymatic prodrug stability in human, dog and simulated intestinal fluids. 2012 , 80, 630-7		27
1135	Overcoming instability and low solubility of new cytostatic compounds: a comparison of two approaches. 2012 , 80, 657-62		17
1134	Accounting for the solubility-permeability interplay in oral formulation development for poor water solubility drugs: the effect of PEG-400 on carbamazepine absorption. 2012 , 81, 386-91		76

1133	Spatial confinement can lead to increased stability of amorphous indomethacin. 2012 , 81, 418-25	50
1132	Melt Extrusion. 2012 , 311-362	13
1131	Pharmaceutical Cryogenic Technologies. 2012 , 443-500	3
1130	Effective absorption modeling in relative bioavailability study risk assessment. 2012 , 14, 895-903	2
1129	Elucidating the role of dose in the biopharmaceutics classification of drugs: the concepts of critical dose, effective in vivo solubility, and dose-dependent BCS. <i>Pharmaceutical Research</i> , 2012 , 29, 3188-98	4-5 20
1128	The right compound in the right assay at the right time: an integrated discovery DMPK strategy. 2012 , 44, 224-52	39
1127	Mechanistic analysis of solute transport in an in vitro physiological two-phase dissolution apparatus. 2012 , 33, 378-402	59
1126	Impact of the pharmaceutical sciences on health care: a reflection over the past 50 years. 2012 , 101, 4075-99	26
1125	A structural powder diffraction study of two polymorphic forms of nortriptyline hydrochloride. 2012 , 101, 4481-9	7
1124	Absorption. 2012 , 41-59	
1123	Solubility. 2012 , 65-85	
1122	The effect of food on the oral bioavailability of drugs: a review of current developments and pharmaceutical technologies for pharmacokinetic control. 2012 , 3, 81-90	19
1121	Crystal engineering of multiple-component organic solids: Pharmaceutical cocrystals of tadalafil with persistent hydrogen bonding motifs. 2012 , 14, 2377-2380	30
1120	Crystal engineering approach to improve the solubility of mebendazole. 2012 , 14, 6221	58
1119	Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes. 2012 , 74, 774-87	34
1118	Ethylene glycol-linked amino acid diester prodrugs of oleanolic acid for PepT1-mediated transport: synthesis, intestinal permeability and pharmacokinetics. 2012 , 9, 2127-35	40
1117	Caco-2 monolayers in experimental and theoretical predictions of drug transport. 2012 , 64, 280-289	158
1116	Transport Model. 2012 , 12-30	1

1115	PermeabilityBAMPA. 2012 , 319-498	8
1114	Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs. 2012 , 1-26	4
1113	Overcoming sink limitations in dissolution testing: a review of traditional methods and the potential utility of biphasic systems. 2012 , 64, 1549-59	102
1112	Oral bioavailability of ketoprofen in suspension and solution formulations in rats: the influence of poloxamer 188. 2012 , 64, 1631-7	11
1111	Microwave-generated bionanocomposites for solubility and dissolution enhancement of poorly water-soluble drug glipizide: in-vitro and in-vivo studies. 2013 , 65, 79-93	12
1110	Vinflunine oral pharmacokinetics and absolute bioavailability of soft and hard gelatin capsules: results of two phase I trials. 2012 , 51, 357-64	3
1109	Development of sildenafil-loaded orally disintegrating tablet with new lactate salt. 2012 , 38, 635-41	9
1108	Molecular buckets: cyclodextrins for oral cancer therapy. 2012 , 3, 43-57	16
1107	Crystal Engineering of Isostructural Quaternary Multicomponent Crystal Forms of Olanzapine. 2012 , 12, 4194-4201	52
1106	Applications of Poly(meth)acrylate Polymers in Melt Extrusion. 2012 , 113-144	1
1105	Drug solubility: importance and enhancement techniques. 2012 , 2012, 195727	645
1104	Crystallization and Polymorphism of Felodipine. 2012 , 12, 4022-4030	44
1103	Statistics on BCS classification of generic drug products approved between 2000 and 2011 in the USA. 2012 , 14, 664-6	13
1102	Felodipine-diazabicyclo[2.2.2]octane-water (1/1/1). 2012 , 68, o456-8	3
1101	Overcoming poor permeability: translating permeation enhancers for oral peptide delivery. 2012 , 9, e71-e174	61
1100	Overcoming poor permeability - the role of prodrugs for oral drug delivery. 2012 , 9, e71-e174	14
1099	Predicting the oral absorption of a poorly soluble, poorly permeable weak base using biorelevant dissolution and transfer model tests coupled with a physiologically based pharmacokinetic model. 2012 , 82, 127-38	58
1098	The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin. 2012 , 82, 187-93	23

1097	Novel pectin-based nanoparticles prepared from nanoemulsion templates for improving in vitro dissolution and in vivo absorption of poorly water-soluble drug. 2012 , 82, 250-61	40
1096	Transepithelial transport of biperiden hydrochloride in Caco-2 cell monolayers. 2012 , 34, 223-227	4
1095	pH-dependent solubility of indomethacin-saccharin and carbamazepine-saccharin cocrystals in aqueous media. 2012 , 9, 2605-12	89
1094	Preparation and Solid-State Characterization of Three Novel Multicomponent Solid Forms of Oxcarbazepine: Improvement in Solubility through Saccharin Cocrystal. 2012 , 12, 4211-4224	28
1093	Bioequivalence and Biopharmaceutical Classification System. 2012 , 322-339	
1092	Circadian variations in exsorbitive transport: in situ intestinal perfusion data and in vivo relevance. 2012 , 29, 443-53	32
1091	Pharmacokinetics. 2012 , 81-94	1
1090	Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. 2012 , 603-629	
1089	A win-win solution in oral delivery of lipophilic drugs: supersaturation via amorphous solid dispersions increases apparent solubility without sacrifice of intestinal membrane permeability. 2012 , 9, 2009-16	186
1088	Analysis of drug interactions with modified proteins by high-performance affinity chromatography: binding of glibenclamide to normal and glycosylated human serum albumin. 2012 , 1265, 114-22	45
1087	Generic drugs: myths, facts, and limitations. 2012 , 6, 146-152	1
1086	Phytomedicine-Loaded Polymeric Nanomedicines: Potential Cancer Therapeutics. 2012 , 203-239	5
1085	Ethanol effects on apparent solubility of poorly soluble drugs in simulated intestinal fluid. 2012 , 9, 1942-52	51
1084	Pharmacokinetics, safety, and tolerability of GLPG0259, a mitogen-activated protein kinase-activated protein kinase 5 (MAPKAPK5) inhibitor, given as single and multiple doses to healthy male subjects. 2012 , 12, 141-63	9
1083	Application of an in vitro DDASS to evaluate oral absorption of two chemicals simultaneously: establishment of a level A in vitro-in vivo correlation. 2012 , 38, 1305-12	3
1082	Discriminatory dissolution method for quality control measurements of carbamazepine immediate release tablets based on in vitro--in vivo investigations. 2012 , 38, 679-88	2
1081	Studying dissolution with a model integrating solid-liquid interface kinetics and diffusion kinetics. 2012 , 84, 10671-8	8
1080	The Impact of Solubility and Dissolution Assessment on Formulation Strategy and Implications for Oral Drug Disposition. 2012 , 1	3

1079	Pharmaceutical nanocrystals. 2012 , 1, 102-107	35
1078	Inorganic matrices: an answer to low drug solubility problem. 2012 , 9, 1559-72	25
1077	Has nanotechnology led to improved therapeutic outcomes?. 2012 , 38, 158-70	32
1076	pH-Dependent solubility and permeability criteria for provisional biopharmaceutics classification (BCS and BDDCS) in early drug discovery. 2012 , 9, 1199-212	115
1075	Development of novel ionic liquids based on ampicillin. 2012 , 3, 494	83
1074	SELF-EMULSIFYING DELIVERY SYSTEMS AND LIPID TRANSPORT. 2012 , 135-170	1
1073	Polymeric Foams for Oral Drug Delivery A Review. 2012 , 68, 32-39	2
1072	Established HPLC fraction analysis to predict furanocoumarin-based herb-drug metabolic interactions. 2012 , 26, 865-77	2
1071	BDDCS class prediction for new molecular entities. 2012 , 9, 570-80	70
1070	Solid-state thermal behavior and stability studies of theophylline citric acid cocrystals prepared by neat cogrinding or thermal treatment. 2012 , 192, 238-245	25
1069	Provisional biopharmaceutical classification of some common herbs used in Western medicine. 2012 , 9, 815-22	36
1068	Bridging solubility between drug discovery and development. 2012 , 17, 486-95	284
1067	Preparation, characterization, and in vitro intestinal permeability evaluation of thalidomide-hydroxypropyl- β -cyclodextrin complexes. 2012 , 13, 118-24	17
1066	Chapter 4: Bioavailability Prediction at Early Drug Discovery Stages: In Vitro Assays and Simple Physico-Chemical Rules. 2012 , 104-127	4
1065	A biopharmaceutical classification-based Right-First-Time formulation approach to reduce human pharmacokinetic variability and project cycle time from First-In-Human to clinical Proof-Of-Concept. 2012 , 17, 285-302	120
1064	Targeted prodrugs in oral drug delivery: the modern molecular biopharmaceutical approach. 2012 , 9, 1001-13	43
1063	Immobilization of 2-mercaptoethylamine on oxidized chitosan: a substantially mucoadhesive and permeation enhancing polymer. 2012 , 22, 3899	13
1062	In silico prediction of drug dissolution and absorption with variation in intestinal pH for BCS class II weak acid drugs: ibuprofen and ketoprofen. 2012 , 33, 366-77	64

1061	Solution-mediated phase transformation: significance during dissolution and implications for bioavailability. 2012 , 101, 2996-3018	89
1060	Influence of lipid composition and drug load on the In Vitro performance of self-nanoemulsifying drug delivery systems. 2012 , 101, 1721-31	59
1059	Biowaiver approach for biopharmaceutics classification system class 3 compound metformin hydrochloride using in silico modeling. 2012 , 101, 1773-82	28
1058	Evaluation of factors affecting gastrointestinal absorption of a novel anticoagulant FX-93 for development of oral formulation. 2012 , 101, 2134-42	5
1057	Improved intestinal absorption of a poorly water-soluble oral drug using mannitol microparticles containing a nanosolid drug dispersion. 2012 , 101, 4191-200	13
1056	Utilizing Pluronic F-127 and Gelucire 50/13 Solid Dispersions for Enhanced Skin Delivery of Flufenamic Acid. 2012 , 73, 299-307	20
1055	Excipients with specialized functions for effective drug delivery. 2012 , 9, 219-30	16
1054	Comparison of the intestinal absorption and bioavailability of Eucotrienol and Eucopherol: in vitro, in situ and in vivo studies. 2012 , 33, 246-56	36
1053	Development strategies for IVIVC in an industrial environment. 2012 , 33, 349-53	11
1052	How good are the crystallisation methods for co-crystals? A comparative study of piroxicam. 2012 , 36, 1969	68
1051	A technique to estimate in vivo dissolution profiles without data from a solution. 2012 , 14, 433-6	5
1050	The solubility-permeability interplay when using cosolvents for solubilization: revising the way we use solubility-enabling formulations. 2012 , 9, 581-90	103
1049	Star-like oligo-arginyl-maltotriosyl derivatives as novel cell-penetrating enhancers for the intracellular delivery of colloidal therapeutic systems. 2012 , 23, 1415-25	14
1048	Pharmacokinetic modeling to assess factors affecting the oral bioavailability of the lactone and carboxylate forms of the lipophilic camptothecin analogue AR-67 in rats. <i>Pharmaceutical Research</i> , 2012 , 29, 1722-36	4.5 9
1047	Sotalol permeability in cultured-cell, rat intestine, and PAMPA system. <i>Pharmaceutical Research</i> , 2012 , 29, 1768-74	4.5 15
1046	Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers. 2012 , 70, 183-90	6
1045	Liquid antisolvent precipitation and stabilization of nanoparticles of poorly water soluble drugs in aqueous suspensions: Recent developments and future perspective. 2012 , 181-182, 1-34	248
1044	Theoretical and experimental analysis of drug release from an ensemble of polymeric particles containing amorphous and nano-crystalline drug. 2012 , 71, 345-355	17

1043	Lipospheres and pro-nano lipospheres for delivery of poorly water soluble compounds. 2012 , 165, 438-53	68
1042	Nano and microparticle engineering of water insoluble drugs using a novel spray-drying process. 2012 , 90, 8-15	100
1041	Bile salt composition is secondary to bile salt concentration in determining hydrocortisone and progesterone solubility in intestinal mimetic fluids. 2012 , 422, 295-301	14
1040	Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology. 2012 , 422, 516-22	28
1039	Drug solubilization and in vitro toxicity evaluation of lipoamino acid surfactants. 2012 , 423, 312-20	36
1038	Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications. 2012 , 423, 496-508	125
1037	Development of a novel ultra cryo-milling technique for a poorly water-soluble drug using dry ice beads and liquid nitrogen. 2012 , 426, 162-169	25
1036	Comparative studies on physicochemical stability of cyclosporine A-loaded amorphous solid dispersions. 2012 , 426, 302-306	16
1035	Relationship between dissolution and bioavailability for nimodipine colloidal dispersions: the critical size in improving bioavailability. 2012 , 427, 358-64	22
1034	Aminoalkyl methacrylate copolymers for improving the solubility of tacrolimus. I: Evaluation of solid dispersion formulations. 2012 , 428, 18-24	38
1033	Solid dispersions of itraconazole for inhalation with enhanced dissolution, solubility and dispersion properties. 2012 , 428, 103-13	49
1032	Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion. 2012 , 429, 58-68	64
1031	Predicting the solubility-permeability interplay when using cyclodextrins in solubility-enabling formulations: model validation. 2012 , 430, 388-91	55
1030	Thermosensitive and mucoadhesive in situ gel based on poloxamer as new carrier for rectal administration of nimesulide. 2012 , 430, 114-9	92
1029	Application of a ternary HP- β -CD-complex approach to improve the dissolution performance of a poorly soluble weak acid under biorelevant conditions. 2012 , 430, 176-83	36
1028	Insight into the solubility and dissolution behavior of piroxicam anhydrate and monohydrate forms. 2012 , 431, 111-9	29
1027	Development of a precipitation-resistant solution formulation to increase in vivo exposure of a poorly water-soluble compound. 2012 , 433, 94-101	6
1026	Soluplus [®] as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo. 2012 , 45, 336-43	163

1025	In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives. 2012 , 45, 235-50	95
1024	Skin-PAMPA: a new method for fast prediction of skin penetration. 2012 , 45, 698-707	109
1023	Human small intestinal and colonic tissue mounted in the Ussing chamber as a tool for characterizing the intestinal absorption of drugs. 2012 , 46, 367-73	98
1022	Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. 2012 , 47, 16-20	51
1021	Application of spray granulation for conversion of a nanosuspension into a dry powder form. 2012 , 47, 35-43	50
1020	Pharmacokinetics and drug interactions of eslicarbazepine acetate. 2012 , 53, 935-46	119
1019	Determination of trans-2,4,3',4',5'-pentamethoxystilbene in rat plasma and its application to a pharmacokinetic study. 2012 , 57, 94-8	13
1018	Thermal analysis and FTIR spectral curve-fitting investigation of formation mechanism and stability of indomethacin-saccharin cocrystals via solid-state grinding process. 2012 , 66, 162-9	61
1017	MCM-41 for furosemide dissolution improvement. 2012 , 147, 343-349	56
1016	Preparation of pH sensitive poly(vinylidene fluoride) porous membranes by grafting of acrylic acid assisted by supercritical carbon dioxide. 2012 , 66, 241-250	18
1015	High pressure homogenization of pharmaceutical solids. 2012 , 66, 380-388	31
1014	Lipid-polymer hybrid nanoparticles with rhamnolipid-triggered release capabilities as anti-biofilm drug delivery vehicles. 2012 , 10, 327-333	54
1013	Microstructured ternary solid dispersions to improve carbamazepine solubility. 2012 , 215-216, 156-165	29
1012	Release profile of ibuprofen in β -cyclodextrin complexes from two different solid dosage forms. 2012 , 221, 245-251	7
1011	Utilization of hydrolytic enzymes for the extraction of ginsenosides from Korean ginseng leaves. 2012 , 47, 538-543	13
1010	Administration of resveratrol: What formulation solutions to bioavailability limitations?. 2012 , 158, 182-93	420
1009	Development and characterization of a novel drug nanocarrier for oral delivery, based on self-assembled β -casein micelles. 2012 , 160, 164-71	113
1008	Formulations based on alpha cyclodextrin and soybean oil: an approach to modulate the oral release of lipophilic drugs. 2012 , 161, 861-7	17

1007	Establishing bioequivalence of veterinary premixes (Type A medicated articles). 2012 , 35 Suppl 1, 53-63	3
1006	The scientific basis for establishing solubility criteria for veterinary species. 2012 , 35 Suppl 1, 81-6	6
1005	How do you define equivalence of the API of biomass products?. 2012 , 35 Suppl 1, 99-101	1
1004	Estimating product bioequivalence for highly variable veterinary drugs. 2012 , 35 Suppl 1, 11-6	5
1003	Biorelevant in-vitro performance testing of orally administered dosage forms. 2012 , 64, 919-30	39
1002	Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim [®] . 2012 , 64, 997-1007	30
1001	Comparison of electrospun and extruded Soluplus [®] -based solid dosage forms of improved dissolution. 2012 , 101, 322-32	161
1000	Novel furosemide cocrystals and selection of high solubility drug forms. 2012 , 101, 664-80	116
999	Effect of lipophilicity on the bioavailability of drugs after percutaneous administration by dissolving microneedles. 2012 , 101, 1145-56	23
998	Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part II: extension to describe performance of solid dosage forms. 2012 , 101, 1267-80	50
997	Suitability of isolated rat jejunum model for demonstration of complete absorption in humans for BCS-based biowaiver request. 2012 , 101, 1436-49	19
996	A formulation strategy for gamma secretase inhibitor ELND006, a BCS class II compound: development of a nanosuspension formulation with improved oral bioavailability and reduced food effects in dogs. 2012 , 101, 1462-74	17
995	A case study on the in silico absorption simulations of levothyroxine sodium immediate-release tablets. 2012 , 33, 146-59	6
994	The effect of food on the bioavailability of panobinostat, an orally active pan-histone deacetylase inhibitor, in patients with advanced cancer. 2012 , 69, 555-62	31
993	Polymeric nanoparticles for increased oral bioavailability and rapid absorption using celecoxib as a model of a low-solubility, high-permeability drug. <i>Pharmaceutical Research</i> , 2012 , 29, 427-40	4-5 95
992	Solid state studies of drugs and chemicals by dielectric and calorimetric analysis. 2012 , 108, 227-233	7
991	Pharmacokinetics of a peroral single dose of two long-acting formulations and an aqueous formulation of doxycycline hyclate in horses. 2013 , 55, 21	12
990	Pharmacokinetic evaluation of three oral formulations of docetaxel boosted with ritonavir: two single-drug formulations vs. a fixed-dose combination tablet. 2013 , 3, 243-51	6

989	Co-solubilization of the Hydrophobic Drugs Carbamazepine and Nifedipine in Aqueous Nonionic Surfactant Media. 2013 , 42, 1374-1392		8
988	Effect of glucosamine HCl on dissolution and solid state behaviours of piroxicam upon milling. 2013 , 103, 189-99		21
987	Characterization of palygorskite clay from Piau^ Brazil and its potential use as excipient for solid dosage forms containing anti-tuberculosis drugs. 2013 , 113, 551-558		13
986	Measurement of drug concentration in the stomach after intragastric administration of drug solution to healthy volunteers: analysis of intragastric fluid dynamics and drug absorption. <i>Pharmaceutical Research</i> , 2013 , 30, 951-8	4-5	24
985	Molecular mobility as a predictor of the water sorption by annealed amorphous trehalose. <i>Pharmaceutical Research</i> , 2013 , 30, 714-20	4-5	6
984	Predictive approaches to increase absorption of compounds during lead optimisation. 2013 , 8, 1225-38		11
983	Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. 2013 , 83, 87-94		59
982	Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems. 2013 , 39, 1431-8		36
981	Seventy-two-hour release formulation of the poorly soluble drug silybin based on porous silica nanoparticles: in vitro release kinetics and in vitro/in vivo correlations in beagle dogs. 2013 , 48, 64-71		45
980	Solid-state dependent dissolution and oral bioavailability of piroxicam in rats. 2013 , 48, 47-54		18
979	Impact of osmotically active excipients on bioavailability and bioequivalence of BCS class III drugs. 2013 , 15, 1043-50		34
978	Design of self-dispersible dry nanosuspension through wet milling and spray freeze-drying for poorly water-soluble drugs. 2013 , 50, 272-81		48
977	Commercially bioavailable proprietary technologies and their marketed products. 2013 , 18, 936-49		40
976	Development of Preclinical Formulations for Toxicology Studies. 2013 , 69-86		4
975	Strategies for the design of orally bioavailable antileishmanial treatments. 2013 , 454, 539-52		42
974	Aqueous solubility: simple predictive methods (in silico, in vitro and bio-relevant approaches). 2013 , 453, 3-11		40
973	Release profiles of indometacin in β -cyclodextrin complexes from HPMC capsules. 2013 , 75, 101-109		3
972	Colon targeting of fluticasone propionate inclusion complex: a novel approach in inflammatory bowel disease. 2013 , 75, 175-184		4

971	Crystal Structures and Physicochemical Properties of Four New Lamotrigine Multicomponent Forms. 2013 , 13, 858-870	39
970	Application of in vitro biopharmaceutical methods in development of immediate release oral dosage forms intended for paediatric patients. 2013 , 85, 833-42	38
969	In vitro-in vivo correlation of efavirenz tablets using GastroPlus® . 2013 , 14, 1244-54	42
968	Spray granulation: importance of process parameters on in vitro and in vivo behavior of dried nanosuspensions. 2013 , 85, 1046-55	29
967	Mesoporous calcium carbonate as a phase stabilizer of amorphous celecoxib--an approach to increase the bioavailability of poorly soluble pharmaceutical substances. 2013 , 2, 1469-76	22
966	The twofold advantage of the amorphous form as an oral drug delivery practice for lipophilic compounds: increased apparent solubility and drug flux through the intestinal membrane. 2013 , 15, 347-53	55
965	Regional-dependent intestinal permeability and BCS classification: elucidation of pH-related complexity in rats using pseudoephedrine. 2013 , 15, 589-97	38
964	Low-viscosity hydroxypropylcellulose (HPC) grades SL and SSL: versatile pharmaceutical polymers for dissolution enhancement, controlled release, and pharmaceutical processing. 2013 , 14, 151-9	31
963	Ketoconazole Salt and Co-crystals with Enhanced Aqueous Solubility. 2013 , 13, 4295-4304	59
962	Impact of amorphous and semicrystalline polymers on the dissolution and crystallization inhibition of pioglitazone solid dispersions. 2013 , 247, 211-221	29
961	Solubility of Ibuprofen, Phytosterol, Salicylic Acid, and Naproxen in Aqueous Solutions. 2013 , 36, 426-434	12
960	Influence of process parameters and equipment on dry foam formulation properties using indomethacin as model drug. 2013 , 455, 189-96	18
959	Mineralogy affects geoavailability, bioaccessibility and bioavailability of zinc. 2013 , 182, 217-24	25
958	Improved human bioavailability of vemurafenib, a practically insoluble drug, using an amorphous polymer-stabilized solid dispersion prepared by a solvent-controlled coprecipitation process. 2013 , 102, 967-81	138
957	Ultrasound-assisted improvement of drug solubility: a simple and useful method for the formation of salts from 4-hydroxy-6-methyl-3-nitropyridin-2(1H)-one. 2013 , 144, 1165-1170	
956	Reduction of melting temperature and enthalpy of drug crystals: theoretical aspects. 2013 , 50, 17-28	24
955	Progressive applications of dissolution, its impact, and implications in the pharmaceutical world. 2013 , 102, 2895-7	4
954	A perspective on the prediction of drug pharmacokinetics and disposition in drug research and development. 2013 , 41, 1975-93	81

953	Experimental and mesoscale computational dynamics studies of the relationship between solubility and release of quercetin from PEG solid dispersions. 2013 , 456, 282-92	20
952	Purely in silico BCS classification: science based quality standards for the world's drugs. 2013 , 10, 4378-90	56
951	Solid crystal suspensions containing griseofulvin--preparation and bioavailability testing. 2013 , 83, 193-202	23
950	Fumaric acid microenvironment tablet formulation and process development for crystalline cenicriviroc mesylate, a BCS IV compound. 2013 , 10, 4005-15	9
949	Optimizing solubility and permeability of a biopharmaceutics classification system (BCS) class 4 antibiotic drug using lipophilic fragments disturbing the crystal lattice. 2013 , 56, 2690-4	32
948	Evidence for oral agmatine sulfate safety--a 95-day high dosage pilot study with rats. 2013 , 62, 758-62	11
947	Clinical pharmacokinetics of second generation antisense oligonucleotides. 2013 , 9, 169-82	94
946	Formulation, characterization and permeability study of nano particles of lipo-endomorphin-1 for oral delivery. 2013 , 23, 311-7	5
945	Biorelevant characterisation of amorphous furosemide salt exhibits conversion to a furosemide hydrate during dissolution. 2013 , 457, 14-24	26
944	Strategies to address low drug solubility in discovery and development. 2013 , 65, 315-499	992
943	Using Dissolution and Pharmacokinetics Studies of Crystal Form to Optimize the Original Iloperidone. 2013 , 13, 5261-5266	21
942	Dose-dependent targeted suppression of P-glycoprotein expression and function in Caco-2 cells. 2013 , 10, 2323-30	16
941	Improving lithium therapeutics by crystal engineering of novel ionic cocrystals. 2013 , 10, 4728-38	60
940	Oral lipid-based drug delivery systems Ìan overview. 2013 , 3, 361-372	266
939	Multivariate analysis of quaternary carbamazepine-saccharin mixtures by X-ray diffraction and infrared spectroscopy. 2013 , 78-79, 269-79	28
938	Influence of borneol and muscone on geniposide transport through MDCK and MDCK-MDR1 cells as blood-brain barrier in vitro model. 2013 , 456, 73-9	43
937	Natural halloysite nanotubes as mesoporous carriers for the loading of ibuprofen. 2013 , 179, 89-98	116
936	In vitro inhibition of metabolism but not transport of gliclazide and repaglinide by Cree medicinal plant extracts. 2013 , 150, 1087-95	6

935	Bioavailability of cinnarizine in dogs: effect of SNEDDS loading level and correlation with cinnarizine solubilization during in vitro lipolysis. <i>Pharmaceutical Research</i> , 2013 , 30, 3101-13	4-5	24
934	New surface hydroxylated and internally quaternised poly(propylene imine) dendrimers as efficient biocompatible drug carriers of norfloxacin. 2013 , 10, 1319-34		13
933	Hot melt extrusion for amorphous solid dispersions: temperature and moisture activated drug-polymer interactions for enhanced stability. 2013 , 10, 3665-75		58
932	In silico prediction of the solubility advantage for amorphous drugs - Are there property-based rules for drug discovery and early pharmaceutical development?. 2013 , 48, 554-62		14
931	Solubility of ranitidine hydrochloride in solvent mixtures of PEG 200, PEG 400, ethanol and propylene glycol at 25°C. 2013 , 182, 91-94		20
930	Preparation and in vitro/in vivo evaluation of fenofibrate nanocrystals. 2013 , 455, 267-75		57
929	Effect of P-glycoprotein on the rat intestinal permeability and metabolism of the BDDCS class 1 drug verapamil. 2013 , 10, 4038-45		2
928	Permutation Test (PT) and Tolerated Difference Test (TDT): two new, robust and powerful nonparametric tests for statistical comparison of dissolution profiles. 2013 , 441, 458-67		10
927	Strategies to avoid electrode fouling for nimesulide detection using unmodified electrodes. 2013 , 5, 3546		9
926	Role of P-glycoprotein in the uptake/efflux transport of oral vitamin K antagonists and rivaroxaban through the Caco-2 cell model. 2013 , 113, 259-65		26
925	Improving Solubility via Structural Modification. 2013 , 69-106		6
924	Current issues in biowaivers and biosimilars. 2013 , 6, 139-142		1
923	Solubility and dissolution enhancement of saquinavir mesylate by inclusion complexation technique. 2013 , 76, 467-472		6
922	Characterization of semi-solid Self-Emulsifying Drug Delivery Systems (SEDDS) of atorvastatin calcium by Raman image spectroscopy and chemometrics. 2013 , 73, 3-12		36
921	A new approach to dissolution testing by UV imaging and finite element simulations. <i>Pharmaceutical Research</i> , 2013 , 30, 1328-37	4-5	28
920	The role of BCS (biopharmaceutics classification system) and BDDCS (biopharmaceutics drug disposition classification system) in drug development. 2013 , 102, 34-42		193
919	Dissolution enhancement of poorly water-soluble APIs processed by hot-melt extrusion using hydrophilic polymers. 2013 , 39, 218-27		81
918	Formulation factors affecting the release of ezetimibe from different liquisolid compacts. 2013 , 18, 417-27		16

917	Polymorphism and solvatomorphism of bicalutamide. 2013 , 111, 655-662		23
916	Case studies for practical food effect assessments across BCS/BDDCS class compounds using in silico, in vitro, and preclinical in vivo data. 2013 , 15, 143-58		41
915	Pharmacokinetics and bioequivalence in the pig of two ivermectin feed formulations. 2013 , 36, 350-7		3
914	Selection of excipient, solvent and packaging to optimize the performance of spray-dried formulations: case example fenofibrate. 2013 , 39, 402-12		22
913	Physicochemical characterization and in vitro dissolution studies of solid dispersions of ketoprofen with PVP K30 and d-mannitol. 2013 , 21, 77-84		60
912	Enhancing the intestinal absorption of poorly water-soluble weak-acidic compound by controlling local pH. 2013 , 39, 1887-94		4
911	Influence of the nanocomposite MgAl-HTlc on gastric absorption of drugs: in vitro and ex vivo studies. <i>Pharmaceutical Research</i> , 2013 , 30, 156-66	4.5	20
910	Metal ions guided self-assembly of therapeutic proteins for controllable release: from random to ordered aggregation. <i>Pharmaceutical Research</i> , 2013 , 30, 269-79	4.5	2
909	Development of meloxicam salts with improved dissolution and pharmacokinetic behaviors in rats with impaired gastric motility. <i>Pharmaceutical Research</i> , 2013 , 30, 377-86	4.5	14
908	A physiologically based pharmacokinetic model of the minipig: data compilation and model implementation. <i>Pharmaceutical Research</i> , 2013 , 30, 1-15	4.5	64
907	In silico physicochemical parameter predictions. 2013 , 10, 1224-35		31
906	Biowaiver monographs for immediate release solid oral dosage forms: efavirenz. 2013 , 102, 318-29		21
905	Role of intestinal microflora in xenobiotic-induced toxicity. 2013 , 57, 84-99		24
904	Evolution of ADME science: where else can modeling and simulation contribute?. 2013 , 10, 1162-70		17
903	Comparison of fenofibrate-mesoporous silica drug-loading processes for enhanced drug delivery. 2013 , 50, 400-9		81
902	Taxanes: old drugs, new oral formulations. 2013 , 717, 40-6		41
901	In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim. 2013 , 49, 679-98		120
900	Profiling biopharmaceutical deciding properties of absorption of lansoprazole enteric-coated tablets using gastrointestinal simulation technology. 2013 , 453, 300-6		12

899	Osmotic pump tablets for delivery of antiretrovirals to the vaginal mucosa. 2013 , 100, 255-8	15
898	Organogels, hydrogels and bigels as transdermal delivery systems for diltiazem hydrochloride. 2013 , 8, 48-57	58
897	From laboratory to pilot plant: the solid-state process development of a highly potent cathepsin S/K inhibitor. 2013 , 83, 436-48	7
896	Technological and biopharmaceutical optimization of nystatin release from a multiparticulate based bioadhesive drug delivery system. 2013 , 49, 258-64	13
895	Dissolution rate enhancement, in vitro evaluation and investigation of drug release kinetics of chloramphenicol and sulphamethoxazole solid dispersions. 2013 , 39, 704-15	12
894	Investigation of clinical pharmacokinetic variability of an opioid antagonist through physiologically based absorption modeling. 2013 , 102, 2859-74	4
893	Study of dissolution profiles and desintegration of capsules containing the dried hydroethanolic extract of <i>Calophyllum brasiliense</i> . 2013 , 23, 194-199	4
892	Characterization, dissolution and in vivo evaluation of solid acetazolamide complexes. 2013 , 98, 380-90	21
891	Precipitation and stabilization of ultrafine particles of Fenofibrate in aqueous suspensions by RESOLV. 2013 , 236, 75-84	33
890	Orbifloxacin: A Review of Properties, Its Antibacterial Activities, Pharmacokinetic/Pharmacodynamic Characteristics, Therapeutic Use, and Analytical Methods. 2013 , 43, 79-99	11
889	Intestinal drug transporters: an overview. 2013 , 65, 1340-56	215
888	Comparison of the permeability of metoprolol and labetalol in rat, mouse, and Caco-2 cells: use as a reference standard for BCS classification. 2013 , 10, 958-66	50
887	Thermal, spectroscopic, and dissolution studies of the simvastatin/acetylsalicylic acid mixtures. 2013 , 111, 2125-2132	29
886	Development and Characterization of a Cocrystal as a Viable Solid Form for an Active Pharmaceutical Ingredient. 2013 , 17, 540-548	10
885	Formation of itraconazole/L-malic acid cocrystals by gas antisolvent cocrystallization. 2013 , 236, 122-131	46
884	New formulation approaches to improve solubility and drug release from fixed dose combinations: case examples pioglitazone/glimepiride and ezetimibe/simvastatin. 2013 , 84, 208-18	51
883	Poly(D, L-lactide-co-glycolide)/montmorillonite nanoparticles for improved oral delivery of exemestane. 2013 , 30, 432-40	23
882	Quality risk management in pharmaceutical development. 2013 , 39, 947-60	27

881	Atmospheric freeze drying for the reduction of powder electrostatics of amorphous, low density, high surface area pharmaceutical powders. 2013 , 39, 205-17	6
880	The oral delivery of peptides and proteins: established versus recently patented approaches. 2013 , 2, 125-45	7
879	Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. 2013 , 52, 399-414	78
878	Formulation and optimization of spray-dried amlodipine solid dispersion for enhanced oral absorption. 2013 , 39, 1133-41	24
877	Drug discovery and regulatory considerations for improving in silico and in vitro predictions that use Caco-2 as a surrogate for human intestinal permeability measurements. 2013 , 15, 483-97	87
876	Cyclodextrins. 2013 , 453, 167-80	549
875	Combination of Cyclodextrin inclusion complex and self-microemulsifying drug delivery system for photostability and enhanced oral bioavailability of methotrexate: novel technique. 2013 , 39, 918-27	22
874	Increased dissolution and oral absorption of itraconazole/Soluplus extrudate compared with itraconazole nanosuspension. 2013 , 85, 1285-92	78
873	A comparative analysis of biopharmaceutics classification system and biopharmaceutics drug disposition classification system: a cross-sectional survey with 500 bioequivalence studies. 2013 , 102, 3136-44	28
872	Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations". 2013 , 50, 8-16	125
871	Specialized Solid Form Screening Techniques. 2013 , 17, 457-471	81
870	Development of PVP/PEG mixtures as appropriate carriers for the preparation of drug solid dispersions by melt mixing technique and optimization of dissolution using artificial neural networks. 2013 , 85, 1219-31	36
869	Drug Metabolism and Pharmacokinetics in Drug Discovery. 2013 , 99-139	1
868	Antiviral Drug Discovery. 2013 , 439-515	
867	Advances in the design of a multipurpose fragment screening library. 2013 , 8, 597-606	15
866	Encapsulation of Acyclovir in new carboxylated cyclodextrin-based nanosponges improves the agent's antiviral efficacy. 2013 , 443, 262-72	113
865	Determination of lamivudine and zidovudine permeability using a different ex vivo method in Franz cells. 2013 , 67, 194-202	18
864	Lipid-based formulations for oral administration of poorly water-soluble drugs. 2013 , 453, 215-24	203

863	Enhancing bioavailability through thermal processing. 2013 , 450, 185-96		31
862	Clinical Pharmacokinetic Studies. 2013 , 1139-1210		2
861	Impact of polymers on crystal growth rate of structurally diverse compounds from aqueous solution. 2013 , 10, 2381-93		81
860	Drug nanocrystals in the commercial pharmaceutical development process. 2013 , 453, 142-56		264
859	An improved prediction of the human in vivo intestinal permeability and BCS class of drugs using the in vitro permeability ratio obtained for rat intestine using an Ussing chamber system. 2013 , 39, 1515-22		15
858	Nimodipine nanocrystals for oral bioavailability improvement: role of mesenteric lymph transport in the oral absorption. 2013 , 448, 290-7		59
857	Development of amorphous solid dispersion formulations of a poorly water-soluble drug, MK-0364. 2013 , 452, 73-81		56
856	Real-time dissolution behavior of furosemide in biorelevant media as determined by UV imaging. 2013 , 18, 1407-16		24
855	Correlation between molecular mobility and physical stability of amorphous itraconazole. 2013 , 10, 694-700		81
854	Differential surface properties of commercial crystalline telmisartan samples. 2013 , 49, 109-16		20
853	Prediction of drug disposition on the basis of its chemical structure. 2013 , 52, 415-31		21
852	Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. <i>Pharmaceutical Research</i> , 2013 , 30, 3029-44	4.5	63
851	Molecular dynamics simulations of PPI dendrimer-drug complexes. 2013 , 9, 6482		41
850	Innovative approaches for demonstration of bioequivalence: the US FDA perspective. 2013 , 4, 725-40		33
849	A new way of stabilization of furosemide upon cryogenic grinding by using acylated saccharides matrices. The role of hydrogen bonds in decomposition mechanism. 2013 , 10, 1824-35		26
848	Hot Melt Extrusion: A Process Overview and Use in Manufacturing Solid Dispersions of Poorly Water-Soluble Drugs. 2013 , 325-358		1
847	Enhanced Solubility of Poorly Soluble Drugs Via Spray Drying. 2013 , 551-585		2
846	Nanosuspensions with Enhanced Drug Dissolution Rates of Poorly Water-Soluble Drugs. 2013 , 265-286		1

845	Novel Top-Down Technologies: Effective Production of Ultra-Fine Drug Nanocrystals. 2013 , 247-263	1
844	Food, physiology and drug delivery. 2013 , 457, 446-60	85
843	Facile Syntheses of Novel Salts of a Triazole Antifungal Agent with Enhanced Solubility. 2013 , 50, 490-495	13
842	Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number. 2013 , 10, 2445-61	56
841	Soluble itraconazole in tablet form using disordered drug delivery approach: critical scale-up considerations and bio-equivalence studies. 2013 , 14, 360-74	11
840	Keeping a critical eye on the science and the regulation of oral drug absorption: a review. 2013 , 102, 3018-36	21
839	Solubility Advantage of Tenoxicam Phenolic Cocrystals Compared to Salts. 2013 , 13, 1988-2003	68
838	Regulatory status on the role of in vitro dissolution testing in quality control and biopharmaceutics in Europe. 2013 , 34, 247-53	14
837	Polymorph Discrimination using Low Wavenumber Raman Spectroscopy. 2013 , 17, 976-980	41
836	Risk analysis in bioequivalence and biowaiver decisions. 2013 , 34, 254-61	8
835	Enhanced dissolution and systemic availability of albendazole formulated as solid dispersions. 2013 , 18, 434-42	20
834	New Solid Forms of the Anti-HIV Drug Etravirine: Salts, Cocrystals, and Solubility. 2013 , 13, 3681-3690	59
833	Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation. 2013 , 36, 69-78	37
832	Olanzapinium Salts, Isostructural Solvates, and Their Physicochemical Properties. 2013 , 13, 3672-3680	52
831	Physicochemical characterization of felodipine-kollidon VA64 amorphous solid dispersions prepared by hot-melt extrusion. 2013 , 102, 1915-1923	44
830	Cyclodextrin-water soluble polymer ternary complexes enhance the solubility and dissolution behaviour of poorly soluble drugs. Case example: itraconazole. 2013 , 83, 378-87	79
829	Hydroxypropyl methylcellulose mediated precipitation inhibition of sirolimus: from a screening campaign to a proof-of-concept human study. 2013 , 10, 2299-310	9
828	Modulation of the nano-tensile mechanical properties of co-blended amphiphilic alginate fibers as oradurable biomaterials for specialized biomedical application. 2013 , 23, 80-102	9

827	Miniaturized screening of polymers for amorphous drug stabilization (SPADS): rapid assessment of solid dispersion systems. 2013 , 84, 583-98	52
826	Establishing the pharmaceutical quality of Chinese herbal medicine: a provisional BCS classification. 2013 , 10, 1623-43	31
825	Simulating the postprandial stomach: biorelevant test methods for the estimation of intragastric drug dissolution. 2013 , 10, 2211-21	36
824	Development of raloxifene-solid dispersion with improved oral bioavailability via spray-drying technique. 2013 , 36, 86-93	16
823	Application of permeability-limited physiologically-based pharmacokinetic models: part I-digoxin pharmacokinetics incorporating P-glycoprotein-mediated efflux. 2013 , 102, 3145-60	47
822	Biorelevant solubility of poorly soluble drugs: rivaroxaban, furosemide, papaverine and niflumic acid. 2013 , 83, 279-85	30
821	Utilizing in vitro and PBPK tools to link ADME characteristics to plasma profiles: case example nifedipine immediate release formulation. 2013 , 102, 3205-19	27
820	Novel Spiro-Derivatives of 1,3-Thiazine Molecular Crystals: Structural and Thermodynamic Aspects. 2013 , 13, 804-815	5
819	A novel lipid nanoemulsion system for improved permeation of granisetron. 2013 , 101, 475-80	25
818	Physical chemical drug-drug interactions from drug discovery to registration: new opportunities for the pharmaceutical scientist to impact drug development. 2013 , 10, 3967-9	
817	DrugDrug Coamorphous Systems: Characterization and Physicochemical Properties of Coamorphous Atorvastatin with Carvedilol and Glibenclamide. 2013 , 8, 218-228	42
816	Intestinal absorption mechanism of mirabegron, a potent and selective β 2-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. 2013 , 10, 1783-94	16
815	Bioavailability of antihypertensive lactoferricin B-derived peptides: Transepithelial transport and resistance to intestinal and plasma peptidases. 2013 , 32, 169-174	38
814	AFN-1252 in vitro absorption studies and pharmacokinetics following microdosing in healthy subjects. 2013 , 50, 440-6	26
813	Biopharmaceutics permeability classification of lorcaserin, a selective 5-hydroxytryptamine 2C agonist: method suitability and permeability class membership. 2013 , 10, 4739-45	1
812	Vibrational spectroscopic investigation of polymorphs and cocrystals of indomethacin. 2013 , 39, 625-34	13
811	Selection of the comparator product in the World Health Organisation Prequalification of Medicines Programme. 2013 , 10, 193-204	2
810	Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS). 2013 , 39, 1-19	92

809	Optimization of self nanoemulsifying drug delivery system for poorly water-soluble drug using response surface methodology. 2013 , 39, 799-806	30
808	A comparison between use of spray and freeze drying techniques for preparation of solid self-microemulsifying formulation of valsartan and in vitro and in vivo evaluation. 2013 , 2013, 909045	15
807	Computer-aided biopharmaceutical characterization: gastrointestinal absorption simulation. 2013 , 177-232	2
806	Pharmacokinetics and bioequivalence evaluation of cyclobenzaprine tablets. 2013 , 2013, 281392	5
805	Characterization and Stability Evaluation of Thymoquinone Nanoemulsions Prepared by High-Pressure Homogenization. 2013 , 2013, 1-6	17
804	Evaluation of exposure properties after injection of nanosuspensions and microsuspensions into the intraperitoneal space in rats. 2013 , 39, 1832-9	6
803	Comparative plasma exposure of albendazole after administration of rapidly disintegrating tablets in dogs. 2013 , 2013, 920305	2
802	Evaluation of a high-throughput screening method for the detection of the excipient-mediated precipitation inhibition of poorly soluble drugs. 2013 , 11, 117-29	10
801	Disposition kinetics of diclofenac in the dual perfused rat liver. 2013 , 102, 3220-7	2
800	Relationship between the urinary excretion mechanisms of drugs and their physicochemical properties. 2013 , 102, 3294-301	16
799	Evaluation of drug crystallinity in aqueous suspension using terahertz time-domain attenuated total reflection spectroscopy. 2013 , 102, 4065-71	14
798	Cyclodextrin-Based Nanoengineered Drug Delivery System. 2013 , 311-335	1
797	Establishment of novel prediction system of intestinal absorption in humans using human intestinal tissues. 2013 , 102, 2564-71	20
796	Methods of amorphization and investigation of the amorphous state. 2013 , 63, 305-34	86
795	Development of novel bepotastine salicylate salt bioequivalent to the commercial bepotastine besilate in beagle dogs. 2013 , 39, 901-8	14
794	Nanoparticle formulation of a poorly soluble cannabinoid receptor 1 antagonist improves absorption by rat and human intestine. 2013 , 41, 1557-65	6
793	Preparation and cyclodextrin assisted dissolution rate enhancement of itraconazolium dinitrate salt. 2013 , 39, 342-51	8
792	Effects of various food ingredients on gall bladder emptying. 2013 , 67, 1182-7	35

791	Recovery Rate of Rat Skin Micropores Made by Dissolving Microneedles. 2013 , 23, 577-581	4
790	Recent developments in oral lipid-based drug delivery. 2013 , 23, 375-382	18
789	Characterization during storage and dissolution of solid dispersions containing furosemide and hydroxypropyl methylcellulose. 2013 , 23, 409-415	4
788	PVA-Ketoprofen Nanofibers Manufacturing Using Electrospinning Method for Dissolution Improvement of Ketoprofen. 2013 , 737, 166-175	2
787	[Strategic formulation study on dry powder inhalation system based on modulated molecular properties and controlled pharmacokinetics]. 2013 , 133, 93-8	1
786	Cyclodextrins as Advanced Materials for Pharmaceutical Applications. 2013 , 141-165	3
785	Mechanism of gastrointestinal drug absorption and application in therapeutic drug delivery. 2013 , 8-22	3
784	An interlaboratory investigation of intrinsic dissolution rate determination using surface dissolution. 2020 , 150, 24-32	7
783	Recent strategies and advances in the fabrication of nano lipid carriers and their application towards brain targeting. 2020 , 321, 372-415	73
782	Experimental study on interactions occurring between Pluronics and leflunomide in solution. 2020 , 302, 112289	3
781	Prediction of Human Renal Clearance of Compounds Using Quantitative Structure-Pharmacokinetic Relationship Models. 2020 , 33, 640-650	7
780	Crystal Structural Analysis of DL-Mandelate Salt of Carvedilol and Its Correlation with Physicochemical Properties. 2020 , 10, 53	2
779	A Mechanistic Physiologically-Based Biopharmaceutics Modeling (PBBM) Approach to Assess the In Vivo Performance of an Orally Administered Drug Product: From IVIVC to IVIVP. 2020 , 12,	25
778	The Evaluation of Valsartan Biopharmaceutics Properties. 2020 , 12, 52-62	0
777	Use of imaging to assess the activity of hepatic transporters. 2020 , 16, 149-164	6
776	Benznidazole self-emulsifying delivery system: A novel alternative dosage form for Chagas disease treatment. 2020 , 145, 105234	11
775	Evaluating supersaturation in vitro and predicting its performance in vivo with Biphasic gastrointestinal Simulator: A case study of a BCS IIB drug. 2020 , 578, 119043	2
774	Colon-targeting of progesterone using hybrid polymeric microspheres improves its bioavailability and in vivo biological efficacy. 2020 , 577, 119070	9

773	Speeding up the Development of 5-[(4-Chlorophenoxy)-Methyl]-1,3,4-Oxadiazole-2-Thiol as Successful Oral Drug Candidate Based on Physicochemical Characteristics. 2020 , 53, 931-941	
772	Lipid nanocarriers for delivery of poorly soluble and poorly permeable drugs. 2020 , 151-174	5
771	Quantitative prediction of human pharmacokinetic responses to drugs via fluidically coupled vascularized organ chips. 2020 , 4, 421-436	154
770	Method development and validation of dissolution testing for nicotine release from smokeless tobacco products using flow-through cell apparatus and UPLC-PDA. 2020 , 1141, 122012	9
769	Tablets of "Hydrochlorothiazide in Cyclodextrin in Nanoclay": A New Nanohybrid System with Enhanced Dissolution Properties. 2020 , 12,	5
768	Direct incorporation of nano graphene oxide (nGO) into hydrophobic drug crystals for enhanced aqueous dissolution. 2020 , 189, 110827	13
767	Formulation and evaluation of cyclodextrin-based nanosponges of griseofulvin as pediatric oral liquid dosage form for enhancing bioavailability and masking bitter taste. 2020 , 28, 349-361	28
766	The function of oxybuprocaine: a effect that sustains the supersaturated state of anhydrous piroxicam crystals.. 2020 , 10, 1572-1579	3
765	Model-Informed Drug Discovery and Development Strategy for the Rapid Development of Anti-Tuberculosis Drug Combinations. 2020 , 10, 2376	4
764	Sofosbuvir as Repurposed Antiviral Drug Against COVID-19: Why Were We Convinced to Evaluate the Drug in a Registered/Approved Clinical Trial?. 2020 , 51, 577-581	47
763	Pharmacokinetic Models to Characterize the Absorption Phase and the Influence of a Proton Pump Inhibitor on the Overall Exposure of Dacomitinib. 2020 , 12,	4
762	Modified Physicochemical Properties of Acidic Model Drugs Immobilized on Fe ₃ O ₄ Magnetic Iron Oxide Nanoparticles. 2020 , 53, 1025-1035	2
761	Amorphous drug stabilization using mesoporous materials. 2020 , 151-166	1
760	Characterization and therapeutic efficacy evaluation of glimepiride and L-arginine co-amorphous formulation prepared by supercritical antisolvent process: Influence of molar ratio and preparation methods. 2020 , 581, 119232	12
759	A candidate drug administered subcutaneously to rodents as drug particles showing hepatic recirculation which influenced the sustained release process. 2020 , 581, 119252	
758	Preparation and characterization of glimepiride eutectic mixture with l-arginine for improvement of dissolution rate. 2020 , 581, 119288	6
757	Current Status of Supersaturable Self-Emulsifying Drug Delivery Systems. 2020 , 12,	19
756	Potentiometric CheqSol and standardized shake-flask solubility methods are complimentary tools in physicochemical profiling. 2020 , 148, 105305	1

755	Trimesic acid☐heophylline and Isophthalic acid☐affeine Cocrystals: Synthesis, Characterization, Solubility, Molecular Docking, and Antimicrobial Activity. 2020 , 20, 3510-3522	10
754	Nanonization techniques to overcome poor water-solubility with drugs. 2020 , 15, 853-864	18
753	Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets. 2020 , 19, 139	4
752	Fundamental aspects of DMPK optimization of targeted protein degraders. 2020 , 25, 969-982	39
751	Effect of supersaturation on absorption of indomethacin and tadalafil in a single pass intestinal perfusion rat model, in the absence and presence of a precipitation inhibitor. 2020 , 151, 108-115	8
750	Loading and Controlled Release of Poorly Water-Soluble Drug Telmisartan from Porous Silicon Microparticles. 2021 , 13, 605-612	
749	Development of effective AmB/AmB-CD complex double loaded liposomes using a factorial design for systemic fungal infection treatment. 2021 , 31, 177-188	1
748	Quality of Glucosamine Products: Is it a Potential Reason for Inconsistent Clinical Outcomes in Osteoarthritis?. 2021 , 104, 211-215	1
747	Design and evaluation of sustained release hydrophilic matrix tablets of Piroxicam based on carboxymethyl xanthan derivatives. 2021 , 19, 178-191	6
746	Atomistic Modeling of Drug Permeability. 2021 , 223-231	
745	Ibuprofen incorporated into unmodified and modified mesoporous silica: From matrix synthesis to drug release. 2021 , 310, 110541	6
744	Policy of Multisource Drug Products in Latin America: Opportunities and Challenges on the Application of Bioequivalence In Vitro Assays. 2021 , 55, 65-81	2
743	The Provisional No-Effect Threshold of Sugar Alcohols on Oral Drug Absorption Estimated by Physiologically Based Biopharmaceutics Model. 2021 , 110, 467-477	6
742	Influence of shellac on the improvement of solubility and supersaturation of loratadine amorphous solid dispersion using a new grade of HPMC. 2021 , 61, 102116	1
741	Aqueous Dissolution and Dispersion Behavior of Polyvinylpyrrolidone Vinyl Acetate-based Amorphous Solid Dispersion of Ritonavir Prepared by Hot-Melt Extrusion with and without Added Surfactants. 2021 , 110, 1480-1494	6
740	In Vitro Biopredictive Methods: A Workshop Summary Report. 2021 , 110, 567-583	8
739	Development and characterization of pullulan-based orally disintegrating films containing amlodipine besylate. 2021 , 156, 105597	7
738	Comparison of co-former performance in co-amorphous formulations: Single amino acids, amino acid physical mixtures, amino acid salts and dipeptides as co-formers. 2021 , 156, 105582	5

737	Characterisation of fasted state gastric and intestinal fluids collected from children. 2021 , 158, 156-165	2
736	Disintegrant Selection in Hydrophobic Tablet Formulations. 2021 , 110, 2028-2037	5
735	Mucoadhesive gastroretentive microparticulate system for programmed delivery of famotidine and clarithromycin. 2021 , 38, 151-163	0
734	What dominates the changeable pharmacokinetics of natural sesquiterpene lactones and diterpene lactones: a review focusing on absorption and metabolism. 2021 , 53, 122-140	5
733	Oral meropenem for superbugs: challenges and opportunities. 2021 , 26, 551-560	6
732	Vicissitudes of liquid crystals for solubility enhancement of poorly soluble drugs. 2021 , 321, 114924	5
731	Sacubitril-valsartan cocrystal revisited: role of polymer excipients in the formulation. 2021 , 18, 515-526	5
730	Characterizing Drug-Polymer Interactions in Aqueous Solution with Analytical Ultracentrifugation. 2021 , 18, 246-256	1
729	Comprehensive two-dimensional liquid chromatography as a biomimetic screening platform for pharmacokinetic profiling of compound libraries in early drug development. 2021 , 1142, 157-168	2
728	Physicochemical properties of dihydromyricetin and the effects of ascorbic acid on its stability and bioavailability. 2021 , 101, 3862-3869	8
727	Partitioning of surfactant into drug-rich nanodroplets and its impact on drug thermodynamic activity and droplet size. 2021 , 330, 229-243	14
726	Freeze-dried crystalline dispersions: Solid-state, triboelectrification and simultaneous dissolution improvements. 2021 , 61, 102173	1
725	Nanosuspension with improved saturated solubility and dissolution rate of cilostazol and effect of solidification on stability. 2021 , 61, 102165	2
724	A comprehensive review of the strategies to improve oral drug absorption with special emphasis on the cellular and molecular mechanisms. 2021 , 61, 102178	1
723	An investigation of drug compact topography as relates to intrinsic dissolution rates determined by dissolution imaging. 2021 , 61, 102143	1
722	Cellulose and its derivatives for application in 3D printing of pharmaceuticals. 2021 , 51, 1-22	9
721	Contemporary Formulation Development for Inhaled Pharmaceuticals. 2021 , 110, 66-86	7
720	Eco-friendly nanocellulose and its biomedical applications: current status and future prospect. 2021 , 32, 112-149	12

719	Synthesis, Crystal Structure and Physicochemical Characterization of Two Ni(II)-Famotidine Metal Complexes. 2021 , 51, 337-351	
718	Oral Drug Delivery, Absorption and Bioavailability. 2021 ,	1
717	The ADME Encyclopedia. 2021 , 1-7	
716	The ADME Encyclopedia. 2021 , 1-8	
715	Exploring the Impact of Intestinal Fluid Components on the Solubility and Supersaturation of Danazol. 2021 , 110, 2479-2488	1
714	The ADME Encyclopedia. 2021 , 1-8	
713	Role of Pharmacokinetics and Pharmacokinetic Modeling in Drug Development. 2021 ,	
712	Dissolution Testing of Nicotine Release from OTDN Pouches: Product Characterization and Product-to-Product Comparison. 2021 , 8, 7	5
711	ADMET tools: Prediction and assessment of chemical ADMET properties of NCEs. 2021 , 299-320	1
710	Effective formulation strategies for poorly water soluble drugs. 2021 , 181-228	0
709	The ADME Encyclopedia. 2021 , 1-10	
708	Case Study 7: Transporters Case Studies-In Vitro Solutions for Translatable Outcomes. 2021 , 2342, 709-735	
707	Study on the solubilization of telmisartan by forming cocrystals with aromatic carboxylic acids. 2021 , 23, 4871-4878	1
706	Biopharmaceutical properties of natural products. 2021 , 173-189	
705	The ADME Encyclopedia. 2021 , 1-9	
704	A quantitative model for metabolic intervention using gut microbes. 2021 , 37, e3125	0
703	Physiologically-based pharmacokinetic modeling after drug inhalation. 2021 , 319-358	1
702	Hot-melt extrusion: a versatile technology. 2021 , 645-653	0

701	The ADME Encyclopedia. 2021 , 1-13	0
700	The ADME Encyclopedia. 2021 , 1-9	
699	The ADME Encyclopedia. 2021 , 1-10	
698	Towards more accurate solubility measurements with real time monitoring: a carvedilol case study. 2021 , 45, 11618-11625	1
697	Ionic Liquid-Based Oral Drug Delivery Systems. 2021 , 91-112	
696	Advances in Oral Drug Delivery. 2021 , 12, 618411	69
695	Challenges of Dissolution Methods Development for Soft Gelatin Capsules. 2021 , 13,	6
694	Tetrahydrofurofuranoid Lignans, Eudesmin, Fargesin, Epimagnolin A, Magnolin, and Yangambin Inhibit UDP-Glucuronosyltransferase 1A1 and 1A3 Activities in Human Liver Microsomes. 2021 , 13,	0
693	Development and Validation of a Discriminative Dissolution Medium for a Poorly Soluble Nutraceutical Tetrahydrocurcumin. 2021 , 18, 565-573	1
692	Bottlebrush Polymer Excipients Enhance Drug Solubility: Influence of End-Group Hydrophilicity and Thermoresponsiveness.. 2021 , 10, 375-381	17
691	Physiologically-based pharmacokinetics modeling to investigate formulation factors influencing the generic substitution of dabigatran etexilate. 2021 , 10, 199-210	3
690	On Absorption Modeling and Food Effect Prediction of Rivaroxaban, a BCS II Drug Orally Administered as an Immediate-Release Tablet. 2021 , 13,	6
689	Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose. 2021 , 10, 1242-1247	2
688	Orally Administered Drug Solubility-Enhancing Formulations: Lesson Learnt from Optimum Solubility-Permeability Balance. 2021 , 22, 63	1
687	Recent trends of self-emulsifying drug delivery system for enhancing the oral bioavailability of poorly water-soluble drugs. 2021 , 51, 439	3
686	Docetaxel/dimethyl-β-cyclodextrin inclusion complexes: preparation, evaluation and physicochemical characterization. 2021 , 47, 319-328	5
685	Resveratrol and Its Analogs as Functional Foods in Periodontal Disease Management. 2021 , 2,	2
684	ICH Guideline for Biopharmaceutics Classification System-Based Biowaiver (M9): Toward Harmonization in Latin American Countries. 2021 , 13,	1

683	How to manage a high-output stoma.. 2022 , 13, 140-151	3
682	Study on Acute Toxicity of Amiodarone New Complexes With Cyclodextrin. 2021 , 12, 640705	0
681	Comparative evaluation study of polycomplex carriers based on Eudragit [®] EPO/S100 copolymers prepared in different media. 2021 , 32, 2761	1
680	Biodegradable nanoparticles from prosopisylated cellulose as a platform for enhanced oral bioavailability of poorly water-soluble drugs. 2021 , 256, 117492	1
679	Dose-Dependent Solubility-Permeability Interplay for Poorly Soluble Drugs under Non-Sink Conditions. 2021 , 13,	1
678	Assessing Food Effects on Oral Drug Absorption Based on the Degree of Renal Excretion. 2021 , 23, 47	1
677	Efficient Treatment of Experimental Cerebral Malaria by an Artemisone-SMEDDS System: Impact of Application Route and Dosing Frequency. 2021 , 65,	4
676	Antimicrobial Activity of Pyrazinamide Coordination Frameworks Synthesized by Mechanochemistry. 2021 , 26,	4
675	Evaluating Solubility of Celecoxib in Age-Appropriate Fasted- and Fed-State Gastric and Intestinal Biorelevant Media Representative of Adult and Pediatric Patients: Implications on Future Pediatric Biopharmaceutical Classification System. 2021 , 22, 84	1
674	Strength-Dependent and Strength-Independent Dissolution Patterns of Poorly-Soluble Drugs. Case Example: Valsartan. 2021 , 54, 1227-1234	
673	Current strategies for oral delivery of BCS IV drug nanocrystals: challenges, solutions and future trends. 2021 , 18, 1211-1228	0
672	Discovery of Potent Carbonic Anhydrase Inhibitors as Effective Anticonvulsant Agents: Drug Design, Synthesis, and In Vitro and In Vivo Investigations. 2021 , 64, 3100-3114	10
671	Leveraging Oral Drug Development to a Next Level: Impact of the IMI-Funded OrBiTo Project on Patient Healthcare. 2021 , 8, 480706	0
670	Modulating Gliclazide Release and Bioavailability Utilizing Multiparticulate Drug Delivery Systems. 1	3
669	Adequate formulation approach for oral chemotherapy: Etoposide solubility, permeability, and overall bioavailability from cosolvent- vs. vitamin E TPGS-based delivery systems. 2021 , 597, 120295	4
668	Evaluation and Comparison of Solid Lipid Nanoparticles (SLNs) and Nanostructured Lipid Carriers (NLCs) as Vectors to Develop Hydrochlorothiazide Effective and Safe Pediatric Oral Liquid Formulations. 2021 , 13,	13
667	Effects of Transport Medium Composition on In vitro Drug Permeation Across Excised Pig Intestinal Tissue. 2021 , 11, 62-70	
666	A versatile, compartmentalised gut-on-a-chip system for pharmacological and toxicological analyses. 2021 , 11, 4920	10

665	Investigating the Impact of Gastric Emptying on Pharmacokinetic Parameters Using Delay Differential Equations and Principal Component Analysis. 2021 , 46, 451-458	
664	Neuroprotective Potential of Ellagic Acid: A Critical Review. 2021 , 12, 1211-1238	13
663	Physiologically Based Biopharmaceutics Modeling of Regional and Colon Absorption in Dogs. 2021 , 18, 1699-1710	2
662	Piroxicam Loading onto Mesoporous Silicas by Supercritical CO Impregnation. 2021 , 26,	2
661	From the pharmaceutical to the clinical: the case for effervescent paracetamol in pain management. A narrative review. 2021 , 37, 1039-1048	3
660	Polymorphic Crystal Forms and Cocrystals in Drug Delivery (Crystal Engineering). 1-32	
659	The Role of Permeability in Drug ADME/PK, Interactions and Toxicity, and the Permeability-Based Classification System (PCS). 1-14	
658	Biopharmaceutical and pharmacokinetic aspects of nanocarrier-mediated oral delivery of poorly soluble drugs. 2021 , 62, 102324	5
657	Development of phospholipid complex loaded self-microemulsifying drug delivery system to improve the oral bioavailability of resveratrol. 2021 , 16, 721-739	1
656	Salt Screening and Selection. 1-31	
655	Provisional BCS Classification of the Leading Oral Drugs on the Global Market. 1-14	
654	Role of Biorelevant Media in the Estimation of In Vitro Lipolysis and Food Impact on Self-emulsifying Drug Delivery Systems. 2021 , 16, 11-21	
653	Eremantholide C from aerial parts of <i>Lychnophora trichocarpa</i> , as drug candidate: fraction absorbed prediction in humans and BCS permeability class determination. 2021 , 29, 195-203	0
652	Mesoporous Carbon: A Versatile Material for Scientific Applications. 2021 , 22,	11
651	Role of Hydrogen Bonds in Formation of Co-amorphous Valsartan/Nicotinamide Compositions of High Solubility and Durability with Anti-hypertension and Anti-COVID-19 Potential. 2021 , 18, 1970-1984	6
650	Effects of Magnesium, Calcium, and Aluminum Chelation on Fluoroquinolone Absorption Rate and Bioavailability: A Computational Study. 2021 , 13,	3
649	Scientific considerations to move towards biowaiver for biopharmaceutical classification system class III drugs: How modeling and simulation can help. 2021 , 42, 118-127	5
648	New In Vitro Coculture Model for Evaluating Intestinal Absorption of Different Lipid Nanocapsules. 2021 , 13,	0

647	Physicochemical Characterization and Oral Dosage Form Design and Selection. 1-49	
646	Testing a Benchtop Wet-Milling Method for Preparing Nanoparticles and Suspensions as Hospital Formulations. 2021 , 13,	1
645	Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs. 2021 , 17, 555-580	3
644	Drug Discovery Beyond the Rule of Five. 1-35	
643	Molecular interactions and vibrational properties of ricobendazole: Insights from quantum chemical calculation and spectroscopic methods. 2021 , 1230, 129889	1
642	A linear scale-up approach to fluid bed granulation. 2021 , 598, 120209	1
641	The application of freeze-drying as a production method of drug nanocrystals and solid dispersions [A review]. 2021 , 62, 102357	8
640	Mechanochemistry: A Green Approach in the Preparation of Pharmaceutical Cocrystals. 2021 , 13,	15
639	Transdermal Film Loaded with Garlic Oil-Acyclovir Nanoemulsion to Overcome Barriers for Its Use in Alleviating Cold Sore Conditions. 2021 , 13,	3
638	Comparing Predictions of a PBPK Model for Cyclosporine With Drug Levels From Therapeutic Drug Monitoring. 2021 , 12, 630904	3
637	The Development of an In Vitro Horizontal Diffusion Cell to Monitor Nasal Powder Penetration Inline. 2021 , 13,	3
636	Achievements in Thermosensitive Gelling Systems for Rectal Administration. 2021 , 22,	4
635	An Overview on Dietary Polyphenols and Their Biopharmaceutical Classification System (BCS). 2021 , 22,	18
634	Formulation of Suppositories of Alum Produced from Bauxite Waste in Ghana for the Treatment of Hemorrhoid. 2021 , 2021, 6667562	
633	Biowaiver Monograph for Immediate-Release Solid Oral Dosage Forms: Carbamazepine. 2021 , 110, 1935-1947	2
632	QbD-steered development of mixed nanomicelles of galantamine: Demonstration of enhanced brain uptake, prolonged systemic retention and improved biopharmaceutical attributes. 2021 , 600, 120482	2
631	Molecular, Solid-State and Surface Structures of the Conformational Polymorphic Forms of Ritonavir in Relation to their Physicochemical Properties. <i>Pharmaceutical Research</i> , 2021 , 38, 971-990	4-5 6
630	Nanoformulation Development to Improve the Biopharmaceutical Properties of Fisetin Using Design of Experiment Approach. 2021 , 26,	4

629	Rational Selection of Bio-Enabling Oral Drug Formulations - A PEARRL Commentary. 2021 , 110, 1921-1930	3
628	Development and Validation of an HPLC Method Using an Experimental Design for Analysis of Amlodipine Besylate and Enalapril Maleate in a Fixed-dose Combination. 2021 , 18, 306-318	2
627	Oral delivery of peptide therapeutics in infants: Challenges and opportunities. 2021 , 173, 112-124	8
626	Improvement of solubility of sparingly water-soluble drug triggered by metal-organic framework. 2021 , 63, 102490	2
625	Novel Formulations of the Antiviral Drug Favipiravir: Improving Permeability and Tabletability. 2021 , 21, 3807-3817	3
624	Small differences in acidic pH condition significantly affect dissolution equivalence between drug products of acidic drug salt. 2021 , 63, 102546	0
623	Obtaining Cocrystals by Reaction Crystallization Method: Pharmaceutical Applications. 2021 , 13,	5
622	Meta-Assessment of Metformin Absorption and Disposition Pharmacokinetics in Nine Species. 2021 , 14,	2
621	Amorphous Drug Solubility and Maximum Free Drug Concentrations in Cyclodextrin Solutions: A Quantitative Study Using NMR Diffusometry. 2021 , 18, 2764-2776	3
620	In vitro and In silico biopharmaceutic regulatory guidelines for generic bioequivalence for oral products: Comparison among various regulatory agencies. 2021 , 42, 297-318	0
619	Precipitation from amorphous solid dispersions in biorelevant dissolution testing: The polymorphism of regorafenib. 2021 , 603, 120716	4
618	Intra-Herb Interactions: Primary Metabolites in Extract Improved the Pharmacokinetics of Oral Berberine Hydrochloride in Mice. 2021 , 12, 675368	1
617	Screening and Preparation of Cocrystals: A Comparative Study of Mechanochemistry vs Slurry Methods. 2021 , 21, 4141-4150	8
616	Synergistic application of twin-screw granulation and selective laser sintering 3D printing for the development of pharmaceutical dosage forms with enhanced dissolution rates and physical properties. 2021 , 163, 141-156	6
615	Exploring porcine gastric and intestinal fluids using microscopic and solubility estimates: Impact of placebo self-emulsifying drug delivery system administration to inform bio-predictive in vitro tools. 2021 , 161, 105778	2
614	Production and isolation of pharmaceutical drug nanoparticles. 2021 , 603, 120708	7
613	Single Crystal Structure of Terfenadine Form I. 1	1
612	Systematic Roadmap for Cancer Drug Screening Using Zebrafish Embryo Xenograft Cancer Models: Melanoma Cell Line as a Case Study. 2021 , 13,	0

611	Propionamide Derivatives as Dual μ Opioid Receptor Agonists and κ Receptor Antagonists for the Treatment of Pain. 2021 , 64, 10139-10154	0
610	Cholinium-based ionic liquids as bioinspired hydrotropes to tackle solubility challenges in drug formulation. 2021 , 164, 86-92	7
609	Natural Product-Based Hybrids as Potential Candidates for the Treatment of Cancer: Focus on Curcumin and Resveratrol. 2021 , 26,	3
608	Harnessing formulation and clinical pharmacology knowledge for efficient pediatric drug development: Overview and discussions from M-CERSI pediatric formulation workshop 2019. 2021 , 164, 66-74	1
607	Combination of a biopharmaceutic classification system and physiologically based pharmacokinetic models to predict absorption properties of baicalein in vitro and in vivo. 2021 , 8, 238-247	1
606	Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process. 2021 , 13,	1
605	Antioxidant and Immunostimulatory Activities of a Submerged Culture of Using Spent Coffee. 2021 , 10,	0
604	Personalization of drug dose thematic issue: introduction article. 2021 , 1-5	
603	Design of Mucoadhesive Strips for Buccal Fast Release of Tramadol. 2021 , 13,	0
602	Inclusion complexes of (S)-naproxen and native cyclodextrins: Supramolecular structure and stability. 2021 , 1235, 130218	2
601	Current trends on cannabidiol delivery systems: where are we and where are we going?. 2021 , 18, 1577-1587	1
600	Pseudoboehmite as a drug delivery system for acyclovir. 2021 , 11, 15448	3
599	Development of self-microemulsifying lipid-based formulations of -resveratrol by systematically constructing lipid-surfactant-water phase diagrams using long-chain lipids. 2021 , 47, 897-907	1
598	Recent Advances in Mesoporous Silica Nanoparticles for Targeted Drug Delivery applications. 2021 ,	4
597	Introduction: Utility of Mathematical Models in Drug Development and Delivery. 2021 , 1-41	
596	Supersaturating drug delivery systems containing fixed-dose combination of two antihypertensive drugs: Formulation, in vitro evaluation and molecular metadynamics simulations. 2021 , 163, 105860	2
595	Quantitative estimation of intra-subject variability in bioequivalence studies of generic solid oral dosage forms by multiple regression analysis. 2021 , 64, 102656	0
594	Repaglinide and Metformin-Loaded Amberlite Resin-Based Floating Microspheres for the Effective Management of Type 2 Diabetes. 2021 , 18, 654-668	0

593	Machine learning directed drug formulation development. 2021 , 175, 113806	17
592	Dissolution Profile Evaluation of Eight Brands of Metformin Hydrochloride Tablets Available in Jimma, Southwest Ethiopia. 2021 , 14, 3499-3506	1
591	Improving Dissolution Behavior and Oral Absorption of Drugs with pH-Dependent Solubility Using pH Modifiers: A Physiologically Realistic Mass Transport Analysis. 2021 , 18, 3326-3341	1
590	Flavonoids as Human Intestinal α -Glucosidase Inhibitors. 2021 , 10,	7
589	Using Porcine Jejunum Ex Vivo to Study Absorption and Biotransformation of Natural Products in Plant Extracts: as a Case Study. 2021 , 11,	2
588	Quality Evaluation of Ethambutol Hydrochloride Tablet Batches Available in Governmental Health Facilities of Jimma Town, Southwest Ethiopia. 2021 , 2021, 9969157	
587	Dissolution profiles of fenbendazole from binary solid dispersions: a mathematical approach. 2021 , 12, 597-610	1
586	Effect of Counterions on Dissolution of Amorphous Solid Dispersions Studied by Surface Area Normalized Dissolution. 2021 , 18, 3429-3438	1
585	Preparation of Fine-Drugs Layered Spherical Particles with Good Micromeritic and Dissolution Properties through Ultra Cryo-Milling and Mechanical Powder Processing. 2021 , 69, 747-759	
584	Maximizing the Oral Bioavailability of Poorly Water-Soluble Drugs Using Novel Oil-Like Materials in Lipid-Based Formulations. 2021 , 18, 3281-3289	2
583	Nanoparticulate Drug Delivery Strategies to Address Intestinal Cytochrome P450 CYP3A4 Metabolism towards Personalized Medicine. 2021 , 13,	5
582	Nanovesicle Formulation Enhances Anti-inflammatory Property and Safe Use of Piroxicam. 2021 , 9, 177-190	0
581	Drug-Polymer Interactions in Acetaminophen/Hydroxypropylmethylcellulose Acetyl Succinate Amorphous Solid Dispersions Revealed by Multidimensional Multinuclear Solid-State NMR Spectroscopy. 2021 , 18, 3519-3531	4
580	Oral Site-Directed Drug Delivery and Influence on PK. 99-219	
579	Unveiling meloxicam monohydrate process of dehydration by an at-line vibrational multi-spectroscopy approach. 2021 , 202, 114164	1
578	Bioavailability and Antidiabetic Activity of Gliclazide-Loaded Cubosomal Nanoparticles. 2021 , 14,	7
577	An Assessment of Occasional Bio-Inequivalence for BCS1 and BCS3 Drugs: What are the Underlying Reasons?. 2021 ,	
576	Quantitative prediction of P-glycoprotein-mediated drug-drug interactions and intestinal absorption using humanized mice. 2021 , 178, 4335-4351	1

575	The effect of serum starvation on tight junctional proteins and barrier formation in Caco-2 cells. 2021 , 27, 101096	
574	Impact of simulated lung fluid components on the solubility of inhaled drugs and predicted in vivo performance. 2021 , 606, 120893	6
573	Development and characterization of standardized model, solid foods with varying breakdown rates during gastric digestion. 2021 , 110827	1
572	"Felodipine-indomethacin" co-amorphous supersaturating drug delivery systems: "Spring-parachute" process, stability, in vivo bioavailability, and underlying molecular mechanisms. 2021 , 166, 111-125	5
571	Characterization of nanoparticles made of ethyl cellulose and stabilizing lipids: Mode of manufacturing, size modulation, and study of their effect on keratinocytes. 2021 , 607, 121003	1
570	Impact of altered hydrophobicity and reduced agglomeration on dissolution of micronized poorly water-soluble drug powders after dry coating. 2021 , 606, 120853	1
569	Supersaturated formulations of poorly soluble weak acid drugs evaluated in rodents; a case study. 2021 , 606, 120883	1
568	Determination of effective concentrations of drug absorption enhancers using in vitro and ex vivo models. 2021 , 167, 106028	
567	Impact on Drug Development and Drug Product Processing. 2021 , 325-364	0
566	Prediction of plasma concentrations using in silico modelling and simulation approach: Case of Acebutolol. 2021 , 79, 530-538	2
565	Subchronic Toxicity Study of Oral Anthrafurin on Rabbits. 2021 , 14,	
564	Regulatory Frameworks Affecting Solid-State Development. 2021 , 449-480	1
563	An updated review of mesoporous carbon as a novel drug delivery system. 2021 , 1-9	5
562	Exploring antibiotics as ligands in metal-organic and hydrogen bonding frameworks: Our novel approach towards enhanced antimicrobial activity (mini-review). 2021 , 525, 120474	1
561	Investigating the Critical Variables of Azithromycin Oral Absorption Using In Vitro Tests and PBPK Modeling. 2021 , 110, 3874-3888	0
560	Understanding the guest binding in the cucurbit[7]uril inclusion complexes of CDK4/6 inhibitors, palbociclib, and ribociclib from a combined experimental and computational study. 2021 , 1241, 130637	0
559	A molecular mechanism investigation of the transdermal/topical absorption classification system on the basis of drug skin permeation and skin retention. 2021 , 608, 121082	0
558	In vivo praziquantel efficacy of Schistosoma japonicum over time: A systematic review and meta-analysis. 2021 , 222, 106048	1

557	Traditional herbal medicine and nanomedicine: Converging disciplines to improve therapeutic efficacy and human health. 2021 , 178, 113964	7
556	Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. 2021 , 100, 102281	1
555	Small scale in vitro method to determine a bioequivalent equilibrium solubility range for fasted human intestinal fluid. 2021 , 168, 90-96	2
554	Formulating a heat- and shear-labile drug in an amorphous solid dispersion: Balancing drug degradation and crystallinity.. 2021 , 3, 100092	3
553	Polymer-mediated drug supersaturation - A spotlight on the interplay between phase-separated amorphous drug colloids and dissolved molecules. 2021 , 603, 370-379	1
552	Characteristic evaluation of the pseudo-polymorphism of amorphous atorvastatin calcium hydrates by terahertz spectroscopy. 2021 , 630, 127551	1
551	Naringin: A potential natural product in the field of biomedical applications. 2021 , 2, 100068	3
550	Concentration and composition dependent aggregation of Pluronic- and Poly-(2-oxazolin)-Efavirenz formulations in biorelevant media. 2022 , 606, 1179-1192	0
549	Balanced lipase interactions for degradation-controlled paclitaxel release from lipid cubic phase formulations. 2022 , 607, 978-991	0
548	Contribution of Particle Design Research to the Development of Patient-Centric Dosage Forms. 2022 ,	0
547	Particle Size Reduction Techniques of Pharmaceutical Compounds for the Enhancement of Their Dissolution Rate and Bioavailability. 1	11
546	Molecular Simulation and Statistical Learning Methods toward Predicting Drug-Polymer Amorphous Solid Dispersion Miscibility, Stability, and Formulation Design. 2021 , 26,	7
545	Molecular photoswitches in aqueous environments. 2021 , 50, 12377-12449	23
544	In vitro ADME and in vivo pharmacokinetics. 2021 , 305-369	
543	Determination of Inherent Dissolution Performance of Drug Substances. 2021 , 13,	0
542	Pharmaceutical product development: A quality by design (QbD) approach. 2021 , 131-146	0
541	New liquid oral formulations of hydroxychloroquine: a physicochemical stability study. 2021 , 6,	
540	Physicochemical Characterization and Principles of Oral Dosage Form Selection. 2003 , 649-682	2

539	Solubility and Dissolution Considerations for Amorphous Solid Dispersions. 1-41	1
538	Translational Development of Amorphous Dispersions. 1-29	1
537	Dissolution Testing: In vitro Characterization of Oral Controlled Release Dosage Forms. 245-256	1
536	A Roadmap To Solid Form Selection. 473-491	2
535	Prodrugs. 2008 , 559-570	1
534	Pharmaceutical Drug Discovery: Designing the Blockbuster Drug. 2006 , 69-114	1
533	Excipients as Absorption Enhancers. 2008 , 139-174	5
532	Polymeric Permeation Enhancers. 2009 , 103-122	4
531	Nonsink In Vitro Dissolution Testing of Amorphous Solid Dispersions. 2013 , 205-220	1
530	Porous Silicon Nanoparticles. 2013 , 235-275	1
529	Diagnosing Biopharmaceutical Limitations. 2015 , 141-175	1
528	Fundamentals of Amorphous Systems: Thermodynamic Aspects. 2014 , 3-34	6
527	Pharmaceutical Development of MBP Solid Dispersions: Case Studies. 2014 , 373-394	2
526	Drug Absorption With Food. 2004 , 129-154	0
525	An Introduction to Drug-Nutrient Interactions. 2009 , 3-26	5
524	Permeability Assessment Using 5-day Cultured Caco-2 Cell Monolayers. 2014 , 49-76	1
523	The Role of Particle Size in Drug Release and Absorption. 2014 , 323-341	8
522	Melt Extrusion. 2016 , 383-435	5

521	Drug Interactions in the Gastrointestinal Tract and Their Impact on Drug Absorption and Systemic Availability: A Mechanistic Review. 1996 , 13-43	1
520	Nanocrystals for Passive Dermal Penetration Enhancement. 2016 , 283-295	2
519	From Molecules to Crystals to Functional Form: Science of Scale. 2017 , 463-478	1
518	Scale-up effects on dissolution and bioavailability of propranolol hydrochloride and metoprolol tartrate tablet formulations. 2000 , 1, 63-71	1
517	Spray drying of API nanosuspensions: Importance of drying temperature, type and content of matrix former and particle size for successful formulation and process development. 2020 , 152, 63-71	7
516	Six years of progress in the oral biopharmaceutics area - A summary from the IMI OrBiTo project. 2020 , 152, 236-247	12
515	The effect of Pro NanoLipospheres (PNL) formulation containing natural absorption enhancers on the oral bioavailability of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) in a rat model. 2017 , 109, 21-30	44
514	Formulation technologies and advances for oral delivery of novel nitroimidazoles and antimicrobial peptides. 2020 , 324, 728-749	19
513	Novel Purine Alkaloid Cocrystals with Trimesic and Hemimellitic Acids as Coformers: Synthetic Approach and Supramolecular Analysis. 2021 , 21, 396-413	5
512	Transcriptomic Analysis of the Activity and Mechanism of Action of a Ruthenium(II)-Based Antimicrobial That Induces Minimal Evolution of Pathogen Resistance. 2021 , 4, 168-178	1
511	Drugs and Excipients: Polymeric Interactions. 2979-3004	1
510	Supramolecular synthon hierarchy in sulfonamide cocrystals with -amides and -oxides. 2019 , 6, 751-760	6
509	A new high-pressure benzocaine polymorph - towards understanding the molecular aggregation in crystals of an important active pharmaceutical ingredient (API). 2020 , 76, 56-64	3
508	Application of BoxBehnken design and desirability function in the development and optimization of self-nanoemulsifying drug delivery system for enhanced dissolution of ezetimibe. 2020 , 6,	8
507	Principles, Issues, and Applications of Interspecies Scaling. 2004 , 137-163	1
506	Historical Development of Dissolution Testing. 2005 , 1-37	2
505	The Role of Dissolution Testing in the Regulation of Pharmaceuticals. 2005 , 81-96	4
504	Orally Administered Drug Products. 2005 , 229-249	1

503	Chapter 12 Dissolution of Stabilized Amorphous Drug Formulations. 2017 , 393-418	2
502	Chapter 17 Regulatory Considerations in Dissolution and Drug Release of BCS Class II and IV Compounds. 2017 , 573-602	1
501	Integrated Drug Product Development [From Lead Candidate Selection to Life-Cycle Management. 2006 , 15-51	1
500	Preformulation Predictions from Small Amounts of Compound as an Aid to Candidate Drug Selection. 2001 , 21-95	1
499	- Biomarkers for Diet in Cancer Prevention Studies. 2016 , 130-157	1
498	Inter-compound and Intra-compound Global Sensitivity Analysis of a Physiological Model for Pulmonary Absorption of Inhaled Compounds. 2020 , 22, 116	3
497	A Randomized, Open Label, 2-Way Crossover Study to Assess the Pharmacokinetic Characteristics and Skin Irritation of Murupee Patch Compared with Trast Patch in Healthy Volunteers. 2013 , 21, 41	1
496	Assessment of Efficacy and Quality of Two Albendazole Brands Commonly Used against Soil-Transmitted Helminth Infections in School Children in Jimma Town, Ethiopia. 2015 , 9, e0004057	20
495	A Novel Diphenylthiosemicarbazide Is a Potential Insulin Secretagogue for Anti-Diabetic Agen. 2016 , 11, e0164785	2
494	Evaluation of the intestinal permeability of rosemary (<i>Rosmarinus officinalis</i> L.) extract polyphenols and terpenoids in Caco-2 cell monolayers. 2017 , 12, e0172063	21
493	Bioequivalence Study of Generic Metformin Hydrochloride in Healthy Nigerian Volunteers. 2017 , 2, 75-81	1
492	Caco-2 Cells, Biopharmaceutics Classification System (BCS) and Biowaiter. 2011 , 54, 3-8	28
491	Systemic and presystemic conversion of carbamazepine to carbamazepine-10,11-epoxide during long term treatment. 2006 , 12, 13-16	10
490	Development of a new rutin nanoemulsion and its application on prostate carcinoma PC3 cell line. 2017 , 16, 810-823	16
489	[The dissolution test in biorelevant media as a prognostic tool for modeling of drug behavior in vivo]. 2011 , 57, 482-9	5
488	Vitamin, mineral, and drug absorption following bariatric surgery. 2012 , 13, 1345-55	88
487	The Solubility-Permeability Interplay for Solubility-Enabling Oral Formulations. 2019 , 20, 1434-1446	2
486	Preparation and Evaluation of Hot-Melt Extruded Patient-Centric Ketoprofen Mini-Tablets. 2016 , 13, 730-41	11

485	Preparation, Characterization and Prevention of Auto-oxidation of Amorphous Sirolimus by Encapsulation in Polymeric Films Using Hot Melt Extrusion. 2019 , 16, 663-671	1
484	Development of Atovaquone Nanosuspension: Quality by Design Approach. 2020 , 17, 112-125	3
483	In Silico Assessment of ADME Properties: Advances in Caco-2 Cell Monolayer Permeability Modeling. 2018 , 18, 2209-2229	18
482	Herbal Drug use in Sickle Cell Disease Management; Trends and Perspectives in Sub-Saharan Africa - A Systematic Review. 2019 , 16, 372-385	1
481	Crystal Engineering to Design of Solids: From Single to Multicomponent Organic Materials. 2020 , 17, 518-538	5
480	Sofosbuvir: Really Meets the Unmet Needs for Hepatitis C Treatment?. 2020 , 20, 2-15	4
479	Polymeric Nanomicelles of Soluplus [®] as a Strategy for Enhancing the Solubility, Bioavailability and Efficacy of Poorly Soluble Active Compounds. 2019 , 9, 184-197	8
478	Approaches for Improving Bioavailability of Poorly Soluble Drugs. 2008 , 51-104	1
477	Praziquantel-Clays as Accelerated Release Systems to Enhance the Low Solubility of the Drug. 2020 , 12,	8
476	Molecular Dynamics Simulations in Drug Discovery and Pharmaceutical Development. 2021 , 9, 71	34
475	Lipid Drug Carriers for Cancer Therapeutics: An Insight into Lymphatic Targeting, P-gp, CYP3A4 Modulation and Bioavailability Enhancement. 2020 , 10, 524-541	4
474	In vivo Evaluation and Application of Central Composite Design in the Optimization of Amisulpride Self-Emulsifying Drug Delivery System. 2011 , 2, 1-16	9
473	Development of a New Carvedilol Tablet with Rapid Onset of Action. 2012 , 2, 55-71	2
472	Study of Dose-linearity of Gemfibrozil Pharmacokinetics in Human. 2005 , 2, 75-78	1
471	An Exhaustive Review on Solubility Enhancement for Hydrophobic Compounds by Possible Applications of Novel Techniques. 2012 , 7, 596-619	5
470	Innovative Strategies for Lipid-Based Drug Delivery. 2018 , 60-84	1
469	Comparative Studies on the Dissolution Profiles of Oral Ibuprofen Suspension and Commercial Tablets using Biopharmaceutical Classification System Criteria. 2012 , 74, 312-8	22
468	Intestinal permeability of Lamivudine using single pass intestinal perfusion. 2012 , 74, 478-81	16

467	Determination of site of absorption of propranolol in rat gut using in situ single-pass intestinal perfusion. 2010 , 72, 625-9	21
466	Nanostructured lipid carriers: An emerging platform for improving oral bioavailability of lipophilic drugs. 2015 , 5, 182-91	96
465	Formulation and evaluation of atenolol floating bioadhesive system using optimized polymer blends. 2016 , 6, 116-22	7
464	Enhanced bioavailability of danazol nanosuspensions by wet milling and high-pressure homogenization. 2016 , 6, 218-224	11
463	Dissolution enhancement of efavirenz by solid dispersion and PEGylation techniques. 2011 , 1, 29-34	24
462	Self-Emulsifying Formulation of Indomethacin with Improved Dissolution and Oral Absorption. 2017 , 14, 108-119	2
461	Formulation and Characterization of Solid Dispersions of Etoricoxib Using Natural Polymers. 2020 , 17, 7-19	4
460	Physicochemical property and skin damage of physical mixture of valsartan and polysorbate 80. 2009 , 39, 107-110	1
459	Pharmaceutical Usefulness of Biopharmaceutics Classification System: Overview and New Trend. 2010 , 40, 1-7	3
458	Preparation and in vivo Evaluation of a Sildenafil Lactate-loaded Solid Self-emulsifying Drug Delivery System. 2011 , 41, 249-253	1
457	Improvement in Solubility in Small Molecule Drug Discovery Programs Focusing on Dihedral Angle and Symmetry. 2013 , 71, 625-636	2
456	LIPID-BASED VEHICLE FOR ORAL DRUG DELIVERY. 2001 , 145, 17-26	41
455	Harmonizing solubility measurement to lower inter-laboratory variance - progress of consortium of biopharmaceutical tools (CoBiTo) in Japan.. 2019 , 7, 183-195	3
454	Electrospun nanofibers: A nanotechnological approach for drug delivery and dissolution optimization in poorly water-soluble drugs.. 2020 , 8, 325-353	3
453	Design of vancomycin RS-100 nanoparticles in order to increase the intestinal permeability. 2012 , 2, 43-56	21
452	The Controversy over Generic Antiepileptic Drugs. 2010 , 15, 81-93	3
451	Establishment of Optimal Fermentation Conditions for Steam-dried Ginseng Berry via Friendly Bacteria and Its Antioxidant Activities. 2013 , 45, 77-83	2
450	ABSORPTION-RELATED APPLICATIONS OF PBPK MODELING. 2021 , 429-455	

- 449 bioavailability for BCS class II efavirenz tablets using biorelevant dissolution media for IVIVR and simulation of formulation changes. **2021**, 1-11
- 448 Cefdinir Inclusion in Mesoporous Silica as Effective Dissolution Enhancer with Improved Physical Stability. **11**, 73-86
- 447 Amorphous Solid Dispersions (ASDs): The Influence of Material Properties, Manufacturing Processes and Analytical Technologies in Drug Product Development. **2021**, 13, 2
- 446 Physiologically Based Biopharmaceutics Modeling to Demonstrate Virtual Bioequivalence and Bioequivalence Safe-space for Ribociclib which has Permeation Rate-controlled Absorption. **2021**, 1
- 445 Atropisomerism - A Neglected Way to Escape Out of Solubility Flatlands. **2021**, 0
- 444 Efficient development of sorafenib tablets with improved oral bioavailability enabled by coprecipitated amorphous solid dispersion. **2021**, 610, 121216 0
- 443 Predicting in vivo performance of fenofibrate amorphous solid dispersions using in vitro non-sink dissolution and dissolution permeation setup. **2021**, 610, 121174 0
- 442 Correlation of Intestinal Drug Permeability in Humans (In Vivo) with Experimentally and Theoretically Derived Parameters. **2000**, 491-492
- 441 Regulatory acceptance of in vitro permeability studies in the context of the biopharmaceutics classification system. **2002**, 130-139 1
- 440 Predicting drug absorption by computational methods. **2002**, 353-377
- 439 Biopharmaceutics. **2002**, 82-102
- 438 In vitro/In vivo Correlation of Sustained Release Diltiazem. **2002**, 32, 321-325
- 437 Relationship Between Dissolution Patterns of Carbamazepine Tablet and Dissolution Medium Composition. **2004**, 34, 185-192
- 436 Dissolution Method Development with a View to Quality Control. **2005**, 315-349 1
- 435 Release, Dissolution and Permeation. **2006**, 141-195
- 434 Dissociation, Partitioning and Solubility. **2006**, 87-140
- 433 Feasibility Assessment and Considerations for Scaling Initial Prototype Lipid-Based Formulations to Phase I/II Clinical Trial Batches. **2007**, 85-100
- 432 Solid Dispersion Technologies. **2007**, 471-512

- 431 Bioavailability and Bioequivalence. **2008**, 262-289 2
- 430 A Biopharmaceutical Classification System Approach to Dissolution: Mechanisms and Strategies. **2008**, 290-316 1
- 429 Physicochemical Profiling in Early Drug Discovery: New Challenges at the Age of High-Throughput Screen and Combinatorial Chemistry. **2008**, 325-334
- 428 Comparison of Caco-2 and MDCK Cells As an In-Vitro ADME Screening Model. **2008**, 38, 183-189
- 427 Use of Animals for the Determination of Absorption and Bioavailability. **2008**, 161-184
- 426 Computational Absorption Prediction. **2008**, 409-432
- 425 Drug Absorption with Food. **2009**, 209-241
- 424 Chapter 36. Bioavailability and Bioequivalence. **2009**,
- 423 Dissolution and Duodenal Permeation Characteristics of Lovastatin from Bile Salt Solid Dispersions. **2009**, 39, 97-106
- 422 Interplay of Drug Metabolizing Enzymes and ABC Transporter. **2009**, 325-347
- 421 Peroral Toxicity.
- 420 Permeability Assessment. 1
- 419 Solid Dosage Forms.
- 418 Absorption of Drugs after Oral Administration. 1
- 417 Biopharmaceutics. **2010**, 170-185
- 416 Drug Polymorphism and its Importance on Drug Development Process. **2010**, 40, 9-17 0
- 415 Surface-attached Solid Dispersion. **2010**, 40, 97-102 1
- 414 Current Methodologies for Membrane Permeability Assessment. **2010**, 40, 19-31 1

413 Design of Solid Dosage Formulations. 673-702

412 Solid State Pharmaceuticals: Solving Complex Problems in Preformulation and Formulation. **2011**, 19-36

411 Hydrophobic Molecules in Water. **2010**, 89-104

410 Introduction. **2011**, 1-7

409 Polymorphism. **2011**, 213-246

408 Drug Discovery and Evaluation: Methods in Clinical Pharmacology. **2011**, 251-264

407 Solid Dispersion as a Strategy to Improve Drug Bioavailability. **2011**, 26, 283-292

406 Dissolution Profiles of Lanoxin Tablets in Media Supplemented with Soluble and Insoluble Forms of Fiber. **2011**, 1,

405 Psychopharmaka-Entwicklung: von der Entdeckung bis zur Zulassung. **2012**, 87-104

404 Frontmatter. i-xxxv

403 Modeling and Simulation of Intracellular Drug Transport and Disposition Pathways with Virtual Cell. **2013**, 1, 1

402 Resveratrol Emerges as a Miracle Cardioprotective Phytochemical Polyphenol and Nutraceutical. **2013**, 401-420

401 Small Molecule Formulation Screening Strategies in Drug Discovery. **2014**, 1-20

400 Mesoporous ASD: Fundamentals. **2014**, 637-663

399 Physiologically Based Pharmacokinetic Modeling in the Development and Evaluation of Hydrophilic Matrix Tablets. **2014**, 191-203 1

398 Bioverfögbarkeit von Phytopharmaka. **1999**, 43-50

397 BCS Wegweiser bei Phytopharmaka. **1999**, 35-42

396 CHAPTER 12: Drug-Drug Interactions: Regulatory and Theoretical Considerations, and an Industry Perspective. **2015**, 263-282

395 CHAPTER 2:Role of Solubility, Permeability and Absorption in Drug Discovery and Development. **2015**, 27-52

394 Development of Spherical Granule of Fermented Red Ginseng Extracts. **2015**, 44, 1064-1071

1

393 The Pharmaceutics of Ibuprofen. 51-80

392 Optimization of Encapsulation Conditions for Fermented Red Ginseng Extracts by Using Cyclodextrin. **2015**, 44, 1708-1714

391 Drug Delivery: Oral Route. 2782-2811

390 Drug Delivery: Poorly Soluble. 2824-2834

389 Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. **2016**, 741-767

388 Gastrointestinal System. **2016**, 279-300

387 Pharmaceutical Cryogenic Technologies. **2016**, 527-607

386 Process Optimization of Ginseng Berry Extract Fermentation by Lactobacillus sp. Strain KYH isolated from Fermented Kimchi and Product Analysis. **2016**, 26, 88-98

385 Improving the Water Solubility of Poorly Soluble Drugs. **2016**, 47-70

384 Crystal structure of a 2:1 piroxicam-gentisic acid co-crystal featuring neutral and zwitterionic piroxicam mol-ecules. **2016**, 72, 1714-1717

0

383 Conventional Concept of Formulations of Nanosuspensions. **2016**, 3,

382 Chapter 2 Solubility Determinations for Pharmaceutical API. **2017**, 19-84

381 The European Union. **2017**, 75-100

380 Chapter 15 Clinically Relevant Dissolution for Low-Solubility Immediate-Release Products. **2017**, 511-552

1

379 Chapter 4 Intrinsic Dissolution Evaluation of Poorly Soluble Drugs. **2017**, 105-124

378 Chapter 14 Dissolution Testing of Poorly Soluble Drugs: Biorelevant Dissolution **2017**, 455-510

- 377 Chapter 1 The Modern Pharmaceutical Development Challenge: BCS Class II and IV Drugs. **2017**, 1-18
- 376 South Africa. **2017**, 229-268
- 375 Chapter 18 Dissolution of Liquid-Filled Capsules Based Formulations. **2017**, 603-660
- 374 Chapter 5 Oral Delivery of Poorly Soluble Drugs. **2017**, 125-186 0
- 373 Biological Classification System (BCS); with a New Perspective. **2017**, 3, 1
- 372 Drugs and Excipients: Polymeric Interactions. **2017**, 451-475
- 371 Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis.
- 370 Simulation-based comparison of Biopharmaceutics Classification System and drug structure.
- 369 Differential Effects of TPM, A Phosphorylated Tocopherol Mixture, and Other Tocopherol Derivatives as Excipients for Enhancing the Solubilization of Co-Enzyme Q10 as a Lipophilic Drug During Digestion of Lipid- Based Formulations. **2019**, 16, 628-636 1
- 368 Understanding the physicochemical properties and degradation kinetics of nicotinamide riboside, a promising vitamin B nutritional supplement. **2019**, 63, 4
- 367 Impurities in New Drug Products. **2019**, 123-129
- 366 Equilibrium solubility study to determine fexofenadine hydrochloride BCS class and challenges in establishing conditions for dissolution profiles applied to suspension. 56, 0
- 365 Evaluating the Pharmacokinetics and Systemic Effects of a Permeability Enhancer Sodium N-[8-(2-hydroxybenzoyl)amino] Caprylate in Rats. **2020**, 109, 2629-2636 1
- 364 Interpolymer Complexes Based on Eudragit[®] EPO/Eudragit[®] S100 as Carriers for Oral Controlled Drug Delivery Systems. **2020**, 9, 36-43
- 363 Solubility-Permeability Interplay of Hydrotropic Solubilization Using Response Surface Methodology. **2020**, 10, 209-218 0
- 362 Improved Bioavailability of Poorly Soluble Drugs through Gastrointestinal Muco-Adhesion of Lipid Nanoparticles. **2021**, 13, 2
- 361 Enhancing Biopharmaceutical Attributes of Khellin by Amorphous Binary Solid Dispersions. **2021**, 22, 260 2
- 360 Nanomedicine for increasing the oral bioavailability of cancer treatments. **2021**, 19, 354 11

- 359 Tablet formulation development focusing on the functional behaviour of water uptake and swelling. **2021**, 3, 100103 1
- 358 Biopharmaceuticals [A New Frontier. **2020**, 1-46
- 357 Anti Diabetic Evaluation of Methanolic Extract of Psoralea Corylifolia L. & Psoralea Esculenta L. Seeds in Streptozotocin Induced Diabetic Rats and Histopathological Changes in Diabetic Rats Pancreas: Comparative Study. **2020**, 10,
- 356 ESTUDO COMPARATIVO DO CONTROLE DA QUALIDADE DE COMPRIMIDOS DE NIMESULIDA COMPLEXADA E N^o 1 COMPLEXADA COM β -CD COMPLEXADA COM β -CICLODEXTRINA. **2020**, 32, 353-365
- 355 Novel Delivery System Used for Oral Bioavailability Enhancement of Poorly Water Soluble Drugs. **2020**, 10, 139-144 0
- 354 In vitro pH dependent passive transport of ketoprofen and metformin.. **2021**, 9, 57-68 1
- 353 Most promising solid dispersion technique of oral dispersible tablet. **2020**, 9, 1
- 352 Drug absorption and bioavailability. **2022**, 43-59
- 351 Relevance of Transporters in Clinical Studies. **2020**, 989-1003
- 350 Screening of Ketoprofen-Poloxamer and Ketoprofen-Eudragit solid dispersions for improved physicochemical characteristics and dissolution profile. 56, 0
- 349 Polymeric Nanoparticles: A Promising Tool to Enhance the Solubility of Poorly Water Soluble Drug. **2020**, 15, 67-77
- 348 Bioequivalence. **2020**, 887-902
- 347 A quantitative model for metabolic intervention using gut microbes.
- 346 Polymers and Nanostructured Materials for Drug Nanoparticles, Bioimaging, and Cell Delivery. 1-43
- 345 Challenges in Design of Drug Delivery Systems. **2021**, 15-38
- 344 Preformulation and Physicochemical Characterization Underpinning the Development of Controlled Drug Delivery Systems. **2021**, 73-94
- 343 Furosemide/Non-Steroidal Anti-Inflammatory Drug Drug Pharmaceutical Solids: Novel Opportunities in Drug Formulation. **2021**, 11, 1339 3
- 342 Effect of Coformer Selection on In Vitro and In Vivo Performance of Adefovir Dipivoxil Cocrystals. *Pharmaceutical Research*, **2021**, 38, 1777-1791 4.5 0

341	Enhanced Supersaturation via Fusion-Assisted Amorphization during FDM 3D Printing of Crystalline Poorly Soluble Drug Loaded Filaments. 2021 , 13,	0
340	Combined Methodologies for Determining Bioavailability of Drugs and Prediction of Bioequivalence From Pharmaceutical Oral Formulations. 2021 , 9, 741876	
339	Impact of Hydroxypropyl Methylcellulose Acetate Succinate Critical Aggregation Concentration on Celecoxib Supersaturation. 2021 , 18, 4299-4309	1
338	Dissolution of an ensemble of differently shaped poly-dispersed drug particles undergoing solubility reduction: mathematical modelling.. 2020 , 8, 297-313	1
337	Application of Neutralization and Freeze-Drying Technique for the Preparation of the Beneficial in Drug Delivery 2-Hydroxypropyl-β-Cyclodextrin Complexes with Bioactive Molecules. 2021 , 2207, 1-11	0
336	Study of homogenization on media milling time in preparation of irbesartan nanosuspension and optimization using design of experiments (DoE). 2020 , 6,	2
335	Solid Lipid Nanoparticles for Oral Drug Delivery: A Review. 2020 , 10, 208-224	1
334	The Controversy over Generic Antiepileptic Drugs. 2010 , 15, 81-93	25
333	Evaluation of the use of partition coefficients and molecular surface properties as predictors of drug absorption: a provisional biopharmaceutical classification of the list of national essential medicines of Pakistan. 2011 , 19, 83-99	22
332	Comparative in vitro and in vivo evaluation of three tablet formulations of amiodarone in healthy subjects. 2010 , 18, 193-9	4
331	Itraconazole nanosuspension for oral delivery: Formulation, characterization and in vitro comparison with marketed formulation. 2010 , 18, 84-90	24
330	Lyophilization monophasic solution technique for improvement of the solubility and dissolution of piroxicam. 2012 , 7, 13-21	10
329	Enhancement of dissolution rate of indomethacin: using liquisolid compacts. 2011 , 10, 25-34	12
328	Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in Cancerous Colon Perfusion Rat Model. 2013 , 5, 313-319	29
327	Study of nimesulide release from solid pharmaceutical formulations in tween 80 solutions. 2010 , 36, 42-9	3
326	Designing in-vitro systems to simulate the in-vivo permeability of drugs. 2014 , 10, 18-21	1
325	Preparation, Optimization and Characterization of Chitosan-coated Liposomes for Solubility Enhancement of Furosemide: A Model BCS IV Drug. 2020 , 19, 366-382	1
324	Development and validation of RP-HPLC method for simultaneous determination of lamivudine, stavudine, and zidovudine in perfusate samples: Application to the Single-Pass Intestinal Perfusion (SPIP) studies. 57,	0

- 323 CocrySTALLIZATION and Coamorphization for Druggability Enhancement of Chinese Medicines. **2021**, 239-276 0
- 322 Drug product performance and scale-up process approval changes. **2022**, 215-240
- 321 Nanocrystal-based 3D-printed tablets: Semi-solid extrusion using melting solidification printing process (MESO-PP) for oral administration of poorly soluble drugs. **2021**, 611, 121311 0
- 320 Machine learning predicts the effect of food on orally administered medicines. **2021**, 611, 121329 1
- 319 Emerging Role of Biopharmaceutical Classification and Biopharmaceutical Drug Disposition System in Dosage form Development: A Systematic Review. **2021**, 0-0
- 318 Effect of pectin oligosaccharides supplementation on infant formulas: The storage stability, formation and intestinal absorption of advanced glycation end products. **2021**, 373, 131571 0
- 317 Mechanochemical synthesis and characterization of a novel AA β -glucosamine drug-drug cocrystal: A versatile model system for green approaches. **2021**, 1251, 132052 0
- 316 Thermodynamics of adsorption of carbon dioxide on different metal oxides at temperatures from 313 to 353 K and pressures up to 25 MPa. **2021**, 182, 105461 3
- 315 Development and Characterization of pH-Dependent Cellulose Acetate Phthalate Nanofibers by Electrospinning Technique.. **2021**, 11, 0
- 314 Critical Aspects in the Preparation of Extemporaneous Flecainide Acetate Oral Solution for Paediatrics. **2021**, 13, 1
- 313 Solubility of Cinnarizine in (Transcutol + Water) Mixtures: Determination, Hansen Solubility Parameters, Correlation, and Thermodynamics. **2021**, 26, 2
- 312 Investigation the phase equilibrium behavior in ternary system (CO₂, DMSO, Capecitabine as anticancer drug) for precipitation of CPT Nanoparticle via the gas antisolvent supercritical process (GAS). 1 0
- 311 A Novel In Vitro Membrane Permeability Methodology Using Three-dimensional Caco-2 Tubules in a Microphysiological System which Better Mimics in Vivo Physiological Conditions. **2021**, 2
- 310 MECHANISTIC STUDY OF DISSOLUTION ENHANCEMENT BY INTERACTIVE MIXTURES OF CHITOSAN WITH MELOXICAM AS MODEL. **2021**, 169, 106087 2
- 309 Enhanced bioavailability and biosafety of cannabidiol nanomicelles for effective anti-inflammatory therapy. **2022**, 69, 1-9 4
- 308 [Original and generic drugs: what does the clinician need to know?]. **2021**, 121, 99-104
- 307 Multi-Component Drug Delivery Systems for Chinese Medicines Based on the TCM Theory. **2021**, 23-48
- 306 Effects of experimental conditions on solubility measurements for BCS classification in order to improve the biowaiver guidelines. 57, 0

305	Morphometric analysis of itraconazole pellets of commonly available brands using dermoscopy. 2021 , 7, 72	0
304	Propylene Glycol Caprylate-Based Nanoemulsion Formulation of Plumbagin: Development and Characterization of Anticancer Activity.. 2022 , 2022, 3549061	0
303	Solubility, Dissolution, Permeability, and Classification Systems. 2022 , 54-85	
302	Solid Dispersions of Gefitinib Prepared by Spray Drying with Improved Mucoadhesive and Drug Dissolution Properties.. 2022 , 23, 48	1
301	Particle synthesis by rapid expansion of supercritical solutions (RESS): Current state, further perspectives and needs. 2022 , 105950	3
300	A new nanosuspension prepared with wet milling method for oral delivery of highly variable drug Cyclosporine A: development, optimization and in vivo evaluation.. 2022 , 171, 106123	0
299	Amino acids and its pharmaceutical applications: A mini review.. 2021 , 613, 121375	3
298	Overview of nanoparticulate strategies for solubility enhancement of poorly soluble drugs.. 2022 , 291, 120301	15
297	Manipulations and age-appropriateness of oral medications in pediatric oncology patients in Sweden: Need for personalized dosage forms.. 2022 , 146, 112576	0
296	Evolution of drug delivery systems: From 1950 to 2020 and beyond.. 2021 , 342, 53-53	13
295	Level A IVIVC for immediate release tablets confirms in vivo predictive dissolution testing for ibuprofen.. 2021 , 121415	1
294	Intestinal absorption of BCS class II drugs administered as nanoparticles: A review based on data from intestinal perfusion models.. 2020 , 8, 375-390	0
293	Global testing of a consensus solubility assessment to enhance robustness of the WHO biopharmaceutical classification system.. 2021 , 9, 23-39	2
292	Use of Solid Lipid Nanoparticles to Improve the Oral Bioavailability of Poorly Water-Soluble Drugs. 2021 , 389-424	
291	SwissADME predictions of pharmacokinetics and drug-likeness properties of small molecules present in <i>Spirulina platensis</i> . 2021 , 890, 012021	4
290	Integration of In Silico, In Vitro and In Situ Tools for the Preformulation and Characterization of a Novel Cardio-Neuroprotective Compound during the Early Stages of Drug Development.. 2022 , 14,	
289	Biorelevant Dissolution/Release Test Method Development for Pharmaceutical Dosage Forms. 2022 , 294-319	
288	Pharmaceutical Dissolution Testing: Fundamentals and Essential Applications (An Overview). 2022 , 1-19	

287	Towards a Better Understanding of the Post-Gastric Behavior of Enteric-Coated Formulations.. <i>Pharmaceutical Research</i> , 2022 , 39, 201	4.5	1
286	Fasted Intestinal Solubility Limits and Distributions Applied to the Biopharmaceutics and Developability Classification Systems.. 2021 ,		2
285	Better and greener: sustainable pharmaceutical manufacturing technologies for highly bioavailable solid dosage forms.. 2022 , 1		1
284	In vitro In vivo Correlations (IVIVCs): What Makes Them Challenging!. 2022 , 269-293		
283	Preparation and Characterization of Furosemide Solid Dispersion with Enhanced Solubility and Bioavailability.. 2022 , 23, 65		
282	Impact of Surfactants on the Performance of Clopidogrel-Copovidone Amorphous Solid Dispersions: Increased Drug Loading and Stabilization of Nanodroplets.. <i>Pharmaceutical Research</i> , 2022 , 1	4.5	2
281	Dissolution/Release Test Data (Profile): Requirements, Analyses, and Regulatory Expectations. 2022 , 237-253		
280	Setting Up Clinical Therapeutics Safety-Based QC Specifications for Dissolution Testing of a Finished Product. 2022 , 473-492		
279	Inhaled Medicines: Past, Present, and Future.. 2022 , 74, 48-118		7
278	Kinetic solubility improvement and influence of polymers on controlled supersaturation of itraconazole-succinic acid nano-co-crystals.. 2022 , 121536		2
277	Applications of PBPK/PBBM modeling in generic product development: An industry perspective. 2022 , 69, 103152		0
276	Synthesis and evaluation of cyclic diamino benzamide based D3 receptor ligands. 2022 , 31, 446		
275	Resveratrol Biotechnological applications: enlightening its antimicrobial and antioxidant properties. 2022 , 32, 100550		5
274	Why 90% of clinical drug development fails and how to improve it?. 2022 ,		28
273	Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling.. 2022 , 89, 383		1
272	Understanding the Impact of Age-Related Changes in Pediatric GI Solubility by Multivariate Data Analysis.. 2022 , 14,		
271	(Co-)amorphization of enantiomers - Investigation of the amorphization process, the physical stability and the dissolution behavior.. 2022 , 616, 121552		0
270	Nanoparticle-mediated delivery of AChE inhibitors for the treatment of Alzheimer's disease. 2022 , 223-242		

- 269 Biopharmaceutics studies applied to goyazensolide: a drug candidate from *Lychnophora* species.. **2022**,
- 268 Heart failure as a risk factor of adverse drug reactions. Part 1: potential changes in pharmacokinetics. **2022**, 53-59
- 267 Dose-dependent alkaloid sequestration and N-methylation of decahydroquinoline in poison frogs.. **2022**, 0
- 266 State of the Art and Uses for the Biopharmaceutics Drug Disposition Classification System (BDDCS): New Additions, Revisions, and Citation References.. **2022**, 24, 37 0
- 265 Development of Solvent-Free Co-Ground Method to Produce Terbinafine Hydrochloride Cyclodextrin Binary Systems; Structural and In Vitro Characterizations.. **2022**, 14, 0
- 264 Effect of Colonic Absorption on the Pharmacokinetic Properties of Delayed-Release and Extended-Release Methylphenidate: In Vivo, In Vitro, and Modeling Evaluations.. **2022**,
- 263 Inclusion Complexation Behaviors of Favipiravir into Cyclodextrins.
- 262 Relative bioavailability enhancement of simvastatin via dry emulsion systems: comparison of spray drying and fluid bed layering technology.. **2021**,
- 261 An Unrevealed Molecular Function of Corannulene Buckybowl Glycoconjugates in Selective Tumor Annihilation by Targeting the Cancer-Specific Warburg Effect.. **2022**, e2105315 2
- 260 Micronization of a poorly water-soluble drug, fenofibrate, via supercritical-fluid-assisted spray-drying. 1 0
- 259 Intestinal Epithelium and Drug Transporters. **2022**, 39-64
- 258 Re-writing Oral Pharmacokinetics Using Physiologically Based Finite Time Pharmacokinetic (PBFTPk) Models.. *Pharmaceutical Research*, **2022**, 1 4.5 3
- 257 Ascertain a Minimum Coating Thickness for Acid Protection of Enteric Coatings by Means of Optical Coherence Tomography.. **2022**, 121680 2
- 256 TRANSPORTERS-MEDIATED DRUG DISPOSITION PHYSIOCHEMISTRY AND IN SILICO APPROACHES. **2022**, 433-452
- 255 Biopharmaceutics considerations for direct oral anticoagulants.. **2022**, 1-14
- 254 Preformulation Considerations for Design of Oral Modified-Release Products. **2022**, 87-102
- 253 Application of In Vivo Imaging Techniques and Diagnostic Tools in Oral Drug Delivery Research.. **2022**, 14, 1
- 252 The Role and Applications of Dissolution Media for the Investigation of Modified-Release Formulations. **2022**, 273-287

251	In Vitro In Vivo Correlations for Modified Release Formulations. 2022 , 341-354	
250	Adding a new Dimension to the Amorphous Solid Dispersion Phase Diagram: Studying Dissolution Kinetics of Crystalline Drugs in a Polymer Matrix using temperature dependent XRPD and DSC.. 2022 ,	0
249	Preformulation studies of dovitinib free base: Solubility, Lipophilicity and Stability.. 2022 , 121721	1
248	The Application of Biopharmaceutics Classification Systems to Modified-Release Formulations. 2022 , 103-117	
247	Lipid-based Formulations. 2022 , 137-160	
246	Biorelevant Dissolution Testing to Forecast the In Vivo Performance of Modified-Release Formulations. 2022 , 289-303	
245	Thermodynamic and transport properties of amoxicillin. 2022 , 354, 118865	1
244	Supercritical CO ₂ impregnation approach for enhancing dissolution of fenofibrate by adsorption onto high-surface area carriers. 2022 , 184, 105584	0
243	Near-infrared spectroscopy-based nondestructive at-line analysis of physicochemical properties of atorvastatin calcium hydrate after grinding. 2022 , 71, 103266	0
242	Nanocrystals as a master key to deliver hydrophobic drugs via multiple administration routes.. 2022 , 345, 334-353	9
241	Untangling Absorption Mechanisms and Variability in Bioequivalence Studies Using Population Analysis.. <i>Pharmaceutical Research</i> , 2021 , 38, 2047	4-5
240	Cyclodextrin-Modified Nanomaterials for Drug Delivery: Classification and Advances in Controlled Release and Bioavailability.. 2021 , 13,	9
239	An Introduction to Biopharmaceutics. 2022 , 1-8	
238	Biopharmaceutic Classification System. 2022 , 135-146	
237	Supramolecular inclusion complexes of 2-hydroxypropyl-β-cyclodextrin with mefenamic acid: preparation and characterization. 2021 , 28,	
236	Solubility Study of Acetylsalicylic Acid in Ethanol + Water Mixtures: Measurement, Mathematical Modeling, and Stability Discussion.. 2021 , 23, 42	0
235	Interpreting the Physicochemical Meaning of a Molecular Descriptor Which Is Predictive of Amorphous Solid Dispersion Formation in Polyvinylpyrrolidone Vinyl Acetate.. 2021 ,	0
234	Exploring the Relationship of Drug BCS Classification, Food Effect, and Gastric pH-Dependent Drug Interactions.. 2021 , 24, 16	0

233	Preparation and Characterization of Stable Amorphous Glassy Solution of BCS II and IV Drugs.. 2021 , 23, 35		
232	The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [¹⁴ C]-BI 425809 in Healthy Males.. 2021 , 42, 87		
231	Comparison of Predictions by BCS, rDCS and Machine Learning for the Effect of Food on Oral Drug Absorption Based on Features Calculated In silico. 2021 , 24, 10		
230	Biopharmaceutics to Inform Candidate Drug Selection and Optimisation. 2022 , 99-111		
229	Nanoconfinement of a Pharmaceutical Cocrystal with Praziquantel in Mesoporous Silica: The Influence of the Solid Form on Dissolution Enhancement.. 2021 ,		2
228	Experimental measurement and thermodynamic modeling of solubility of flufenamic acid in different pure solvents. 2021 ,		0
227	pH-Dependent supersaturation from amorphous solid dispersions of weakly basic drugs. <i>Pharmaceutical Research</i> , 2021 , 1	4.5	1
226	Topical drug delivery to the retina: obstacles and routes to success. 2021 ,		1
225	Orodispersible tablets for pediatric drug delivery: current challenges and recent advances. 2021 , 1-18		2
224	Synthesis, crystal structure, hirshfeld surface analysis, molecular docking and molecular dynamics studies of novel olanzapinium 2,5-dihydroxybenzoate as potential and active antipsychotic compound. 2022 , 17, 247-273		1
223	Combining Liquisolid and Co-grinding Techniques to Enhance the Dissolution Rate of Celecoxib. 1		1
222	NMR-Based Mechanistic Study of Crystal Nucleation Inhibition in a Supersaturated Drug Solution by Polyvinylpyrrolidone.		1
221	Supramolecular Synthron Promiscuity in Phosphoric Acid-Dihydrogen Phosphate Ionic Cocrystals.. 2022 , 22, 3333-3342		1
220	Cocrystals of Nitrofurantoin: How Coformers Can Modify Its Solubility and Permeability Across Intestinal Cell Monolayers.		0
219	Design and physico-mechanical evaluation of fast-dissolving valsartan polymeric drug delivery system by electrospinning method.. 2021 , 24, 1683-1694		0
218	Near-Infrared Spectroscopy-Based Nondestructive At-Line Analysis of Physicochemical Properties of Atorvastatin Calcium Hydrate after Grinding.		
217	Overcoming Bioavailability Challenges of Dasabuvir and Enabling a Triple-Combination Direct-Acting Antiviral HCV Regimen through a Salt of Very Weak Acid for Oral Delivery.. 2022 ,		0
216	Development and In Vitro Evaluation of Oral Capsules from : A Convenient Substitute for Peripheral Neuropathy.. 2022 , 2022, 5340953		0

- 215 Supersaturation-Based Drug Delivery Systems: Strategy for Bioavailability Enhancement of Poorly Water-Soluble Drugs.. **2022**, 27, 1
- 214 Formulation and Evaluation of SNEDDS Loaded with Original Lipophenol for the Oral Route to Prevent Dry AMD and Stragardt Disease. **2022**, 14, 1029 0
- 213 Next-generation probiotics as a therapeutic strategy for the treatment of phenylketonuria: a review.. **2022**, 0
- 212 Pharmacometric characterization of entero-hepatic circulation processes of orally administered formulations of amiodarone under complex binding kinetics.. **2022**, 174, 106198 0
- 211 Do Thickening Agents Used in Dysphagia Diet Affect Drug Bioavailability?. **2022**, 106197
- 210 iBCS: 1. Principles and Framework of an Inhalation-Based Biopharmaceutics Classification System.. **2022**, 1
- 209 Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs. **2022**, 651-673
- 208 Pharmaceutical Cryogenic Technologies. **2022**, 453-528
- 207 Melt Extrusion. **2022**, 327-376
- 206 Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs. **2022**, 1-31
- 205 Biocoating A Critical Step Governing the Oral Delivery of Polymeric Nanoparticles. 2107559 0
- 204 In Vitro Predictive Dissolution Test Should Be Developed and Recommended as a Bioequivalence Standard for the Immediate-Release Solid Oral Dosage Forms of the Highly Variable Mycophenolate Mofetil. 0
- 203 Physico-chemical characterization of aspirated and simulated human gastric fluids to study their influence on the intrinsic dissolution rate of cinnarizine. **2022**, 622, 121856 1
- 202 Structured solubility behaviour in bioequivalent fasted simulated intestinal fluids. **2022**, 176, 108-121 0
- 201 A Paracetamol - Poly(3,4-Ethylendioxythiophene) Composite Film for Drug Release Studies.
- 200 Computer-Aided Biopharmaceutical Characterization: Gastrointestinal Absorption Simulation and In Silico Computational Modeling. **2022**, 189-215
- 199 Optimization and evaluation of resveratrol amorphous solid dispersions with a novel polymeric system. **2022**, 19, 8019-8034
- 198 Formulation and Characterization of Raloxifene Nanostructured Lipid Carriers for Permeability and Uptake Enhancement Applications. 1

197	iBCS. 2: Mechanistic Modeling of Pulmonary Availability of Inhaled Drugs versus Critical Product Attributes.	1
196	Lipid-Coated Nanocrystals as a Tool for Improving the Antioxidant Activity of Resveratrol. 2022 , 11, 1007	1
195	Thermogelling Hydroxypropyl Methylcellulose Nanoemulsions as Templates to Formulate Poorly Water-Soluble Drugs into Oral Thin Films Containing Drug Nanoparticles.	0
194	Crystal Engineering of Pharmaceutical Cocrystals in the Discovery and Development of Improved Drugs.	23
193	Biopharmaceutics Drug Disposition Classification System. 2022 , 185-189	
192	Biopharmaceutical Classification System Subclasses. 2022 , 158-164	
191	Drug Solubility Assessment. 2022 , 429-435	
190	Biowaivers. 2022 , 210-217	
189	Drug Permeability and Transporter Assessment: Polarized Cell Lines. 2022 , 401-412	
188	Drug-Drug and Food-Drug Interactions. 2022 , 448-456	0
187	In Vitro Drug Dissolution: Modalities. 2022 , 547-557	
186	Biopharmaceutics Classification System. 2022 , 179-185	
185	Biorelevant Dissolution Media. 2022 , 190-198	
184	Bioavailability. 2022 , 107-116	
183	Intestinal Perfusion Models. 2022 , 558-566	
182	Exploring Fenofibrate Formulations for the Treatment of Lipid Disorders: Past, Present, and Future. 2,	0
181	Crystallization: Its Mechanisms and Pharmaceutical Applications.	
180	Effect of functional excipients on the dissolution and membrane permeation of furosemide formulated into multiple-unit pellet system (MUPS) tablets. 1-16	0

179	Enhanced oral bioavailability and antitumor therapeutic efficacy of sorafenib administered in core-shell protein nanoparticle.	0
178	Lack of an Effect of Polysorbate 80 on Intestinal Drug Permeability in Humans. <i>Pharmaceutical Research</i> ,	4.5 0
177	Crystal Engineering of Ionic Cocrystals Sustained by the Phenol-Phenolate Supramolecular Heterosynthon.	3
176	Pickering Dry Emulsion System for Improved Oral Delivery of Fenofibrate. 2022 , 23,	
175	Small scale in vitro method to determine a potential bioequivalent equilibrium solubility range for fed human intestinal fluid. 2022 ,	0
174	Evaluation of the Intestinal Permeability of Rosmarinic Acid from <i>Thunbergia laurifolia</i> Leaf Water Extract in a Caco-2 Cell Model. 2022 , 27, 3884	1
173	Cyclodextrin Complexation of Fenofibrate by Co-Grinding Method and Monitoring the Process Using Complementary Analytical Tools. 2022 , 14, 1329	0
172	Development of a Microgram Scale Video-Microscopic Method to Investigate Dissolution Behavior of Poorly Water-Soluble Drugs. 2022 , 23,	
171	Evaluation of an Ussing Chamber System Equipped with Rat Intestinal Tissues to Predict Intestinal Absorption and Metabolism in Humans.	1
170	Self-emulsifying drug delivery systems: a novel approach to deliver drugs. 2022 , 29, 1811-1823	5
169	pH-driven self-assembly of alcohol-free curcumin-loaded zein-propylene glycol alginate complex nanoparticles. 2022 , 213, 1057-1067	0
168	Biopharmaceutical evaluation of kavain in <i>Piper methysticum</i> G. Forst dried extract: Equilibrium solubility and intestinal permeability in Caco-2 cell model. 2022 , 296, 115480	
167	Use of biorelevant dissolution media in dissolution tests as a predictive method of oral bioavailability. 58,	
166	Dissolution test for oral suspension: an overview about use and importance. 58,	
165	Comparator product issues for biowaiver implementation: the case of Fluconazole. 58,	
164	Liposomal Nanotechnology in Nutraceuticals. 2022 , 29-62	0
163	Chemical and Pharmacological Properties of Decoquinatone: A Review of Its Pharmaceutical Potential and Future Perspectives. 2022 , 14, 1383	
162	A review of transglycosylated compounds as food additives to enhance the solubility and oral absorption of hydrophobic compounds in nutraceuticals and pharmaceuticals. 1-18	

161	Two Novel Co-Crystals of Naproxen: Comparison of Stability, Solubility and Intermolecular Interaction. 2022 , 15, 807	0
160	The Role of Paracellular Transport in the Intestinal Absorption and Biopharmaceutical Characterization of Minoxidil. 2022 , 14, 1360	0
159	Synthesis of Ternary Cocrystals, Salts, and Hydrates of Acefylline with Enhanced Dissolution and High Permeability. 2022 , 22, 4165-4181	2
158	Role of Drug Delivery System in Improving the Bioavailability of Resveratrol. 2022 , 28, 1632-1642	1
157	Applications of bio-predictive dissolution tools for the development of solid oral dosage forms: current industry experience. 1-19	0
156	Exploration of natural flavones bioactivity and bioavailability in chronic inflammation induced-type-2 diabetes mellitus. 1-28	0
155	PAMAM Dendrimers: A review of methodologies employed in biopharmaceutical classification. 2022 ,	
154	Insights into Cocrystallization and Coamorphization Engineering Techniques in the Delivery of Traditional Chinese Medicine: Formation Mechanism, Solid-State Characterization, and Improved Pharmaceutical Properties.	
153	Strategies for enhancing the oral bioavailability of cannabinoids. 1-10	2
152	Luteolin Phosphate Derivatives Generated by Cultivating <i>Bacillus subtilis</i> var. Natto BCRC 80517 with Luteolin.	0
151	Donepezil hydrochloride BCS class ambiguity: relevant aspects to be considered in drug classification. 2022 ,	
150	Dissolution of irregularly-shaped drug particles: mathematical modelling. 2022 , 177, 199-210	
149	Folic acid-mesoporous silicon nanoparticles enhance the anticancer activity of the p73-activating small molecule LEM2. 2022 , 624, 121959	
148	Filament-based 3D-printing of placebo dosage forms using brittle lipid-based excipients. 2022 , 624, 122013	1
147	Combining lipid based drug delivery and amorphous solid dispersions for improved oral drug absorption of a poorly water-soluble drug. 2022 , 349, 206-212	1
146	Conformational Effects on the Passive Membrane Permeability of Synthetic Macrocycles.	3
145	Nanodrugs against cancer: biological considerations in its redesign. 1-20	
144	The effect of dietary fibers on the absorption of oral hypoglycemic drugs: a systematic review of controlled trials.	

- 143 Introduction to Chemistry Manufacturing and Controls [From Compound and Development Candidate to Drug. **2022**, 99-118
- 142 Rational Design of Self-Emulsifying Pellet Formulation of Thymol: Technology Development Guided by Molecular-Level Structure Characterization and Ex Vivo Testing. **2022**, 14, 1545
- 141 Nanoparticle Engineering of Aprepitant Using Nano-by-Design (NbD) Approach. **2022**, 23,
- 140 Formulation, optimization, and in-vivo evaluation of nanostructured lipid carriers loaded with Fexofenadine HCL for oral delivery. **2022**, 74, 103607
- 139 Poloxamer-enhanced solubility of griseofulvin and its related antifungal activity against *Trichophyton* spp.. 58,
- 138 Convolution- and Deconvolution-Based Approaches for Prediction of Pharmacokinetic Parameters of Diltiazem Extended-Release Products in Flow-Through Cell Dissolution Tester. **2022**, 23, 0
- 137 Ultrasound-Assisted Anti-Solvent Crystallization of Ibuprofen: Effect of Ultrasonic Treatment and Additive.
- 136 Modeling of In Vitro Dissolution Profiles of Carvedilol Immediate-Release Tablets in Different Dissolution Media. **2022**, 23, 0
- 135 Simulation of Intraluminal Performance of Lipophilic Weak Bases in Fasted Healthy Adults Using DDDPlus™. **2022**, 24,
- 134 Intestinal Absorption Study: Challenges and Absorption Enhancement Strategies in Improving Oral Drug Delivery. **2022**, 15, 975 2
- 133 Unusual Correlation between the Apparent Amorphous Solubility of a Drug and Solubilizer Concentration Revealed by NMR Analysis. 2
- 132 Lipid-based solubilization technology via hot melt extrusion: promises and challenges. 1-20 0
- 131 Evaluation of the Formulation Parameter-Dependent Redispersibility of API Nanoparticles from Fluid Bed Granules. **2022**, 14, 1688
- 130 Heterosynthons, Solid Form Design and Enhanced Drug Bioavailability. 1
- 129 Comparisons of in Vitro Models to Evaluate the Membrane Permeability of Amorphous Drug Nanoparticles. 0
- 128 Development of stability indicating reversed-phase high-performance liquid chromatography method for determination of elobixibat in pure form and laboratory prepared tablets: Application to dissolution study.
- 127 Cubosomes for Enhancing Intestinal Absorption of Fexofenadine Hydrochloride: In situ and in vivo Investigation. Volume 17, 3543-3560 0
- 126 Interchangeability between Generic and Reference Products: Limits of Average Bioequivalence Methodology. 0

125	A translational strategy employing physiologically based modeling to predict the pharmacological active dose of RO7119929, an oral prodrug of a targeted cancer immunotherapy TLR7 agonist. 1-42	
124	Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics. 2022 , 10, 2055	7
123	Heterosynthons, Solid Form Design and Enhanced Drug Bioavailability.	1
122	Nanocrystals as an effective strategy to improve Pomalidomide bioavailability in rodent. 2022 , 625, 122079	
121	Structural, Physicochemical, and Biopharmaceutical Properties of Cocrystals with RS- and R-Praziquantel-Generation and Prolongation of the Supersaturation State in the Presence of Cellulosic Polymers.	1
120	Solubility and Dissolution Study by Applying the Fusion Method of Solid Dispersion, the Hydrophobic Drugs Glimepiride Solubility is Improved.	0
119	An outlook on permeability escalation through cocrystallization for developing pharmaceuticals with improved biopharmaceutical properties. 2022 , 76, 103757	1
118	Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population. 2022 , 190, 114507	0
117	Application of ionic liquid to enhance the nose-to-brain delivery of etodolac. 2022 , 178, 106290	1
116	Multiscale mathematical modelling of drug activation by co-grinding. 2022 , 263, 118073	0
115	Pharmacokinetics and Bioavailability of a Metformin/Glyburide Tablet Administered Alone and with Food. 2000 , 40, 1494-1502	12
114	Nanotechnological Applications in the Diagnosis and Treatment of Alzheimer's Dementia. 2022 , 577-616	0
113	Pharmaceutical co-crystals of posaconazole for improvement of physicochemical properties. 58,	0
112	Current practices in drug delivery for metabolic disorders. 2022 , 31-45	0
111	Drug delivery and in vivo absorption. 2022 , 335-390	0
110	Facile production of quercetin nanoparticles using 3D printed centrifugal flow reactors. 2022 , 12, 20696-20713	1
109	The Product Design Process. 2022 , 187-213	0
108	Comparison study of physicochemical and biopharmaceutics properties of hydrophobic drugs ground by two dry milling processes. 1-13	0

107	Oncology Phase I Trial Design and Conduct: Time for a Change MDICT Guidelines 2022. 2022,	1
106	Optimization of Lipid Nanoparticles by Response Surface Methodology to Improve the Ocular Delivery of Diosmin: Characterization and In-Vitro Anti-Inflammatory Assessment. 2022, 14, 1961	4
105	Uso de probióticos em pacientes com doença renal crônica em hemodiálise: um ensaio clínico randomizado.	0
104	Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial.	0
103	Molecular Biosimilarity: An AI-Driven Paradigm Shift. 2022, 23, 10690	0
102	Predictive Pharmacokinetics. 2022, 148-177	0
101	Quantifying the transport of biologics across intestinal barrier models in real-time by fluorescent imaging. 10,	0
100	Pharmacokinetics and Anti-Diabetic Studies of Gliclazide Nanosuspension. 2022, 14, 1947	0
99	Evaluating the bioequivalence of two pitavastatin calcium formulations based on IVIVC modeling and clinical study.	0
98	High spatial resolution ToF-SIMS imaging and image analysis strategies to monitor and quantify early phase separation in amorphous solid dispersions. 2022, 122191	1
97	Exploring solid states of atovaquone: crystal or glass?. 2022, 55, 1267-1276	0
96	Pharmacokinetics and Toxicology of Pharmaceutical Excipients. 2022, 168-181	0
95	Conformational Trimorphism in an Ionic Cocrystal of Hesperetin.	0
94	Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Treatment Option for Acyclovir-Resistant Herpes Simplex Virus Infections.	1
93	Studying the right transporter at the right time: an in vitro strategy for assessing drug-drug interaction risk during drug discovery and development.	1
92	Rivaroxaban lyospheres prepared by a dimethyl sulfoxide-based spray-freeze-drying process. 2022, 627, 122235	0
91	Preparation, characterization and pharmacokinetics of Cucurbitacin B solid dispersion. 2022, 8, 100088	0
90	Energy framework and solubility: a new predictive model in the evaluation of the structure-property relationship of pharmaceutical solid forms.	0

- 89 Physical aging of hydroxypropyl methylcellulose acetate succinate via enthalpy recovery. ○
- 88 Nanoparticulate System Based on Calcium-Crosslinked Carbomer Retards Percutaneous Drug Permeation: New Insight Into Skin Barrier Functions. ○
- 87 Silk fibroin nanoparticles as a versatile oral delivery system for drugs of different biopharmaceutics classification system (BCS) classes: A comprehensive comparison. ○
- 86 Current Trends on Solid Dispersions: Past, Present, and Future. **2022**, 2022, 1-17 ○
- 85 Crystal Engineering of Ionic Cocrystals Sustained by Azolium- π -Azole Heterosynthons. **2022**, 14, 2321 ○
- 84 Production of Hydrochlorothiazide Nanoparticles with Increased Permeability Using Top-Spray Coating Process. **2022**, 105788 ○
- 83 Nanoaggregates of Biphilic Carboxyl-Containing Copolymers as Carriers for Ionically Bound Doxorubicin. **2022**, 15, 7136 ○
- 82 3D printed bilayer mucoadhesive buccal film of estradiol: Impact of design on film properties, release kinetics and predicted in vivo performance. **2022**, 628, 122324 ○
- 81 Nanovesicles for delivery of antiviral agents. **2023**, 493-518 ○
- 80 Isomeric Cofomer Responsive Conformational Adjustment to Recuperate Stability, Solubility, and In Vitro Permeation Behavior of Drug Molecular Salts. ○
- 79 Approaches of formulation bridging in support of orally administered drug product development. **2022**, 122380 ○
- 78 Engineered Fenofibrate as Oxidation-Sensitive Nanoparticles with ROS Scavenging and PPAR α -Activating Bioactivity to Ameliorate Nonalcoholic Fatty Liver Disease. ○
- 77 Impact of solvent properties on the precipitation of active pharmaceutical ingredients. **2022**, 118032 ○
- 76 Thermodynamic modeling of determined the optimal condition of the gas antisolvent process with different solvent. **2022**, 8, 100094 ○
- 75 Perspective on a chemistry classification system for AI-assisted formulation development. **2022**, 352, 833-839 ○
- 74 Enhancement of water solubilization of quercetin by meglumine and application of the solubilization concept to a similar system. **2022**, 368, 120756 ○
- 73 Interaction of polymers with bile salts - Impact on solubilisation and absorption of poorly water-soluble drugs. **2022**, 113044 ○
- 72 Pharmaceutical evaluation of compounded furosemide capsules and excipient performance. 58, ○

- 71 Novel nano-crystalline solid dispersion of nobiletin with improved dissolution behavior and oral absorption. **2023**, 79, 104013 ○
- 70 Bioanalytical method validation, biopharmaceutical and pharmacokinetic evaluation of GSK-650394, a serum- and glucocorticoid-regulated kinase 1 inhibitor. **2023**, 16, 104462 ○
- 69 A paracetamol - poly(3,4-ethylenedioxythiophene) composite film for drug release studies. **2023**, 34, 105084 ○
- 68 Exploring a Bioequivalence Failure for Silodosin Products Due to Disintegrant Excipients. **2022**, 14, 2565 ○
- 67 The flavonoid components of *Scutellaria baicalensis*: Biopharmaceutical properties and their improvement using nanoformulation techniques. **2022**, 23, ○
- 66 Therapeutic Importance of Kaempferol in the Treatment of Cancer through the Modulation of Cell Signalling Pathways. **2022**, 27, 8864 ○
- 65 Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degradator of Mutant PI3K. **2022**, 65, 16589-16621 2
- 64 The Effect of In-Situ-Generated Moisture on Disproportionation of Pharmaceutical Salt. ○
- 63 Pharmacokinetic modulation of substrate drugs via the inhibition of drug-metabolizing enzymes and transporters using pharmaceutical excipients. ○
- 62 Reduction of submicron particle agglomeration via melt foaming in solid crystalline suspension. 1-10 ○
- 61 Influence of Hydrophobic and Hydrophilic Chain Length of C₁₂E₈ Surfactants on the Solubilization of Active Pharmaceutical Ingredients. ○
- 60 The Unphysical Hypothesis of Infinite Absorption Time. **2023**, 9-23 ○
- 59 Improving the Antimycobacterial Drug Clofazimine through Formation of Organic Salts by Combination with Fluoroquinolones. **2023**, 24, 1402 ○
- 58 Citrus, Milk Thistle, and Propolis Extracts Improved the Intestinal Permeability of Curcuminoids from Turmeric Extract- an In Silico and In Vitro Permeability Caco-2 Cells Approach. ○
- 57 The Rise of Physiologically Based Finite Time Pharmacokinetic (PBFTPk) Models. **2023**, 43-77 ○
- 56 The Effect of the Particle Size Reduction on the Biorelevant Solubility and Dissolution of Poorly Soluble Drugs with Different Acid-Base Character. **2023**, 15, 278 ○
- 55 Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry. **2023**, 28, 474 2
- 54 Preparation and characterization of self-emulsifying drug delivery system (SEDDS) for enhancing oral bioavailability of metformin hydrochloride using hydrophobic ion pairing complexation. 1-21 ○

- 53 Pharmacokinetic and Bioequivalence Studies of 2 Metformin Glibenclamide Tablets in Healthy Chinese Subjects Under Fasting and Fed Conditions. ○
- 52 A New Challenge for the Old Excipient Calcium Carbonate: To Improve the Dissolution Rate of Poorly Soluble Drugs. **2023**, 15, 300 ○
- 51 Identification of Nanoparticle Properties for Optimal Drug Delivery across a Physiological Cell Barrier. **2023**, 15, 200 ○
- 50 Preparation and in vitro evaluation of hot-melt extruded pectin-based pellets containing ketoprofen for colon targeting. **2023**, 5, 100156 ○
- 49 Design of ciprofloxacin impregnated dietary fiber psyllium-moringa gum-alginate network hydrogels via green approach for use in gastro-retentive drug delivery system. **2023**, 29, 100345 ○
- 48 Diammonium Glycyrrhizinate-Based Micelles for Improving the Hepatoprotective Effect of Baicalin: Characterization and Biopharmaceutical Study. **2023**, 15, 125 ○
- 47 The impact of viscosity on the dissolution of naproxen immediate-release tablets. **2022**, ○
- 46 Microfluidic synthesis of multilayered lipid-polymer hybrid nanoparticles for the formulation of low solubility drugs. ○
- 45 Structural Modifications of Polyethylenimine to Control Drug Loading and Release Characteristics of Amorphous Solid Dispersions. ○
- 44 Dimeric Polyphenols to Pave the Way for New Antimalarial Drugs.. ○
- 43 In vitro dissolution profile comparison using bootstrap bias corrected similarity factor, f2. 1-12 ○
- 42 Formulation and evaluation of Piroxicam nanosponge for improved internal solubility and analgesic activity. **2023**, 30, ○
- 41 Predictive Potential of BCS and Pharmacokinetic Parameters on Study Outcome: Analysis of 198 In Vivo Bioequivalence Studies. ○
- 40 Optimisation of a Greener-Approach for the Synthesis of Cyclodextrin-Based Nanosponges for the Solubility Enhancement of Domperidone, a BCS Class II Drug. **2023**, 16, 567 ○
- 39 Co-amorphous systems consisting of indomethacin and the chiral co-former tryptophan: Solid-state properties and molecular mobilities. **2023**, 636, 122840 ○
- 38 Effect of different seed crystals on the supersaturation state of ritonavir tablets prepared by hot-melt extrusion. **2023**, 185, 106440 ○
- 37 Evaluation and prediction of oral drug absorption and bioequivalence with food-drug interaction. **2023**, 50, 100502 ○
- 36 Fed intestinal solubility limits and distributions applied to the Developability classification system. **2023**, 186, 74-84 ○

- 35 A new modelling approach for dissolution of polydisperse powders. **2023**, 633, 122626 ○
- 34 Co-amorphous formulation of dipyridamole with p-hydroxybenzoic acid: Underlying molecular mechanisms, physical stability, dissolution behavior and pharmacokinetic study. **2023**, 184, 139-149 ○
- 33 Structural features, dissolution performance and anthelmintic efficacy of multicomponent solid forms of fenbendazole with maleic and oxalic acids. **2023**, 25, 1301-1312 ○
- 32 Implications of Drug-Polymer Interactions on Time-Temperature-Transformation: A Tool to Assess the Crystallization Propensity in Amorphous Solid Dispersions. **2023**, 20, 1806-1817 ○
- 31 Enhanced NSAIDs Solubility in Drug-Drug Formulations with Ciprofloxacin. **2023**, 24, 3305 ○
- 30 Commercially Available Cell-Free Permeability Tests for Industrial Drug Development: Increased Sustainability through Reduction of In Vivo Studies. **2023**, 15, 592 ○
- 29 Enhancement of the Solubility of BS Class II Drugs with MOF and MOF/GO Composite Materials: Case Studies of Felodipine, Ketoprofen and Ibuprofen. **2023**, 16, 1554 ○
- 28 Exploring the Use of a Kinetic pH Calculation to Correct the ACAT Model with a Single Stomach Compartment Setting: Impact of Stomach Setting on Food Effect Prediction for Basic Compounds. **2023**, ○
- 27 Systematic investigation of the mechanism of herbal medicines for the treatment of prostate cancer. ○
- 26 Development of a quaternary ammonium poly (amidoamine) dendrimer-based drug carrier for the solubility enhancement and sustained release of furosemide. 11, ○
- 25 pH-dependent solubility prediction for optimized drug absorption and compound uptake by plants. **2023**, 37, 129-145 ○
- 24 Enhancement of itraconazole solubility and release by hot-melt extrusion with Soluplus®. **2023**, 81, 104280 ○
- 23 A Validated, Stability-Indicating, Eco-Friendly HPTLC Method for the Determination of Cinnarizine. **2023**, 10, 138 ○
- 22 Selected Aspects of the Analytical and Pharmaceutical Profiles of Nifurtimox. **2023**, ○
- 21 Multi-Compartmental Dissolution Method, an Efficient Tool for the Development of Enhanced Bioavailability Formulations Containing Poorly Soluble Acidic Drugs. **2023**, 15, 753 ○
- 20 Pharmacokinetics and Pharmacodynamics of Anthocyanins after Administration of Tart Cherry Juice to Individuals with Gout. 2200550 ○
- 19 Potentiel Impact thérapeutique de la substitution en cours de traitement d'un princeps par un générique: limites de la bioéquivalence moyenne pour les médicaments à marge thérapeutique étroite. **2023**, 207, 490-500 ○
- 18 Supersaturation and Precipitation Applied in Drug Delivery Systems: Development Strategies and Evaluation Approaches. **2023**, 28, 2212 ○

- 17 Bioequivalence Dissolution Test Criteria for Formulation Development of High Solubility-Low Permeability Drugs. **2023**, 71, 213-219 ○
- 16 Simplifying the Extended Clearance Concept Classification System (EC3S) to Guide Clearance Prediction in Drug Discovery. ○
- 15 Lipid as a Vehicle/Carrier for Oral Drug Delivery. ○
- 14 The effect of adding an organic solvent to povidone aqueous solution on the size of MCC granules obtained by wet granulation. **2023**, 43-46 ○
- 13 RECENT PATENTS ON SOLID DISPERSIONS OF ANTIHYPERLIPIDEMIC DRUGS. 23-31 ○
- 12 Characterization of Mass Transfer within the Crystal-Solution Boundary Layer of l-Alanine {120} Faces Using Laser Interferometry during Growth and Dissolution. **2023**, 23, 2755-2769 ○
- 11 A critical review on cellulose nano structures based polymer nanocomposites for packaging applications. **2022**, 61, 1933-1958 ○
- 10 Exploring in vitro solubility of lamotrigine in physiologically mimetic conditions to prospect the in vivo dissolution in pediatric population. ○
- 9 Introduction to Pharmaceutical Co-amorphous Systems Using a Green Co-milling Technique. **2023**, 100, 1627-1632 ○
- 8 Diffusion and Flux Improvement of Drugs through Complexation. ○
- 7 New Lidocaine-Based Pharmaceutical Cocrystals: Preparation, Characterization, and Influence of the Racemic vs. Enantiopure Coformer on the Physico-Chemical Properties. **2023**, 15, 1102 ○
- 6 Formulation and Optimization of Repaglinide Nanoparticles Using Microfluidics for Enhanced Bioavailability and Management of Diabetes. **2023**, 11, 1064 ○
- 5 Factors influencing bioequivalence evaluation of insulin biosimilars based on a structural equation model. 14, ○
- 4 Modification of Physicochemical Properties of Active Pharmaceutical Ingredient by Pharmaceutical Co-Crystals. ○
- 3 Establishment of In Vitro Dissolution Based on Similarity with In Vivo Dissolution: A Case Study on Aripiprazole. ○
- 2 Artificial Intelligence-Based Quantitative StructureProperty Relationship Model for Predicting Human Intestinal Absorption of Compounds with Serotonergic Activity. ○
- 1 Accelerating therapeutic protein design with computational approaches toward the clinical stage. **2023**, 21, 2909-2926 ○